










The handle http://hdl.handle.net/1887/35116  holds various files of this Leiden University 
dissertation 
 
Author: Punt, Simone 
Title: The IL-17 and Th17 cell immune response in cervical cancer : angels or demons : it 
depends on the context   




The IL-17 and Th17 cell

















Cover art:  Diede Beckers 
Design: Simone Punt 
Print:  Ipskamp Drukkers 
ISBN:             978-94-62596-88-7
©  Simone Punt, 2015 
All rights reserved. No part of this thesis may be reproduced or transmitted, in 
any form or by any means, without permission of the author. 
 
The studies described in this thesis were supported by grant UL2010-4801 from 
the Dutch Cancer Society and a SASC sequencing grant. 
 
Financial support for the printing of this thesis was provided by: 
ChipSoft BV, Dako Netherlands BV, SouthernBiotech and BD Biosciences 
 
This thesis was printed on recycled BalancePure® paper, with ink from 
renewable resources and alcohol free fountain solution. 
 
The IL-17 and Th17 cell 
immune response in cervical cancer
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus Prof. Mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties





















Cover art:  Diede Beckers 
Design: Simone Punt 
Print:  Ipskamp Drukkers 
ISBN:             978-94-62596-88-7
©  Simone Punt, 2015 
All rights reserved. No part of this thesis may be reproduced or transmitted, in 
any form or by any means, without permission of the author. 
 
The studies described in this thesis were supported by grant UL2010-4801 from 
the Dutch Cancer Society and a SASC sequencing grant. 
 
Financial support for the printing of this thesis was provided by: 
ChipSoft BV, Dako Netherlands BV, SouthernBiotech and BD Biosciences 
 
This thesis was printed on recycled BalancePure® paper, with ink from 
renewable resources and alcohol free fountain solution. 
 
The IL-17 and Th17 cell 
immune response in cervical cancer
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus Prof. Mr. C.J.J.M. Stolker,
volgens besluit van het College voor Promoties








Promotor Prof. Dr. G.J. Fleuren
Copromotores Dr. A. Gorter
Dr. E.S. Jordanova
Leden promotiecommissie Prof. Dr. S. van der Burg
Prof. Dr. T.D. de Gruijl
Prof. Dr. P. Hwu 
Dr. E. Lubberts
Prof. Dr. J. Morreau
Dr. V.L.J.L. Thijssen
Prof. Dr. J.B.M.Z. Trimbos
With an open mind, 
in combination with the right amount of curiosity,
dreams and the need to explore,
you will find things beyond imagination.
Freddy van der Garde
208970-L-bw-Punt
Promotores en promotiecommissie
Promotor Prof. Dr. G.J. Fleuren
Copromotores Dr. A. Gorter
Dr. E.S. Jordanova
Leden promotiecommissie Prof. Dr. S. van der Burg
Prof. Dr. T.D. de Gruijl
Prof. Dr. P. Hwu 
Dr. E. Lubberts
Prof. Dr. J. Morreau
Dr. V.L.J.L. Thijssen
Prof. Dr. J.B.M.Z. Trimbos
With an open mind, 
in combination with the right amount of curiosity,
dreams and the need to explore,
you will find things beyond imagination.
Freddy van der Garde
208970-L-bw-Punt
                                                                                                                                                                                                                                                                                                                                                                               
Table of contents
I General introduction 8
II Role of IL-12p40 in cervical carcinoma 36
British Journal of Cancer, 2012, 107: 1956-62
III Angels and demons: Th17 cells represent a beneficial 54
response, while neutrophil IL-17 is associated with 
poor prognosis in squamous cervical cancer
OncoImmunology, 2015, 4: e984539
IV FoxP3+ and IL-17+ cells are correlated with improved 80
prognosis in cervical adenocarcinoma
Cancer Immunology, Immunotherapy, 2015, 64: 745-53
V Correlations between immune response and 98
vascularization qRT-PCR gene expression clusters 
in squamous cervical cancer
Molecular Cancer, 2015, 14: 71
VI Whole-transcriptome analysis of flow-sorted cervical 120
cancer samples reveals that B cell expressed TCL1A is
correlated with improved survival
Oncotarget, 2015
VII The correlations between IL-17 versus Th17 cells and 144
cancer patient survival: a systematic review
OncoImmunology, 2015, 4: e984547
VIII Conclusion and discussion 180
IX Nederlandse samenvatting 194
List of abbreviations 204




                                                                                                                                                                                                                                                                                                                                                                               
Table of contents
I General introduction 8
II Role of IL-12p40 in cervical carcinoma 36
British Journal of Cancer, 2012, 107: 1956-62
III Angels and demons: Th17 cells represent a beneficial 54
response, while neutrophil IL-17 is associated with 
poor prognosis in squamous cervical cancer
OncoImmunology, 2015, 4: e984539
IV FoxP3+ and IL-17+ cells are correlated with improved 80
prognosis in cervical adenocarcinoma
Cancer Immunology, Immunotherapy, 2015, 64: 745-53
V Correlations between immune response and 98
vascularization qRT-PCR gene expression clusters 
in squamous cervical cancer
Molecular Cancer, 2015, 14: 71
VI Whole-transcriptome analysis of flow-sorted cervical 120
cancer samples reveals that B cell expressed TCL1A is
correlated with improved survival
Oncotarget, 2015
VII The correlations between IL-17 versus Th17 cells and 144
cancer patient survival: a systematic review
OncoImmunology, 2015, 4: e984547
VIII Conclusion and discussion 180
IX Nederlandse samenvatting 194
List of abbreviations 204








1.2 Staging and treatment
2. The immune response to cancer
2.1 The tumor microenvironment
2.2 The innate immune response
2.3 Cytokines and chemokines
2.4 Antigen presentation
2.5 The adaptive immune response
3. The Th17 cell immune response
3.1 Phenotype and function of Th17 cells
3.2 Interleukin-17
3.3 Th17 cells in autoimmunity





The cervix is located in the lower part of the female uterus. Cervical cancer most 
frequently affects women under the age of 50.1 Cervical cancer is the fourth leading 
cause of death by cancer in women worldwide.2 This is mainly attributable to the high 
incidence in developing countries. In developed countries, the incidence and mortality 
of cervical cancer have declined by up to 80% between 1930 and 2010 because of 
widespread screening programs for early detection and prevention.3,4 Although efforts 
are being undertaken to screen women for cervical cancer precursor lesions in a cost-
effective way in developing countries,5 cervical cancer is still the third most common 
cancer type and cause of death by cancer in these countries.2
Screening for cervical cancer using the Papanicolaou cytology test (Pap smear) has been 
introduced in the Netherlands in the 1970s. Cervical cancer is currently the sixth most 
prevalent cancer type in the Netherlands, with 736 new cases in 2012.6 The incidence 
and mortality of cervical cancer in the Netherlands in 2012 were 8.0 new cervical 
cancer cases and 2.1 deaths per 100,000 age adjusted person years. In Europe, 13.4 new 
cervical cancer cases and 4.9 deaths per 100,000 years occurred in the same year.7
1.1 Etiology
Different risk factors for the development of cervical cancer have been identified, 
including high parity, smoking, co-infection with human immunodeficiency virus (HIV) 
or other sexually transmitted infections and long-term oral contraceptive use.8 The only 
absolute requirement for the development of cervical cancer is a persistent infection 
with high-risk human papillomavirus (HPV).9 HPV is a double-stranded DNA virus that 
encodes for seven early (E1-7) and two late (L1-2) proteins. HPV is the most common 
sexually transmitted infection, with about 40 of the 150 known HPV types infecting 
cells at anogenital lesions.8 Low-risk HPV types are associated with the development of 
warts. Fifteen high-risk carcinogenic HPV types can cause precancerous lesions, an 
estimated 65% of which are infected with HPV type 16 or 18.10
The endocervix is covered with simple columnar epithelium, which continues toward 
stratified squamous epithelium covering the ectocervix. Under the influence of 
hormones during puberty or pregnancy, or in response to physical or chemical stress, 
the columnar epithelium is replaced by squamous epithelium at the border between the 
ectocervix and endocervix. This process of metaplasia relocates the epithelium 
transition area from the endocervix to the ectocervix and is termed the transformation 
zone. This area is thought to be vulnerable for transformation toward precancerous 
conditions.11 The abnormal expansion of immature cells in the transformation zone is 
termed dysplasia. This can be caused by HPV infection of the basal cells of the
squamous epithelium at a local site of micro-trauma in the transformation zone. The 
10
virus replicates episomally in these cells and induces cellular proliferation by the 
expression of viral proteins E5-7. Upon replication of the basal cells, these move to 
suprabasal epithelial layers, which induces the expression of the late viral structural 
proteins. This leads to the assembly and release of complete viruses. The expression of 
viral proteins also leads to viral antigen expression on the cellular membrane. 
Recognition by the immune system of these non-self proteins leads to clearance of the 
infected cells in over 80% of infected women.12 So although about 80% of women are 
assumed to be infected by HPV in a lifetime,13 only about 10-20% of HPV infections 
progress to cervical intraepithelial neoplasia (CIN).14 Progression to invasive cancer 
occurs in approximately 38% of untreated precancerous CIN3 lesions.15
Figure 1. Etiology of cervical cancer
The relationship between infection with high-risk HPV, development of precancerous dysplastic lesions and 
progression to invasive cancer. From Meijer et al.16
Upon replication of the basal cell, the viral genome may integrate into the host genome. 
This typically disrupts the expression of viral gene E2.17,18 Since the E2 protein
suppresses the expression of E6 and E7, this leads to E6 and E7 protein overexpression. 
The E6 protein binds and causes degradation of the tumor suppressor proteins p53 and 
Bak.19,20 Additionally, E6 increases the activity of telomerase.21 Viral protein E7 binds 
cyclin related proteins and the tumor suppressor protein family retinoblastoma, leading 
to their degradation.22 This deregulates the cell cycle by removing multiple checkpoints, 
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The three predominant histological subtypes of cervical cancer are squamous cell 
carcinoma, adenosquamous cell carcinoma and adenocarcinoma. Although squamous 
cell carcinoma accounts for about 75% of all cervical cancer, its incidence rate has 
decreased over the past 40 years, while the incidence of cervical adenocarcinoma has 
increased to approximately 20%-25% of cases.23 The prognosis of patients with cervical 
adenocarcinoma may be worse than for patients with squamous cell carcinoma,24-29
although the data on this topic are controversial.30,31
1.2 Staging and treatment
Precancerous dysplasia as well as cervical cancer can be detected by analyzing a Pap 
smear for abnormal cells. If abnormal cells are identified, a biopsy is taken for further 
assessment. Treatment depends on the stage of the (pre)cancerous lesion. CIN1 is a mild 
dysplasia characterized by mitotic activity and nuclear atypia in the lower one third of 
the epithelium. CIN1 regresses in 60% of cases32-34 and only 2% of cases progresses to 
severe dysplasia or invasive cancer in two years.34 Treatment of CIN1 consists of 
follow-up cytology for two years. In case of moderate (CIN2) or severe (CIN3) 
dysplasia, the abnormal cells extend toward the middle and upper third of the 
epithelium, respectively. In the case of CIN2, 16% of cases is expected to progress to a 
higher stage within two years.34 The risk of progression from CIN2 and CIN3 to 
cervical cancer in situ or invasive cancer is 2.5 and 4.2 times higher than for CIN1, 
respectively. CIN2 and CIN3 are usually treated by large loop excision of the 
transformation zone (LLETZ). 
In the case of cervical cancer, cancer cells have invaded the underlying stromal tissue 
through the epithelial basement membrane. Cervical cancer is staged both according to 
the Fédération Internationale de Gynécologie et d’Obstétrique (FIGO) and the tumor 
size, lymph node, distant metastasis (TNM) staging system. The FIGO stage is based on 
clinical examination of tumor size and invasion into the underlying stroma, parametria, 
vagina and pelvic wall and distant metastases at the time of diagnosis. The TNM stage 
also includes metastasis to the lymph nodes and is determined by a pathologist 
postoperatively. Treatment depends on FIGO stage and for early cancer stages (FIGO
stage 1A) usually consists of conization or radical hysterectomy with or without 
lymphadenectomy (Wertheim procedure).1 A larger tumor (stages IB and IIA) can be 
treated with a Wertheim surgery or (concurrent) radiotherapy with or without 
chemotherapy.  Advanced stage cancer (stages IIB to IV) is treated with a combination 
of radio- and chemotherapy. Clinical criteria that influence prognosis are lymphatic 










IA 100% 99% 99% 98% 98%
IB 98% 94% 91% 89% 87%
IIA 95% 84% 80% 76% 76%
IIB 92% 79% 70% 67% 64%
IIIA 71% 56% 52% 48% 38%
IIIB 71% 51% 42% 37% 37%
IVA 47% 32% 24% 22% 21%
IVB 35% 17% 12% 9% 7%
Table 1. Prognosis of cervical cancer stages
Survival rates of cervical cancer patients in the Netherlands, stratified for FIGO stage.1
2. The immune response to cancer
The immune response developed very early in evolution to protect organisms against 
pathogens. At the beginning of this millennium, the immune system was also shown to 
protect the body against cancer formation by a mechanism termed cancer 
immunosurveillance.35 The immunosurveillance hypothesis states that T lymphocytes 
continuously survey the body for tumor cells expressing aberrant proteins. These 
proteins may be pathogen derived proteins, but also host proteins that are altered due to 
the high mutation rate of cancer cells. Although leukocytes had already been observed 
in tumors by Rudolf Virchow in 1863, and immunosurveillance had already been 
predicted to occur by Paul Ehrlich in 1909,36 a century passed before this theory was 
proven. The identification of tumor specific antigens in a variety of tumors transplanted 
in inbred mouse models37 and the protection from cancer development by a functional 
immune response, potentially leading to cancer immune escape,38 have been crucial to 
establish the concept of cancer immunoediting. Immunoediting comprises three phases: 
elimination, equilibrium and tumor escape.39 Highly immunogenic tumors are thought 
to be eliminated by the immune system, as was envisioned in the original 
immunosurveillance hypothesis. The resulting selection pressure may in some cases 
induce a daughter cell variant to arise that can escape from immune recognition and 
form a tumor despite the presence of an immune response. Clinically apparent tumors 
are thus likely to have already adapted to the immune response induced. Tumor immune 
escape has been recognized as one of the ‘hallmarks of cancer’ required for tumor 
development.40 Tumor infiltrating T lymphocytes have been shown to be an 
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In contrast to an acute pro-inflammatory tumor targeting immune response, chronic 
inflammation may rather favor tumor growth. All tumors contain chronic inflammatory 
infiltrate that can promote cancer progression.43 High expression of the inflammatory 
cytokine interleukin-6 (IL-6) has for instance been shown to be an independent 
predictor of poor survival.44-46 Chronic inflammation can increase the risk of oncogenic 
transformation through promoting cell survival and suppressing the adaptive immune 
response.47 The production of radicals by immune cells may furthermore cause DNA 
mutations. The other way around, transformed cells induce tumor promoting 
inflammation by producing cytokines that recruit inflammatory cells.47 Thus, the 
composition of the immune response in cancer determines tumor progression and 
patient prognosis.
2.1 The tumor microenvironment
Besides tumor cells, the tumor microenvironment also comprises blood vessels, 
different host cell types and extracellular matrix (ECM) proteins and glycans. Most
ECM components are synthesized by fibroblasts. The ECM provides a scaffold to 
organize cellular structure and trafficking, but also mediates cytokine signaling to 
regulate cell growth and function.48 The structure and composition of the ECM are 
altered in cancer and both the biochemical and biomechanical properties support cancer 
cell growth.
While some resident immune cells will be present, most immune cells are recruited to 
the tumor via the vasculature. The blood vessels deliver both nutrients and immune cells 
to the tumor tissue, and are critical for tumors to grow beyond a few millimeters in size. 
An inverse correlation between tumor growth promoting vessel formation 
(angiogenesis) and vessel adhesiveness supporting immune cell infiltration (maturation) 
has been reported.49 Angiogenesis is represented by a high number of blood vessels, 
which supports tumor growth and has been correlated with poor survival in cervical 
cancer.50 Vessel maturation is characterized by the expression of signaling and adhesion 
proteins and supports the infiltration of immune cells in the tumor tissue.49,51
2.2 The innate immune response
Both innate and adaptive immune cells are recruited to a tissue in response to danger or 
stress signals. Innate immune cells are cells that respond to common danger signals, for 
instance dead cell fragments or viral double-stranded RNA. The innate immune 
response is well conserved in animals, and plants have a similar defense mechanism 
against pathogenic microorganisms.52 The innate immune cells act directly upon 
triggering of their pattern-recognition receptors (PRRs), for instance Toll-like receptors 
(TLRs) or Nod proteins. Activation involves phagocytosis of pathogens or particles, 
secretion of toxic molecules, but also production of cytokines and chemokines to recruit 
and activate an adaptive immune response. The innate immune response provides the 
14
first line of defense at the natural anatomical barriers (i.e. the skin, digestive tract and
lungs).
Since cell death is a common phenomenon in cancer, innate immune cells regularly 
infiltrate tumor tissue. Despite this infiltration of the different types of innate immune 
cells in tumors, their effect has not been well studied. High frequencies of 
neutrophilic53-55 or eosinophilic56 granulocytes in cancer have been shown to be 
correlated with poor survival. Mast cells have been ascribed both tumor targeting as 
well as tumor promoting effects.57-59 Innate γδ-T and natural killer (NK) cells are 
generally not found in large numbers, but do seem to have favorable tumor growth 
suppressing effects.60-62 Finally, subpopulations of a certain cell type may have different 
impacts. Macrophages can for instance be categorized as classically activated M1 type 
macrophages, which promote a tumor targeting immune response and favorable 
prognosis,63 or alternatively activated M2 type macrophages, which are correlated with 
tumor progression and poor prognosis.64,65 Similarly, inflammation may drive the 
differentiation of neutrophils toward a tumor promoting inflammatory state by a 
combination of TGF-β, IL-10 and prostaglandin E2 (PGE2).66 Alternatively activated 
macrophages and neutrophils express different cytokines, are less capable to activate T 
cells or kill tumor cells and induce more angiogenesis.67 In line with these cell 
subpopulations, myeloid derived suppressor cells (MDSCs) are a heterogeneous and 
difficult to define population of innate immune cells frequently infiltrating tumor tissue. 
Granulocytic MDSCs are functionally and phenotypically similar to neutrophils, 
although neutrophils mainly seem to regulate angiogenesis, tumor invasion and 
metastasis, while MDSCs are predominantly involved in immunosuppression.68
In normal tissue, the immune response ultimately induces a repair process, upon which 
the inflammation resolves. Since tumors can be envisioned as ‘wounds that never 
heal’,69 the immune response results in a chronic inflammation. Both the innate immune 
cells and the tumor cells then produce a variety of chemokines and pro-inflammatory 
cytokines that promote tumor growth, such as IL-1β, IL-6, IL-8 (CXCL8) and tumor 
necrosis factor α (TNFα).70
2.3 Cytokines and chemokines
Cytokines are small (glyco)proteins that are mainly produced by immune cells to 
communicate with other cells.70 Potential effects induced include cell growth, 
differentiation and activation. These key regulatory molecules can be pro- or anti-
inflammatory, and play a dominant role in the correlation between chronic inflammation 
and cancer burden.71 Upon TLR activation, innate immune cells produce cytokines that 
direct the type and magnitude of the adaptive immune response. Cancer cells can 
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similarly produce cytokines to modulate the immune response to favor tumor growth 
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and stimulate angiogenesis.72 Adaptive immune cells also communicate with each other 
and with target cells through cytokines. 
Chemokines are small chemotactic cytokines. Chemotaxis is important to signal specific 
target cells to infiltrate the tissue along a chemokine gradient. Different cell types 
express different chemokine receptors. Not only stromal but also tumor cells express 
chemokines, regulating the type and number of infiltrating immune cells.73
2.4 Antigen presentation
Intracellular as well as extracellular constituents of the cellular environment are 
presented on the cell membrane to the immune system by the human leukocyte antigen 
(HLA) protein family. HLA class I molecules are expressed on all nucleated cells and 
present peptide fragments from intracellular proteins. HLA class II is expressed on 
professional antigen presenting cells and present peptides derived from processed 
material present in the micro-environment, for example peptides derived from 
pathogens or dead cells. Combined with co-stimulatory molecules and cytokines, this 
induces an adaptive immune response and ensures that infected cells expressing 
aberrant non-self peptides are eliminated.74 Through presentation of HPV derived 
peptides by HLA molecules, the immune system usually recognizes and destroys HPV 
infected cells.12 In some cases though, a small number of infected cells may remain 
present despite an immune response. This leads to selection pressure for a daughter cell 
to emerge that can escape from immune recognition and may eventually develop into 
cancer. Different pathways can be involved in immune escape, including suppression of 
the tumor targeting immune response, inhibiting apoptosis induced by immune cells or 
altering HLA expression.75,76 Altered HLA class I expression was detected in 90% of 
cervical cancers.77 Still, the presence and frequencies of different types of immune cells 
influence tumor progression. The HPV related immunogenicity of cervical cancer cells 
is already used to prevent cervical cancer by vaccination.78 However, immunotherapy 
with the aim to treat cervical cancer has so far yielded limited efficacy.79 Investigating 
the local immune response in cervical cancer is thus important to be able to improve the 
outcome of therapeutic immunotherapies, which offer the potential of treating patients 
more specifically and effectively, with less accompanying side effects than the currently 
used radio- and chemotherapies.
2.5 The adaptive immune response
Vertebrates have developed an adaptive immune response. T and B lymphocytes, 
belonging to the adaptive immune system, require stimulation to proliferate and 
differentiate, are highly specific and provide long-lasting memory.80 T cell progenitors 
mature in the thymus by developing a unique T cell receptor (TCR) through a process of 
positive and negative selection. Mature naïve T cells circulate through the body until 
they encounter cells expressing the specific antigen that activates TCR signaling in the 
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context of HLA. T cells require three so-called signals to be activated: (1) the specific 
antigen recognized in the context of HLA presentation mediated through TCR 
triggering, (2) co-stimulatory molecules expressed by antigen presenting cells and (3) 
cytokine modulation of the type of response. This induces T cell proliferation, 
differentiation and migration to the tissue. Activated CD8+ cytotoxic T lymphocytes 
(CTL) are able to directly kill cells that express antigen in the context of HLA class I. A 
high frequency of cytotoxic T cells has been shown to correlate with improved survival 
in different cancer types,81,82 including cervical cancer.83 Activated naïve CD4+ T cells 
may differentiate toward T helper 1 (Th1), Th2, Th17 and regulatory T cells (Tregs). 
Recently, a number of additional T cell subpopulations have been described, like Th9 
and Th22 cells.84 Because of their low frequency and underexplored significance, these 
cell types will not be discussed in this thesis. T helper cells provide help in the 
activation of CTL and B cells and produce a variety of cytokines and chemokines that 
can recruit and activate different cell types.
Figure 2. T helper cell subtypes
Upon encountering specific antigen and costimulatory molecules (e.g. B7, ICOSL), different combinations of 
cytokines induce differentiation of naïve T cells toward different T helper cell subtypes. The role of the 
different subtypes under normal homeostasis as well as in cancer is indicated in the boxes below each T helper 
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Th1 cells are required to facilitate the clearance of pathogen infected cells. In cancer, 
Th1 cells are generally appreciated for their potential to induce or stimulate a tumor 
targeting immune response. An effective tumor targeting immune response is thus 
characterized by IL-2, IL-12 and interferon-γ (IFNγ). T  ce s rotect a ainst 
extracellular pathogens, induce allergic reactions and have been shown to support 
cervical cancer progression,86 but their general role in cancer is not clear. Th17 cells are 
essential to protect against extracellular pathogens, particularly those not handled well 
by a Th1 or Th2 response, and play a dominant role in autoimmune diseases.87,88 Their 
role in cancer is unclear, since they have been shown to both be able to promote as well 
as to counteract tumor growth.89 The characteristics of Th17 cells are discussed in 
paragraph 3. Tregs are essential to suppress an immune response when it is not required, 
for instance to prevent autoimmunity. In cancer, these cells also suppress the activity of 
other T cells, which may dampen either a tumor suppressing or tumor promoting 
immune response. Indeed, Tregs have been found to be correlated with poor survival in 
cervical cancer,83 but also with less invasion in thyroid cancer and improved recurrence-
free survival in head and neck cancer.90,91 Tumor growth supporting Th2/Treg-mediated 
chronic immunosuppressive inflammation is induced by a combination of IL-4, IL-5, 
IL-6, IL-10, IL-13 and transforming gro t  factor β (T F-β).70
B lymphocytes are the other component of the adaptive immune response. Similar to T 
cells, B cells mature by developing a unique B cell receptor (BCR) in the bone marrow. 
The BCR is composed of two identical light and heavy chains, and is identical to an 
antibody when secreted. Upon binding the specifically recognized antigen combined 
with T cell stimulation, the B cell is stimulated to proliferate and undergo BCR 
hypermutation to increase its antigen binding affinity. B cells are typically stimulated by 
Th2 cells, driving a humoral antibody response. B cell clones with the highest binding 
affinity are sufficiently stimulated to grow out, undergo antibody class switching and 
differentiate toward antibody producing plasma cells or memory B cells. Depending on 
the antibody isotype, antibody binding to a target antigen facilitates phagocytosis, 
triggers the complement cascade or induces antibody dependent cell-mediated 
cytotoxicity.
Although it is difficult to assess the role of B cells in immunoediting and the clinical 
response, circulating antibodies directed against p53 have been shown to be correlated 
with increased p53 mutational load and accumulation, tumor progression and poor 
survival.92 This suggests that circulating antibodies may merely be a reflection of 
antigenic stimulation that does not necessarily induce an effective immune response. 
However, a high number of tumor infiltrating B cells has been correlated with improved 
patient survival in different cancer types.93,94 Antibodies have furthermore been shown 
to undergo antigenic selection and affinity maturation in cervical cancer.95
Differentiation toward regulatory B cells may prevent a tumor targeting immune 
response,96 but data on this topic are yet insufficient.
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3. The Th17 cell immune response
Human naïve T cells can be differentiated toward Th17 cells by a combination of IL-1β, 
IL-6 and IL-23, although the exact conditions required are still under debate.97 Despite 
otherwise being pleiotropic in nature, these cytokines also have in common that they are 
generally correlated with poor prognosis in cancer patients. The pro-inflammatory 
cytokine IL-1β, re o inant  ro ce   acro a es, in ces t e e ression of 
other signaling molecules like IL-6 and IL-8 and is correlated with an increased risk of 
developing cancer.98 After initial chemoattraction of neutrophils by IL-8, IL-6 may 
subsequently attract monocytes and T cells.99 Both signaling molecules have been
correlated with poor disease-specific survival in cancer. IL-6 may induce signal 
transducer and activator of transcription 3 (STAT3) expression in tumor cells,100
epithelial-mesenchymal transition and angiogenesis101,102 and differentiation of 
macrophages toward the M2 phenotype, thus supporting tumor growth.103,104 The 
cytokine IL-23 belongs to the IL-12 family of heterodimeric cytokines, but antagonizes 
the functions of IL-1  an  IFNγ. IL-23 also induces angiogenesis and infiltration of 
neutrophils and macrophages.105 IL-23 is furthermore required to maintain a stable Th17 
cell population. Although mouse Th17 cells can be stably induced by the combination 
of IL-6 and TGF-β, t e absolute requirement of TGF-β for T 1  ifferentiation is still 
under debate.97 It seems that IL-1β re ace  T F-β for an T 1  ifferentiation, 
while TGF-β ro a  in irect  fa ors T 1  ifferentiation  in i itin  
differentiation toward Th1 cells.
3.1 Phenotype and function of Th17 cells
Th17 lymphocytes were first described as a unique T helper cell subpopulation in
2000106 and further characterized in 2005.107 These cells were termed Th17 cells 
because of their production of IL-17, which is generally used as a marker to characterize 
Th17 cells.108 Th17 cells are also characterized by the lineage specific transcription 
factors retinoic acid receptor-re ate  or an rece tor γ t ( γt) an  α,109,110
which are induced by IL-6 signaling through STAT3 activation.111 STAT3 induces    
IL-23R expression, while IL-23 signaling stabilizes the Th17 cell phenotype and 
induces IL-22 secretion.88,112,113 IL-23 expression has been associated with tumor 
development.105,114
Th17 cells also produce IL-21, which in an autocrine manner inhibits forkhead box P3 
(FoxP3)115 an  IFNγ116 expression and further supports the Th17 cell phenotype.117 Th1 
or T  ce  in cin  c to ines (IFNγ, IL-4) rather inhibit differentiation toward Th17 
cells.118 The effect of TGF-β as een s o n to e en  on its oca  concentration  i e 
low levels of TGF-β faci itate T 1  ifferentiation, i  T F-β e e s in ce t e 
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transcriptional activity of RORyt, leading to differentiation toward Tregs. IL-6
abrogates this inhibition and induces Th17 differentiation.120 Although TGF-β oes not 
seem to be required for Th17 cell differentiation, Th17 cells generated in the presence 
of TGF-β in vitro have been reported to be less pathogenic in an autoimmune mouse 
model.121 Counteracting this effect, IL-23 suppresses IL-10 expression by Th17 cells.122
Besides inhibiting Th17 cell differentiation, Tregs may also regulate the pathogenicity 
of Th17 cells.123 Finally, through consuming the IL-2 present in the microenvironment, 
Tregs may even promote Th17 differentiation.124
Th17 cells have been described to display a high degree of plasticity and to be able to 
differentiate to Th1 cells in vivo.125 An intermediary phenotype comprising Th17/Th1
cells that co-produce IL-1  an  IFNγ as a so een escri e .116 On the other hand, 
Th17 cells have been shown to potentially originate from Tregs.126-128 CD8+ CTL and 
FoxP3+ Tregs can also express IL-17, although the specific characteristics of these Tc17 
and IL-17+ Treg cells are unclear.129,130
Figure 3. Th17 cell phenotype
Human Th17 cell differentiation is induced by the combination of IL-1β, IL-6 and IL-23. This induces the 
e ression of T T , γt an  ifferent c to ines inc in  IL-17. Th17 cells may derive from naïve 
CD4+ T cells or Tregs, and they may also be stimulated to differentiate toward Th1 cells. Adapted from Ji et 
al.97
20
Th17 cells are thought to provide a first line of defense, particularly against pathogens 
that are not handled well by a Th1 or Th2 response.88 Job’s syndrome or 
hyperimmunoglobulin E syndrome patients, classically characterized by a dominant 
STAT3 mutation and thus inability to produce IL-17 or Th17 cells, suffer from 
recurrent staphylococcal and candidal infections.131,132 A mutation in the IL-17 receptor 
A (IL-17RA) or a mutation causing aberrant IL-17 cytokines predominantly lead to an
inability to clear Candida albicans infections.133
Th17 cells can induce the production of a variety a pro-inflammatory cytokines, as 
described in the next paragraph. IL-2, IL-10 and IL-27 can regulate the Th17 response 
and suppress the production of these pro-inflammatory cytokines.118,123,134 IL-17
production may however be crucial to mount an immune response in the presence of 
pathogen-induced IL-10.135 The effect of IL-2 may have a temporal nature by inhibiting 
early differentiation of Th17 cells, but promoting the expansion of differentiated Th17 
cells.136
3.2 Interleukin-17
The cytokine IL-17 was discovered in 1993 and originally named cytotoxic T 
lymphocyte-associated-8 (CTLA-8).137 IL-17, also known as IL-17A, is a member of 
the IL-17 family. The IL-17 cytokine family also comprises IL-17B through IL-17F.138
IL-17F shows some homology in structure and functions with IL-17A. The other family
members are produced by different cell types and have distinct functions. The IL-17 
cytokines are homodimeric disulfide-linked proteins, although IL-17A and IL-17F also 
form a heterodimeric complex. IL-17 can be produced by Th17 cells, but also by innate
i ne ce  t es inc in  ne tro i s, acro a es, ast ce s, γδT ce s, in ariant 
natural killer T cells and innate lymphoid cells.139-141 It may thus create a bridge 
between the innate and adaptive immune response.142
The affinity of the IL-17RA receptor is high for IL-17A, weaker for IL-17F and 
intermediate for IL-17A/F. The affinities for IL-17B-D are much weaker. Binding of 
IL-17A or IL-17F to IL-17RA induces conformational changes that inhibit the binding 
of another IL-17RA molecule.143 Both IL-17A and IL-17F preferentially subsequently 
engage an IL-17RC molecule. 
IL-17RA signaling activates tumor necrosis factor receptor-associated factor-6 (TRAF-
6) and nuclear factor-  (NF- ) acti ator rotein 1 ( ct1) to acti ate NF- and
mitogen-activated protein kinases.112,115,144 This leads to the production of a variety of 
pro-inflammatory cytokines and chemokines in target cells, including G-CSF, GM-CSF, 
IL-1β, IL-6, IL-8, PGE2, TNFα,  c e o ine i an  20 (CCL20), CXC chemokine 
ligand 1 (CXCL1), CXCL2, CXCL5, CXCL10 and matrix metalloproteinases 
(MMPs).87,112,145-147 Target cells are predominantly epithelial and endothelial cells, 
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intermediate for IL-17A/F. The affinities for IL-17B-D are much weaker. Binding of 
IL-17A or IL-17F to IL-17RA induces conformational changes that inhibit the binding 
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fibroblasts and hematopoietic cells, but practically all cell types express the IL-17 
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receptor. Through inducing IL-8 expression, IL-17 stimulates neutrophil recruitment.148
Besides inducing neutrophil infiltration, IL-17 also enhances the activity of neutrophil 
elastase and myeloperoxidase.112 Another well-known effect of IL-17 signaling is the 
induction of vascular endothelial growth factor (VEGF) production and 
angiogenesis.146,149-152 Finally, IL-17 can induce the formation of epithelial tight 
junctions.153
3.3 Th17 cells in autoimmunity
Th17 cells play a dominant role in a variety of autoimmune diseases, including 
psoriasis, asthma, rheumatoid arthritis (RA), encephalomyelitis, multiple sclerosis 
(MS), systemic lupus erythematosus (SLE), Crohn's disease, type 1 diabetes and 
Sjögren syndrome.87,134 Psoriatic skin lesions as well as the peripheral blood of psoriasis 
patients contain increased Th17 cell frequencies.154 IL-17 has been shown to induce the 
expression of antimicrobial peptides and neutrophil chemoattractants in psoriasis 
patients.155 Th17 cells are increased in asthma patients,156 and the sputum IL-17 
expression level has been found to be correlated with the neutrophil frequency and 
disease severity.157,158 The development of RA has been shown to be correlated with an 
increased circulating Th17 cell frequency and IL-17 level.159 An increased Th17 or IL-
17+ cell frequency has also been observed in active MS lesions,160 SLE disease,161
Behcet’s disease and uveitis.162 The presence of Th17 cells thus represents a poorly 
controlled immune response causing tissue damage in autoimmune diseases. Therapies 
directed at targeting the Th17 cell immune response using antibodies against IL-17 and 
its receptor are already used in clinical trials to treat autoimmune diseases like psoriasis, 
asthma, RA, MS and Crohn’s disease.163,164 This type of therapy might be extended to 
be used as an anti-cancer treatment, if the role of Th17 cells in cancer is further 
elucidated.
3.4 Th17 cells and IL-17 in cancer
A low frequency of circulating Th17 cells is generally present in cancer patients, which 
is usually increased in tumors compared with healthy tissues.165,166 The role of Th17 
cells in cancer is unclear. Both tumor suppressing and tumor promoting functions have 
been described. Tumor growth control has mainly been corre ate  it  IFNγ ro ction 
and a CTL response.85,167 Th17 cells have also been described to display a stem-cell like 
phenotype, with the ability to differentiate to Th1 cells in vivo.125 The tumor targeting 
immune response observed after Th17 cell adoptive transfer may thus partly be due to 
the conversion of Th17 to Th1 cells.112 Th17 cells have a memory phenotype and 
express CC chemokine receptor 4 (CCR4) and CCR6.112,118 The ligand of CCR6 is 
CCL20, which is also expressed by Th17 cells and might thus facilitate their continued 
recruitment.115 Tumor promoting functions are the recruitment of myeloid cells and 
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other functions ascribed to the pro-inflammatory cytokines produced, as described
before.
The role of IL-17 in cancer is also poorly understood. Although IL-17, as described 
efore for T 1  ce s, as een corre ate  it  t e ro ction of IFNγ an  t or 
suppression, the induction of angiogenesis and neutrophil recruitment have been 
correlated with poor survival in cancer patients.53,54,151 IL-17 has also been shown to 
directly induce survival and proliferation of cancer cells in mice,168 and to induce 
human cervical cancer cell lines to secrete pro-inflammatory cytokines and obtain 
increased tumor size when transplanted.169,170 IL-17 signaling has furthermore been 
shown to directly promote tumorigenesis in mouse transformed intestinal epithelial 
cells.171 Since the functions of IL-17 and Th17 cells in cancer are controversial, their 
role in cervical cancer is investigated in this thesis.
4. Thesis outline
The IL-17 cytokine and Th17 cell type have recently been identified. The aim of the 
present thesis was to elucidate the role of the IL-17 and Th17 cell immune response in 
cervical cancer. Different aspects of the IL-17 and Th17 pathway have been 
investigated. In chapter 2 the roles of the cytokines IL-1β, IL-6, IL-23 and IL-12 are
described. While IL-12 stimulates a tumor targeting Th1/CTL response, the IL-12 
family member IL-23 as well as the unrelated cytokines IL-1β an  IL-6 can induce a 
Th17 cell immune response.97 Expression of the cytokine subunits IL12p35, IL12p40
and IL23p19 was analyzed by mRNA in situ hybridization. Protein expression of IL-1β 
and IL-6 was studied by immunohistochemistry. In this study, the correlations between 
cytokine expression levels and patient survival were determined. 
After studying the roles of IL-1β, IL-6 and IL-23 in cervical cancer, we studied the 
frequency and localization of Th17 cells using immunohistochemistry (chapter 3). The 
frequency of the two most important cell types expressing IL-17, granulocytes and Th17 
cells, was also determined in other common cancer types. The correlation between the 
frequency of neutrophils, mast cells and Th17 cells, which expressed IL-17 in the tumor 
microenvironment to varying degrees, and clinical outcome was analyzed in squamous 
cervical cancer. The effect of IL-17 on cervical cancer cell lines was studied in a real-
time cell analysis device to explain part of its function.
Many aspects of the immune response have so far been found to differ in cervical 
adenocarcinoma when compared to cervical squamous cell cancer. To study whether the 
role of IL-17 and Th17 cells was similar in cervical squamous cell cancer and cervical
adenocarcinoma, the correlations between the number of total T cells, Tregs, Th17 cells 
and other IL-17 expressing cells and survival were studied in cervical adenocarcinoma 




receptor. Through inducing IL-8 expression, IL-17 stimulates neutrophil recruitment.148
Besides inducing neutrophil infiltration, IL-17 also enhances the activity of neutrophil 
elastase and myeloperoxidase.112 Another well-known effect of IL-17 signaling is the 
induction of vascular endothelial growth factor (VEGF) production and 
angiogenesis.146,149-152 Finally, IL-17 can induce the formation of epithelial tight 
junctions.153
3.3 Th17 cells in autoimmunity
Th17 cells play a dominant role in a variety of autoimmune diseases, including 
psoriasis, asthma, rheumatoid arthritis (RA), encephalomyelitis, multiple sclerosis 
(MS), systemic lupus erythematosus (SLE), Crohn's disease, type 1 diabetes and 
Sjögren syndrome.87,134 Psoriatic skin lesions as well as the peripheral blood of psoriasis 
patients contain increased Th17 cell frequencies.154 IL-17 has been shown to induce the 
expression of antimicrobial peptides and neutrophil chemoattractants in psoriasis 
patients.155 Th17 cells are increased in asthma patients,156 and the sputum IL-17 
expression level has been found to be correlated with the neutrophil frequency and 
disease severity.157,158 The development of RA has been shown to be correlated with an 
increased circulating Th17 cell frequency and IL-17 level.159 An increased Th17 or IL-
17+ cell frequency has also been observed in active MS lesions,160 SLE disease,161
Behcet’s disease and uveitis.162 The presence of Th17 cells thus represents a poorly 
controlled immune response causing tissue damage in autoimmune diseases. Therapies 
directed at targeting the Th17 cell immune response using antibodies against IL-17 and 
its receptor are already used in clinical trials to treat autoimmune diseases like psoriasis, 
asthma, RA, MS and Crohn’s disease.163,164 This type of therapy might be extended to 
be used as an anti-cancer treatment, if the role of Th17 cells in cancer is further 
elucidated.
3.4 Th17 cells and IL-17 in cancer
A low frequency of circulating Th17 cells is generally present in cancer patients, which 
is usually increased in tumors compared with healthy tissues.165,166 The role of Th17 
cells in cancer is unclear. Both tumor suppressing and tumor promoting functions have 
been described. Tumor growth control has mainly been corre ate  it  IFNγ ro ction 
and a CTL response.85,167 Th17 cells have also been described to display a stem-cell like 
phenotype, with the ability to differentiate to Th1 cells in vivo.125 The tumor targeting 
immune response observed after Th17 cell adoptive transfer may thus partly be due to 
the conversion of Th17 to Th1 cells.112 Th17 cells have a memory phenotype and 
express CC chemokine receptor 4 (CCR4) and CCR6.112,118 The ligand of CCR6 is 
CCL20, which is also expressed by Th17 cells and might thus facilitate their continued 
recruitment.115 Tumor promoting functions are the recruitment of myeloid cells and 
22
other functions ascribed to the pro-inflammatory cytokines produced, as described
before.
The role of IL-17 in cancer is also poorly understood. Although IL-17, as described 
efore for T 1  ce s, as een corre ate  it  t e ro ction of IFNγ an  t or 
suppression, the induction of angiogenesis and neutrophil recruitment have been 
correlated with poor survival in cancer patients.53,54,151 IL-17 has also been shown to 
directly induce survival and proliferation of cancer cells in mice,168 and to induce 
human cervical cancer cell lines to secrete pro-inflammatory cytokines and obtain 
increased tumor size when transplanted.169,170 IL-17 signaling has furthermore been 
shown to directly promote tumorigenesis in mouse transformed intestinal epithelial 
cells.171 Since the functions of IL-17 and Th17 cells in cancer are controversial, their 
role in cervical cancer is investigated in this thesis.
4. Thesis outline
The IL-17 cytokine and Th17 cell type have recently been identified. The aim of the 
present thesis was to elucidate the role of the IL-17 and Th17 cell immune response in 
cervical cancer. Different aspects of the IL-17 and Th17 pathway have been 
investigated. In chapter 2 the roles of the cytokines IL-1β, IL-6, IL-23 and IL-12 are
described. While IL-12 stimulates a tumor targeting Th1/CTL response, the IL-12 
family member IL-23 as well as the unrelated cytokines IL-1β an  IL-6 can induce a 
Th17 cell immune response.97 Expression of the cytokine subunits IL12p35, IL12p40
and IL23p19 was analyzed by mRNA in situ hybridization. Protein expression of IL-1β 
and IL-6 was studied by immunohistochemistry. In this study, the correlations between 
cytokine expression levels and patient survival were determined. 
After studying the roles of IL-1β, IL-6 and IL-23 in cervical cancer, we studied the 
frequency and localization of Th17 cells using immunohistochemistry (chapter 3). The 
frequency of the two most important cell types expressing IL-17, granulocytes and Th17 
cells, was also determined in other common cancer types. The correlation between the 
frequency of neutrophils, mast cells and Th17 cells, which expressed IL-17 in the tumor 
microenvironment to varying degrees, and clinical outcome was analyzed in squamous 
cervical cancer. The effect of IL-17 on cervical cancer cell lines was studied in a real-
time cell analysis device to explain part of its function.
Many aspects of the immune response have so far been found to differ in cervical 
adenocarcinoma when compared to cervical squamous cell cancer. To study whether the 
role of IL-17 and Th17 cells was similar in cervical squamous cell cancer and cervical
adenocarcinoma, the correlations between the number of total T cells, Tregs, Th17 cells 
and other IL-17 expressing cells and survival were studied in cervical adenocarcinoma 
in chapter 4. 
23
208970-L-bw-Punt
The tumor microenvironment comprises a complex network of immune response and 
vascularization factors. The correlations between different immune cell pathways 
including IL-17/Th17 cells, vessel formation pathways and clinical outcome were
studied in chapter 5. The inverse correlation suggested to exist between the formation 
of new vessels, termed angiogenesis, and vessel adhesiveness or maturation, was also 
studied. The expression levels of markers characterizing the different pathways were
determined by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) 
analysis. 
Distinguishing between tumor and immune cell processes is often hampered by the 
mixed cellular composition of the tumor. To identify novel biomarkers for patient 
survival specifically derived from tumor epithelial cells versus infiltrating immune cells, 
we performed whole transcriptome analysis on both the tumor cells and the immune 
cells in chapter 6. Fluorescence-activated cell sorting of cervical cancer cell
suspensions was used to separate the tumor infiltrating immune cells from the tumor 
epithelial cells. Total mRNA was sequenced and genes that were significantly 
differentially expressed in either the tumor cells or the immune cells based on clinical 
outcome were analyzed. Additionally, we studied the differential expression based on 
the presence of a Th17 cell immune response, which is described in the discussion of 
this thesis (chapter 8).
A small number of studies have investigated the correlation between IL-17 or Th17 
cells and cancer patient survival to date. A systematic search of the literature was 
performed to study this correlation (chapter 7). We hypothesized that IL-17 is 
correlated with poor survival and Th17 cells are correlated with improved survival in 
cancer patients. 
The results described in chapters 2 to 7 and the implications of our findings for future 
research are discussed in chapter 8.
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Previously, we have shown that low IL12p40 mRNA expression by cervical cancer cells 
is associated with poor survival of cervical cancer patients. As IL-12p40 is both a 
subcomponent of IL-12 and IL-23, the aim of this study was to elucidate the role of    
IL-12p40 in cervical cancer. We have measured the expression of IL23p19, IL12p35
and IL12p40 mRNA using mRNA in situ hybridization. As IL-23 is a component of the 
IL-17/IL-23 pathway, a pathway induced by IL-6 in humans, we have studied IL-1β an  
IL-6 expression. IL-1β an  IL-6 were measured by immunohistochemistry. Only a high 
number of stromal IL-6+ cells was correlated with poor disease-specific survival. The 
worst disease-specific survival was associated with a subgroup of patients that displayed 
a high number of IL-6+ cells and low IL12p40 expression (p<0.001). Both a high 
number of IL-6+ cells and a high number of IL-6+ cells plus low IL12p40 expression 
were shown to be clinico-pathological parameters independent of lymph node 
metastasis, parametrial involvement and Sedlis score (p=0.009 and p=0.007, 
respectively). These results are in accordance with the hypothesis that the IL-17/IL-23
pathway has a tumor promoting role in cervical cancer.
Introduction
Cervical cancer is a leading cause of morbidity and mortality among women worldwide, 
especially in the developing countries.1,2 Infection with oncogenic types of human 
papillomavirus (HPV) is an important factor in the development of cervical cancer.3,4
The persistent HPV infection induces an inflammatory response. Inflammation is an 
important component in the majority of tumor types. The outcome of this inflammatory 
response surrounding the cancer cells is dependent on the composition of the 
inflammatory infiltrate and locally produced signaling molecules.5 Although 
inflammatory cells within the neoplastic lesion are capable of generating an anti-tumor 
response this does not efficiently occur.6,7
Inflammatory cells are attracted to the tumor site by locally produced cytokines and 
chemokines.8,9 Cervical cancer cells are known to produce an extensive range of 
cytokines and chemokines, such as CCL2, GM- F, TNFα an  IL-12.10-12 In addition 
to attracting inflammatory cells, these cytokines and chemokines influence the 
activation status and function of infiltrating antigen presenting cells and stromal cells, 
thus influencing the course of the disease.9,13
In a previous study, we have shown that high expression levels or undetectable levels of 
IL12p40 mRNA in cervical carcinoma are associated with improved overall survival, as 
compared to low IL12p40 levels that were associated with poor survival.14 As IL-12 is 
known to stimulate effector cell populations such as cytotoxic T cells and natural killer 
cells,15,16 our results suggest a dual role for IL-12p40.
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The IL-12 cytokine family includes IL-12, IL-23, IL-27 and IL-35.17 From this family 
IL-12 and IL-23 share the IL-12p40 subchain. IL-12 is composed of IL-12p40 and IL-
12p35, whereas IL-23 is composed of IL-12p40 and IL-23p19. IL-23 plays, amongst 
others, an important a role in the IL-17/IL-23 pathway resulting in the maintenance and 
expansion of Th17 cells.18 In addition to IL-23, IL-1β an  IL-6 are thought to play an 
important role in the induction of Th17 cells in humans.19 The effect of IL-23 on cancer 
progression or cancer eradication is still not clear.20,21
To further delineate the role of IL-12p40 in cervical carcinoma, we have quantified the 
mRNA expression levels of IL23p19 and compared its expression level with IL12p35 
and IL12p40 to investigate the relative importance of IL-12 and IL-23 in the tumor 
microenvironment. In addition, we have investigated the roles of IL-1β an  IL-6 in the 
tumor microenvironment by determining the number of IL-1β+ and IL-6+ cells. Finally, 
we have assessed the correlations between IL23p19, IL12p35, IL12p40, IL-12 and IL-23




Between 1985 and 1995, 254 untreated patients suffering from primary cervical 
carcinoma with stage IB and IIA underwent a radical hysterectomy type III with 
lymphadenectomy. From the tissue obtained, based on the availability of the material, 
90 tissue samples were accessible for research. Tissues were routinely embedded in 
paraffin after 10% formalin fixation. The tissue samples of each patient were examined 
by a pathologist for the presence of tumor. Tumor percentage varied between 20% and 
90%, median 60%. The characteristics of the patients are depicted in Table 1. Forty-
seven patients received postoperative radiotherapy because of either tumor positive 
lymph nodes or the presence of positive risk factors described by the Sedlis criteria22 (a 
combination of two of the following unfavorable prognostic parameters: depth of 
infi tration  1  ( ee  stro a  in asion  i e or ee  t ir ), t or si e    
and presence of vasoinvasion). Human tissue samples were used according to the 
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Table 1. Patient and tumor clinico-pathological characteristics
Clinico-pathological parameter Category N
Age 45 (mean) 90
29 – 76 (range)
FIGO stage1 IB 68
IIA 21
Lymph node metastasis No 66
Yes 22
Tumor size1 < 40 mm 37
  26
Depth of infiltration1 < 15 mm 58
 1  26
Vascular space involvement1 No 39
Yes 47
Sedlis criteria2 Positive 28
Negative 52
Parametrial invasion1 No 74
Yes 14






1Data were not available for all patients. 2Sedlis criteria (Sedlis et al, 1999): a combination of two of the 
following unfavorable prognostic parameters: e t  of infi tration  1   ( ee  stro a  in asion  i e or 
ee  t ir ), t or si e    an  resence of vasoinvasion. 3Only data for cervical carcinoma samples 
with a determined HPV type were included. HPV subtypes other than 16 and 18 included: HPV31 (n=2), 
HPV33 (n=6), HPV35 (n=1), HPV45 (n=3), HPV58 (n=1), HPV59 (n=2), HPV68 (n=1). Abbreviations: 
FIGO=Fédération Internationale de Gynécologie et d’Obstétrique
Preparation of IL12p35, IL12p40 and IL23p19 probes
RNA was isolated from frozen human spleen using TRIzol® (Invitrogen, Breda, The 
Netherlands) and first-strand cDNA was synthesized with oligoDT primers and Reverse 
Transcriptase AMV (both Roche Diagnostics GmbH, Mannheim, Germany), both 
according to manufacturer's instructions. Oligonucleotide primers for IL23p19, IL12p35
40
and IL12p40 were chosen on the basis of known sequences (see Table 2) and cDNA 
encoding for the different cytokines was amplified. A pGEM-3Zf(+) Vector (Promega, 
Madison, WI) was linearized with SmaI and the PCR products were cloned into the 
vector. After transferring the vector to E. coli strain Top 10 (Invitrogen Corp., San
Diego, CA), the plasmids were isolated by using the QIAfilter Maxi KITS protocol 
(QIAGEN GmbH, Hilden, Germany). The sequence of the PCR product was confirmed 
by DNA sequencing. Plasmids were linearized with BamH1 and EcoR1 (both 
Boehringer, Mannheim, Germany) in case of IL12p40, BamH1 and SacI in case of 
IL12p35 and SacII, SalI and SpeI (Boehringer, Mannheim, Germany) in case of 
IL23p19 using One-Phor-All Buffer Plus (Amersham Biosciences, Roosendaal, The 
Netherlands). Both strands were translated in a digoxigenin (DIG) labeled RNA probe 
according to manufacturer’s instructions (Roche Diagnostics GmbH, Mannheim, 
Germany). The concentration of the DIG-labeled sense and antisense RNA probes were 
determined on a 1% agarose gel stained with ethidium bromide (Sigma, St. Louis, MO). 
Probes were stored at -20°C until further use.
Table 2. RNA probes used and RNA in situ hybridization conditions




Accession nr Position Hybr. temp. 
(ºC)
IL23p19 Fw AGAGCCAGCCAGATTTGAGA 487 NM_016584.2 134-620 55
Rev GCAGATTCCAAGCCTCAGTC
IL12p35 Fw TGCTCCAGAAGGCCAGACAAAC 465 XM_003121 320-784 42
Rev CCCGAATTCTGAAAGCATGAAG
IL12p40 Fw GGACCAGAGCAGTGAGGTCTT 373 XM_004011 189-561 42
Rev CTCCTTGTTGTCCCCTCTGA
Abbreviations: Fw=forward; Rev=reverse Hybr. temp.=hybridization temperature
RNA in situ hybridization
RNA in situ hybridization (RISH) was performed as previously described.23,24 In short,
  t ic  araffin sections ere re-treated and hybridized with 100 ng/ml DIG 
labeled RNA probe diluted in hybridization mixture containing NaCl and saline-sodium 
citrate (SSC; Table 2). Hybridization was allowed for 16 hrs at either 55°C (IL23p19) or 
42°C (IL12p35 and IL12p40), in a humidified chamber. Slides were washed in 2x SSC
for 30 min fo o e   .1   it    β-mercaptoethanol for 45 min (Merck, 
Darmstadt, Germany), both at used hybridization temperature (see Table 2). 
Subsequently the slides were incubated with 2 U/ml ribonuclease (RNase) T1 (Roche 
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RNA hybrids were detected using subsequently mouse anti-digoxigenin (1:2000, 
Sigma-Aldrich Chemie GmbH, Steinham, Germany), rabbit anti-mouse Ig (1:50, 
DAKO, Glostrup, Denmark) and mouse alkaline phosphatase anti-alkaline phosphatase 
(APAAP, DAKO, Glostrup, Denmark).10
Immunohistochemistry
Serial sections of formalin-fixed and paraffin-embedded tissue,   t ic , were 
mounted on aminopropylethoxysilane-coated slides. Sections were deparaffinized, 
rehydrated and treated with 0.3% H2O2 in methanol for 20 min to block endogenous 
peroxidase activity. 
Antigen retrieval was performed (0.01 M citrate, pH 6.0) and sections were rinsed in 
phosphate-buffered saline (PBS). Subsequently, sections were stained overnight using 
either a 1:100 dilution of an affinity-purified polyclonal goat anti-human IL-1β anti o  
(AF-201-NA; R&D Systems, Minneapolis, MN, USA) or a 1:300 dilution of anti-
human polyclonal rabbit anti-IL-6 antibody (Abcam, Cambridge, UK). For anti-IL-1β, 
the slides were incubated with a goat HRP-polymer kit (Biocare Medical, Concord, CA, 
USA) according to the manufacturer’s instructions. For anti-IL-6, the slides were 
incubated with a biotinylated swine anti-rabbit antibody (1:200; DAKO, Glostrup, 
Denmark) and subsequently with a biotinylated horseradish peroxidase-streptavidin 
complex (1:100, DAKO). Immune complexes were visualized with diaminobenzidine as 
previously described.24
Evaluation of RISH and immunohistochemistry
RISH was scored as previously described.25 Intensity was scored as none (0), mild (1), 
moderate (2) or intense (3) at low magnification (100x). Furthermore, the percentage of 
positive tumor cells was determined and divided in six groups: 0% (0, absent), 1-5% (1, 
sporadic), 6-25% (2, local), 26-50% (3, occasional), 51-75% (4, majority) and 76-100% 
(5, large majority). The sum of both the percentage and the staining intensity of the 
positive cells resulted in an overall score (0 or 2 to 8). The scores were combined into 
three groups: category 0 (score 0, no expression), category 1 (scores 2, 3, 4 and 5, low 
expression) and category 2 (scores 6, 7 and 8, high expression). mRNA expression was 
scored by two independent researchers without knowing the identity and clinical 
outcome of patients. IL-1β+ and IL-6+ cells were quantified in the tumor by counting the 
number of stained cells per 6, randomly selected, high-power fields of view (HPF, 
400x). 
Statistical analysis
Data from immunohistochemistry as well as RISH are given as the mean + the standard 
deviation. Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL). 
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Data were processed using the Chi-square test. Kaplan-Meier survival curves were 
generated to assess differences in disease-free period (defined as the observation time in 
months from surgery to relapse of the disease (disease-free survival)) or cumulative 
disease-specific survival (defined as time in months from surgery to death due to 
cervical cancer). A Cox regression was used for multivariate survival analysis. P values 
below 0.05 were considered statistically significant.
Results
Patients
Of the group of 90 patients, 68 patients were diagnosed with FIGO stage IB and 21 with
FIGO stage IIA and all underwent a radical hysterectomy combined with pelvic lymph 
adenectomy (Table 1). Fortyseven patients received postoperative radiotherapy because 
of either tumor positive lymph nodes or meeting the terms of the Sedlis criteria22 (a 
combination of two of the following unfavorable prognostic parameters: depth of 
infi tration  1  , t or si e    an  resence of vasoinvasion). Twentyfive 
patients suffered from recurrent disease. At the end of the study 70 patients were alive, 
7 suffered from a recurrence and 18 patients had died of disease.
Expression of IL23p19, IL12p35 and IL12p40 in cervical cancer
As IL-12p40 is a subunit of both IL-12 and IL-23, we have determined the expression
pattern of IL23p19. Both IL23p19 and IL12p40 were expressed by cervical cancer cells 
(Figure 1A, C). The expression of IL12p40 was stronger than the expression of 
IL23p19. IL23p19 was expressed in 63% of the samples (n=54), IL12p40 was expressed 
in 54% of the samples (n=90) and IL12p35 was expressed in 84% of the samples (n=90; 
Table 3). All samples that expressed either IL23p19 or IL12p40 also expressed IL12p35. 
In contrast, 13 out of 44 samples that expressed IL12p40 did not express IL23p19.
A slightly positive correlation between IL23p19 and IL12p40 was found (n=54, r2 =
0.117, p=0.011; data not shown). No statistically significant correlation between
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generated to assess differences in disease-free period (defined as the observation time in 
months from surgery to relapse of the disease (disease-free survival)) or cumulative 
disease-specific survival (defined as time in months from surgery to death due to 
cervical cancer). A Cox regression was used for multivariate survival analysis. P values 
below 0.05 were considered statistically significant.
Results
Patients
Of the group of 90 patients, 68 patients were diagnosed with FIGO stage IB and 21 with
FIGO stage IIA and all underwent a radical hysterectomy combined with pelvic lymph 
adenectomy (Table 1). Fortyseven patients received postoperative radiotherapy because 
of either tumor positive lymph nodes or meeting the terms of the Sedlis criteria22 (a 
combination of two of the following unfavorable prognostic parameters: depth of 
infi tration  1  , t or si e    an  resence of vasoinvasion). Twentyfive 
patients suffered from recurrent disease. At the end of the study 70 patients were alive, 
7 suffered from a recurrence and 18 patients had died of disease.
Expression of IL23p19, IL12p35 and IL12p40 in cervical cancer
As IL-12p40 is a subunit of both IL-12 and IL-23, we have determined the expression
pattern of IL23p19. Both IL23p19 and IL12p40 were expressed by cervical cancer cells 
(Figure 1A, C). The expression of IL12p40 was stronger than the expression of 
IL23p19. IL23p19 was expressed in 63% of the samples (n=54), IL12p40 was expressed 
in 54% of the samples (n=90) and IL12p35 was expressed in 84% of the samples (n=90; 
Table 3). All samples that expressed either IL23p19 or IL12p40 also expressed IL12p35. 
In contrast, 13 out of 44 samples that expressed IL12p40 did not express IL23p19.
A slightly positive correlation between IL23p19 and IL12p40 was found (n=54, r2 =
0.117, p=0.011; data not shown). No statistically significant correlation between
IL23p19 and IL12p35 was found (n=54, r2 = 0.061, p=0.072; data not shown).
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Figure 1. The expression of IL23p19, IL12p40 and IL-6
Representative images of a cervical tumor expressing IL23p19 (A) and IL12p40 (C) determined using RISH 
(x250 magnification). Tumor cells stained positive (moderate) for IL23p19 and positive (strong) for IL12p40.
The negative (sense) controls of IL23p19 and IL12p40 RISH are shown in figures B and D, respectively. A 
representative image of cervical tumor expressing IL-6 determined by immunohistochemistry is shown in E. 
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epithelial compartment with low (IL-6 EC low) and high IL-6 (IL-6 EC high) expression and disease-specific 
survival is shown in F. Bars correspond to 50 mm in A–E and to 10 mm in the inset of E.
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p value     0.619 
The scores were combined into three groups: absent expression, low expression and high expression as 
described in the Materials and Methods. Statistically significant p values are shown in bold. 
Association between IL-12 and IL-23 and disease-specific 
survival in cervical cancer 
To investigate the relationship between the expression of IL23p19, IL12p35 and 
IL12p40 and disease-specific survival, Kaplan Meier plots were created. A log rank test 
was used to determine statistical differences in disease-specific survival. As the absence 
of IL12p40 will result in neither IL-12 nor IL-23, we first confirmed that low expression 
of IL12p40 was correlated with poor disease-specific survival (Figure 2A; n=48, log 
rank test 5.753, p=0.017) in this cohort. The expression of IL12p35 (Figure 2B; n=74, 
log rank test 0.2019, p=0.653) and the expression of IL23p19 (Figure 2C; n=33, log 
rank test 1.930, p=0.165) were both not significantly correlated with disease-specific 
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survival. The expression of IL23p19, IL12p35 or IL12p40 showed no significant 
difference in disease-free survival (data not shown).
Figure 2. Correlation between IL-12 and IL-23 cytokine subunits and survival
The correlation between IL12p40 (A), IL12p35 (B) and IL23p19 (C) expression and disease-specific survival 
in cervical cancer.
Presence of IL-6+ cells and association with disease-specific 
survival in cervical cancer
The presence of IL23p19 suggests that IL-23 may sustain a Th17 cell population in 
cervical cancer. As differentiation toward the IL-17/IL-23 pathway is thought to occur 
in the presence of IL-1β an  IL-6 in humans,19 we have determined the presence of    
IL-1β+ and IL-6+ cells using immunohistochemistry. IL-1β as re o inant  
expressed by cells in the stromal compartment. Occasionally, tumor cells also showed 
weak IL-1β e ression. No statistica  si nificant association et een a low or high 
number of IL-1β-expressing cells and disease-specific survival was observed (Figure 
3A). IL-6 was expressed by both cells in the epithelial (tumor cell) compartment as well 
as cells in the stromal compartment (Figure 1E). No significant association was 
observed between a low or high number of IL-6+ cells in the epithelial compartment and 
disease-specific survival (Figure 1F). Subsequently, we quantified the number of IL-6+
cells in the stroma. The presence of a high number of stromal IL-6+ cells (median 17 
IL-6+ cells/HPF) was significantly correlated with disease-specific survival (Figure 3B; 
n=83, log rank test 12.57, p<0.001). No statistically significant difference was observed 
for disease-free survival (data not shown). We also determined whether the presence of 
both a high number of stromal IL-6+ cells and low IL12p40 expression was correlated
with disease-specific survival. In this latter case an even stronger decrease in disease-
specific survival was observed (Figure 3C; n=47, log rank test 20.38, p<0.001).
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Figure 3. Correlations between IL-1β and IL-6 and survival
The correlation between a high number of IL-1β+ cells (A), stromal IL-6+ stromal cells (B) and IL12p40
expression in combination with a high number of stromal IL-6+ cells (C) and disease-specific survival.
Association between low IL12p40 expression, high number of 
stromal IL-6+ cells and clinico-pathological parameters
To determine the relevance of our findings, we studied the correlations between our 
immunological findings and clinico-pathological parameters. First a univariate Cox
analysis was performed, using the clinical parameters Sedlis criteria (two out of three of 
the following criteria positive  t or si e   , asoin asion an  ee  stro a  
invasion), lymph node metastasis and parametrial involvement and the immunological 
parameters low IL12p40 expression, a high number of IL-6+ cells and a high number of 
IL-6+ cells plus low IL12p40 expression. In the univariate Cox analyses, all the included 
parameters showed a significantly increased hazard ratio (HR; Table 4). Subsequently, a 
multivariate Cox analysis with the three clinico-pathological parameters and each of the 
statistically significant immunological parameters was performed. In this case two of 
the three immunological parameters were shown to be independent predictors of poor 
disease-specific survival: a high number of stromal IL-6+ cells (HR 7.447, p=0.009) and 
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Table 4. Cox regression of clinico-pathological variables and IL12p40 and the number of 
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The hazard ratios and p values of compared expression levels are shown. Statistically significant p values are 
shown in bold.
Discussion
In a previous study, we found an association between low expression of IL12p40 and 
poor disease-specific survival, whereas high expression of IL12p40 or lack of 
expression of IL12p40 were associated with a favorable disease-specific survival.14 As 
IL-12p40 combines with both IL-12p35 and IL-23p19, to form IL-12 and IL-23, 
respectively, in the present study, we have further investigated the role of IL-12p40 in 
cervical cancer.
Both IL23p19 and IL12p35 were expressed in the majority of the samples. Of the 44 
samples that expressed IL12p40, 13 samples did not express IL23p19. As IL12p35
expression seems to be ubiquitous in cervical cancer,14 the level of IL12p40 or IL23p19 
expression most probably determines whether IL-12, IL-23 or both are expressed. In our 
study, we observed a trend between IL23p19 and IL12p35 expression, whereas in the 
study of Wolf et al. in ovarian cancer (n=112), a significant correlation between the 
expression of IL23p19 and IL12p35 was found.26 The discrepancy between our results 
and the results of Wolf et al. may be due to the smaller size of our study group. Very 
few studies have investigated the association between local expression of IL-12 or IL-23 
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and prognosis. Using immmunohistochemistry, IL-12 has been associated with 
improved survival in patients with (advanced) gastric carcinoma.27,28 In the study of 
Wolf et al., using RT PCR, both IL12p35 and IL23p19 were associated with a superior 
outcome.26 In a multivariate analysis, IL12p35 was found to be an independent factor 
for overall survival of ovarian carcinoma. As stated previously, we have observed a 
statistically significant correlation between low expression of IL12p40 and poor 
disease-specific survival in cervical carcinoma.14 In the present study and our previous 
study,14 we did not find a significant correlation between either IL23p19 or IL12p35
expression and disease-specific survival. As IL23p19 and IL12p35 are both expressed, it 
is important to determine which cytokine, IL-23 or IL-12, has a dominant effect on the 
tumor microenvironment. 
The molecular interaction between IL-23p19 and IL-12p40 has been studied by Beyer et 
al.29 These authors reported that the interface region of IL-23p19 and IL-12p35 on      
IL-12p40 overlap. Due to different interresidue interactions of IL-12p35 and IL-23p19 
with IL-12p40, these molecules interact with a different affinity with IL-12p40. 
Therefore, the availability of IL-12p40 in combination with the affinity for IL-12p35 
and IL-23-p19 may result in skewing of the IL12/IL23 response. This is supported by 
experiments performed by Zwiers et al. These authors showed that in an experimental 
animal model, polymorphic variants of IL-12p40 can skew IL-12/IL-23 synthesis.30
Thus, both differences in protein interactions between IL-23p19 and IL-12p35 on the 
one hand and IL-12p40 on the other hand and genetic polymorphisms in the protein 
chains, such as IL-12p40, contribute to the amounts of IL-12 and IL-23 formed.  Our 
results support a previously suggested immunosuppressive role for IL-23.20 This is 
further supported by a study in ovarian carcinoma were genetic differences in the IL-23
receptor have been reported to influence prognosis.31
In contrast, it has also been shown that overexpression of IL-23 reduces tumor growth 
and metastasis formation and that IL-23 is able to elicit a strong cytotoxic T-cell 
memory response,21,32 underscoring our view that the level of expression of the different 
cytokines and chemokines plays an import role in the final outcome. 
Our data suggest that in the presence of a limited amount of IL12p40, the biological 
effect of IL-23 dominate, whereas in the presence of a high amount of IL12p40, the 
biological effect of IL-12 prevails. As IL-12 polarizes the immune response toward an 
anti-viral response,33 the favorable cumulative overall survival of patients with a high 
IL-12+ cell density,27,28 high expression level of IL12p3526 and IL12p4014 can be 
explained by the capacity of this cytokine to increase the lytic activity and the 
production of interferon-γ of nat ra  i er ce s an  c totoxic T-lymphocytes.33
Interestingly, we previously observed an association between high expression of 
IL12p40 and high expression of TGF-β (p=0.024),14 suggesting that the tumor cells are 
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In humans, in addition to TGF-β, IL-1β an  IL-6 have been implicated to play a role in 
the IL-17/IL-23 pathway.19,34 Previously, we have shown that it is likely that activated 
TGF-β is resent in t e t or icroen iron ent, as I-1 expression, a target gene of 
TGF-β,  is corre ate  it  s r i a .35 Further ore, ot  t e inte rin a β  an  acti e 
matrix metalloproteinase-2, known to activate TGF-β, are associate  it  oor isease-
specific survival.36,37 Even though the role of TGF-β in in cin  T 1  in ans as
been questioned, TGF-β a  s ress T 1 an  T  e e o ent t s fa orin  T 1  
development.38,39
In our study, low or high numbers of IL-1β-positive cells were not correlated with 
disease-specific survival. The presence of a high number of stromal IL-6+ cells was 
significantly associated with poor disease-specific survival. Previously, IL-6 has been 
implicated as an autocrine or paracrine growth factor for cervical cancer.40,41 IL-6 has 
been shown to induce VEGF transcription via the STAT3 signaling pathway, thus 
promoting an angiogenic switch.42 Indeed, blockade of the IL-6 receptor on cervical 
cancer cell lines was shown to interfere with cell survival signals and blocked 
expression of VEGF.43
As HPV vaccines will become available for the treatment of metastasized cervical 
carcinoma, the local cytokine/chemokine profile may be important to discriminate 
patients with a beneficial immune response from non-responding patients.   
In conclusion, IL-12p40 plays at least a dual role in cervical carcinoma by associating 
with both IL-23p19 and IL-12p35. We have shown that low IL12p40 expression was 
significantly correlated with poor disease-specific survival. Also, a high number of 
stromal IL-6+ cells was shown to associate with poor disease-specific survival. The 
worst disease-specific survival was observed in a subgroup of patients that displayed a 
high number of stromal IL-6 expressing cells and low IL12p40 expression. Furthermore, 
both a high number of stromal IL-6 expressing cells and a high number of stromal IL-6
plus low IL12p40 expression were shown to be independent clinico-pathological 
parameters as compared to lymph node metastasis, parametrial involvement and Sedlis 
score. Our results support the hypothesis that IL-23 plays a tumor promoting role in 
cervical cancer. 
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Angels and demons: Th17 cells 
represent a beneficial response, 
while neutrophil IL-17 is associated 













The role of IL-17 in cancer remains controversial. In view of the growing interest in the 
targeting of IL-17, knowing its cellular sources and clinical implications is crucial. In 
the present study, we unraveled the phenotype of IL-17 expressing cells in cervical 
cancer using immunohistochemical double and immunofluorescent triple stainings. In 
the tumor stroma, IL-17 was found to be predominantly expressed by neutrophils 
(66%), mast cells (23%) and innate lymphoid cells (8%). Remarkably, Th17 cells were 
a minor IL-17 expressing population (4%). A similar distribution was observed in the 
tumor epithelium. The Th17 and granulocyte fractions were confirmed in head and
neck, ovarian, endometrial, prostate, breast, lung and colon carcinoma. An above 
median number of total IL-17 expressing cells was an independent prognostic factor for 
poor survival in early stage cervical cancer (p=0.016). While a high number of 
neutrophils showed a trend toward poor survival, the lowest quartile of mast cells 
correlated with poor disease-specific survival (p=0.011). IL-17 expressing cells and 
neutrophils were also correlated with the absence of vaso-invasion (p<0.01). IL-17 was 
found to increase cell growth or tightness of cervical cancer cell lines, which may be a 
mechanism for tumorigenesis in early stage disease. These data suggest that IL-17, 
primarily expressed by neutrophils, predominantly promotes tumor growth, correlated 
with poor prognosis in early stage disease. Strikingly, a high number of Th17 cells was 
an independent prognostic factor for improved disease-specific survival (p=0.026), 
suggesting that Th17 cells are part of a tumor suppressing immune response.
Introduction
Cervical cancer is the second leading cause of death by cancer in young women.1
Virtually all cervical cancers are initiated by infection with high risk human papilloma 
virus (HPV).2 The persistent HPV infection induces an inflammatory response, which is 
thought to contribute to tumor growth and progression, rather than to induce an effective 
immune response.3 This is partly caused by tumor cells regulating the immune response 
by downregulating Human Leukocyte Antigen (HLA) expression, producing 
immunosuppressive cytokines, such as interleukin (IL)-10 and transforming growth 
factor β (T F-β)4-6 and attracting regulatory T cells (Tregs) and myeloid derived 
suppressor cells (MDSCs). Locally produced inflammatory cytokines, chemokines and 
angiogenic factors also often favor tumor growth and metastasis.7
Previously, we have shown that the presence of IL-6 in the tumor microenvironment, 
especially in combination with a low level of IL-12p40 expressed by tumor cells, 
probably indicative of the presence of IL-23, is associated with poor disease-specific 
survival in cervical carcinoma patients.8 Since IL-6 and IL-23 are both involved in the 
IL-23/IL-17 pathway, in the present study we aimed to elucidate the role of IL-17 in 
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cervical cancer. The function of IL-17 is tissue and context dependent and includes 
activation of nuclear factor-  (NF- ),9 vascular endothelial growth factor (VEGF) 
production and angiogenesis,10-14 stimulation of pro-inflammatory cytokine 
production,15 neutrophil recruitment16 and formation of epithelial tight junctions.17
While it is clear that IL-17 plays a prominent role in both the protection of the host from 
invading extracellular pathogens and the destruction of host tissues in several chronic 
inflammatory and auto-immune disorders, there is controversy about its role in cancer.18
Different studies have shown that IL-17 can favor or counteract tumor growth, 
depending on tumor type and the balance of other factors in the microenvironment.19,20
Although IL-17 is regarded as the key cytokine of T helper 17 (Th17) cells, other cell 
types also have the ability to express IL-17.21-23 A number of publications on chronic 
inflammatory and auto-immune disorders have reported that neutrophils and mast cells 
are the predominant source of IL-17.23-25 To elucidate the localization and phenotype of 
IL-17 expressing cells, we performed an extensive analysis of the cell types that express 
IL-17 in cervical cancer. Subsequently, we investigated the distribution of the main IL-
17 expressing cell populations in head and neck, ovarian, endometrial, prostate, breast, 
lung and colon cancer. The associations between the different IL-17 expressing cell 
types and clinico-pathological parameters were studied in a cervical carcinoma cohort 




Formalin-fixed, paraffin-embedded (FFPE) squamous cervical cancer specimens 
obtained from all patients who underwent primary surgical treatment for cervical cancer 
between 1985 and 2005 with sufficient material available for analysis were retrieved 
from the archives of the Department of Pathology, Leiden University Medical Center 
(n=160). None of the patients had received preoperative anticancer therapy and follow-
up data were obtained from patient medical records. Mean follow-up time was 9.4 years 
(ranged 8.1 – 10.6 ± 2 standard errors). Patient and tumor characteristics are listed in 
Table 1. Tumor node metastasis (TNM) stages below stage IIA were defined early 
stage. FFPE specimens from three squamous cell head and neck carcinomas, two serous 
and one endometrioid ovarian carcinomas, one serous endometrial carcinoma, three 
prostate adenocarcinomas, five ductal breast adenocarcinomas, four non-small-cell lung 
adenocarcinomas, three colon adenocarcinomas, three Crohn’s disease and three normal 
colon samples were also retrieved. Patient samples were handled according to the 
medical ethical guidelines described in the Code of Conduct for Proper Secondary Use 
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medical ethical guidelines described in the Code of Conduct for Proper Secondary Use 
of Human Tissue of the Dutch Federation of Biomedical Scientific Societies. 
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Table 1. Patient and tumor clinico-pathological characteristics
Clinico-pathological parameter Category N = 160 (%)
Age Median 45
Range 22-87
FIGO stage1,2 IB 123 (77)
IIA 35 (22)
IIB 1 (1)








Lymph nodes2 negative 109 (68)
positive 50 (31)
Tumor size (mm)2 <40 63 (39)
77 (48)
Vaso-invasion2 Absent 67 (42)
Present 88 (55)
Infiltration depth (mm)2 <15 81 (51)
1 70 (44)
HPV type 16 96 (60)
18 28 (18)
other 36 (23)
1FIGO=Fédération Internationale de Gynécologie et d’Obstétrique
2Data were not available for all patients.
Immunohistochemistry
I nostainin s ere erfor e  on   t ic  FF  sections as escri e  efore.8
Deparaffinized sections were treated with 0.3% H2O2 in methanol for 20 minutes to 
block endogenous peroxidase activity. After rehydration, antigen retrieval was 
performed in citrate, or for double and triple stainings in Tris-EDTA buffer (10 mM 
TRIS plus 1 mM EDTA pH 9.0). Antibodies were diluted in 1% w/v bovine serum 
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albumin (BSA) in phosphate buffered saline (PBS), or for stainings involving antibodies 
conjugated to alkaline phosphatase (AP) in Tris-buffered saline pH=7.6 (TBS). Primary 
antibodies were incubated at room temperature overnight; secondary antibodies were 
incubated at room temperature for one hour (listed in Supplementary Table S1). The 
activity of horseradish peroxidase (HRP) was visualized using 0.5% 3,3’-diamino-
benzidine-tetrahydrochloride (DAB) and 0.002% H2O2 in TRIS-HCl. Donkey-anti-goat-
HRP was visualized by DAB+ (Dako). The activity of AP was visualized using 
PermaBlue (Diagnostic BioSystems). Antibodies of the same isotype class with an 
unknown specificity were used as negative controls. Sections single-stained with DAB 
were counterstained with haematoxylin, while slides stained with PermaBlue were 
counterstained with nuclear Fast Red. Slides were mounted using CV Mount (Leica 
Microsystems) or VectaShield mounting medium containing DAPI (Vector 
Laboratories). 
The IL-17 staining was validated on stimulated CD4+CD45RO+ memory T cells 
obtained from healthy volunteer peripheral blood samples as described before.26 The 
obtained memory T cells including Th17 cells were mixed with HeLa cells, fixed in 4% 
paraformaldehyde and paraffin embedded. Images were acquired with an LSM700 
confocal laser scanning microscope equipped with an LCI Plan-Neofluar 25x/0.8 Imm 
Korr DIC M27 and C-Apochromat 40x/1.20 W Korr objectives (Zeiss; Supplementary 
Figure S1). Crohn’s tissue, containing a relatively high number of Th17 cells,27 was 
used as a positive control for the IL-17/CD3 double staining (Supplementary Figure 
S2). As a reference, normal colon tissue was stained for IL-17 and CD3 (Supplementary 
Figure S3). The staining of IL-17 by goat-anti-IL-17 (AF-317-NA, R&D Systems) was 
furthermore validated by comparative single and double stainings with rabbit-anti-IL-17 
(sc-7927, Santa Cruz).
Microscopic analyses
All cervical cancer FFPE tissue specimens were stained for IL-17, CD15 and tryptase 
and digitized with a Pannoramic Midi automated slide scanner (3DHISTECH). Slides 
were analyzed using Mirax Viewer (Zeiss). At least 4 but generally 6 random images
were taken at a 200x magnification, sampling a total tumor area of 2.5 to 3.7 mm2 of 
each slide, comprising vital areas of both tumor epithelium and stroma. Images were 
analyzed by the open source image processing program ImageJ version 1.44 
(http://rsb.info.nih.gov/ij/). DAB and haematoxylin stainings were separated by the 
imageJ color deconvolution method Haematoxylin, Eosin and DAB (H&E DAB; plugin 
ImageJ website). Suitable threshold levels for Haematoxylin and DAB were determined 
on random pictures. The noise was removed by the ‘despeckle’ command, cells were 
separated by the ‘watershed’ command and all stained cells were counted. For statistical 
purposes, patients were divided in two groups based on the median numbers of positive 




Table 1. Patient and tumor clinico-pathological characteristics
Clinico-pathological parameter Category N = 160 (%)
Age Median 45
Range 22-87
FIGO stage1,2 IB 123 (77)
IIA 35 (22)
IIB 1 (1)








Lymph nodes2 negative 109 (68)
positive 50 (31)
Tumor size (mm)2 <40 63 (39)
77 (48)
Vaso-invasion2 Absent 67 (42)
Present 88 (55)
Infiltration depth (mm)2 <15 81 (51)
1 70 (44)
HPV type 16 96 (60)
18 28 (18)
other 36 (23)
1FIGO=Fédération Internationale de Gynécologie et d’Obstétrique
2Data were not available for all patients.
Immunohistochemistry
I nostainin s ere erfor e  on   t ic  FF  sections as escri e  efore.8
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58
albumin (BSA) in phosphate buffered saline (PBS), or for stainings involving antibodies 
conjugated to alkaline phosphatase (AP) in Tris-buffered saline pH=7.6 (TBS). Primary 
antibodies were incubated at room temperature overnight; secondary antibodies were 
incubated at room temperature for one hour (listed in Supplementary Table S1). The 
activity of horseradish peroxidase (HRP) was visualized using 0.5% 3,3’-diamino-
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HRP was visualized by DAB+ (Dako). The activity of AP was visualized using 
PermaBlue (Diagnostic BioSystems). Antibodies of the same isotype class with an 
unknown specificity were used as negative controls. Sections single-stained with DAB 
were counterstained with haematoxylin, while slides stained with PermaBlue were 
counterstained with nuclear Fast Red. Slides were mounted using CV Mount (Leica 
Microsystems) or VectaShield mounting medium containing DAPI (Vector 
Laboratories). 
The IL-17 staining was validated on stimulated CD4+CD45RO+ memory T cells 
obtained from healthy volunteer peripheral blood samples as described before.26 The 
obtained memory T cells including Th17 cells were mixed with HeLa cells, fixed in 4% 
paraformaldehyde and paraffin embedded. Images were acquired with an LSM700 
confocal laser scanning microscope equipped with an LCI Plan-Neofluar 25x/0.8 Imm 
Korr DIC M27 and C-Apochromat 40x/1.20 W Korr objectives (Zeiss; Supplementary 
Figure S1). Crohn’s tissue, containing a relatively high number of Th17 cells,27 was 
used as a positive control for the IL-17/CD3 double staining (Supplementary Figure 
S2). As a reference, normal colon tissue was stained for IL-17 and CD3 (Supplementary 
Figure S3). The staining of IL-17 by goat-anti-IL-17 (AF-317-NA, R&D Systems) was 
furthermore validated by comparative single and double stainings with rabbit-anti-IL-17 
(sc-7927, Santa Cruz).
Microscopic analyses
All cervical cancer FFPE tissue specimens were stained for IL-17, CD15 and tryptase 
and digitized with a Pannoramic Midi automated slide scanner (3DHISTECH). Slides 
were analyzed using Mirax Viewer (Zeiss). At least 4 but generally 6 random images
were taken at a 200x magnification, sampling a total tumor area of 2.5 to 3.7 mm2 of 
each slide, comprising vital areas of both tumor epithelium and stroma. Images were 
analyzed by the open source image processing program ImageJ version 1.44 
(http://rsb.info.nih.gov/ij/). DAB and haematoxylin stainings were separated by the 
imageJ color deconvolution method Haematoxylin, Eosin and DAB (H&E DAB; plugin 
ImageJ website). Suitable threshold levels for Haematoxylin and DAB were determined 
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619) for the total cohort, 57 (range 2-619) for the early stage cohort and 43 (range 1-
487) for the cohort of samples obtained until 1993. The median number of CD15+ cells 
was 38 (range 1-939); 59 (range 1-939) for the early stage cohort and 56 (range 2-362) 
for the cohort until 1993. The median number of tryptase+ cells was 22 (range 1-201); 
23 (range 1-201) for the early stage cohort and 20 (range 2-112) for the cohort until 
1993.
Four cervical cancer sections were double stained for IL-17 and different phenotype 
markers and analyzed with a Leica DM4000B spectral microscope equipped with HC 
PLAN APO 20x/0.70, HCX PLAN APO 40x/0.85 Corr and 63x/1.32-0.60 oil objectives 
(Leica Microsystems). Spectra between 420 and 720 nm were acquired with an interval 
of 20 nm and an exposure time of 100 ms per frame. All cells were quantified manually 
in 6 random high-power fields (40x objective HPF) in vital areas of both the tumor 
epithelium and tumor stroma, sampling a total area of 0.52 mm2 of each. Three random 
images were taken in the other carcinoma types, comprising vital areas of both tumor 
epithelium and stroma. The spectra for DAB, PermaBlue and nuclear Fast Red were 
unmixed using the Nuance Fx Multispectral Imaging System version 2.1 (Cambridge 
Research and Instrumentation). High magnification pictures were taken with the 63x 
objective and an exposure time of 50 ms per frame for illustration purposes of the 
different double stainings in the same tissue specimen. A subcohort of 51 consecutive 
specimens obtained before 1993 was double stained for IL-17 and CD3. Six random 
images were taken with the 20x objective, sampling a total area of 2.1 mm2. The median 
number of Th17 cells per image was 6 (range 1-62).
Immunofluorescence
Immunofluorescent images were acquired with a Zeiss LSM510 confocal laser scanning 
microscope equipped with a Plan-Apochromat 63x/1.4 Oil Ph3 objective (Zeiss). 
Pictures were taken in the same tissue sample the immunohistochemical pictures were 
taken in and analyzed using LSM Image Browser software (Zeiss).
Real-time cancer cell analysis
Cervical cancer cell lines CC8, CC10a, CC10b and CSCC7 were generated in our 
department as described previously.28 These cell lines and the commercially available 
CaSki, HeLa and SiHa were grown in the xCELLigence RTCA DP system (Roche 
Applied Science). Cells were seeded at a concentration of 20,000 cells/well, except for 
HeLa en SiHa, which were seeded at a concentration of 10,000 cells/well in RPMI 1640 
medium (Sigma-Aldrich) supplemented with 10% FBS, 50 U/ml penicillin, 50  
streptomycin and GlutaMax (Gibco Life Technologies). Six hrs after seeding, the 
culture medium was refreshed, and 24 hrs after seeding, the culture medium was 
replaced by culture medium containing 100 ng/ml recombinant human IL-17A (R&D 
Systems) dissolved in 40 nM HCl or medium supplemented with 40 nM HCl only. The 
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electrical impedance imposed on the plate by the cells was measured every 30 minutes 
and is represented as the cell index, a measure of cell number and status. At least two 
independent experiments were performed at least in duplicate, but usually in triplicate 
or quadruplicate, with paired control and test wells equally distributed over the plate.
Statistical analysis
Statistical analyses were performed using SPSS version 20.0 (IBM). Correlations 
between immunohistochemical data and survival were tested using the Kaplan-Meier 
and Cox proportional hazards models. Correlations among immunohistochemical data 
and with clinico-pathological variables were tested using the Spearman’s rank 
correlation rho and Wilcoxon Mann-Whitney tests. All tests were two-sided and
p-values below 0.05 were considered statistically significant.
Results
Phenotype of IL-17+ cells in squamous cervical carcinoma
To determine the phenotype of the cell populations expressing IL-17, we double stained 
four FFPE squamous cervical carcinoma specimens for IL-17 and different phenotype 
markers: CD1a (Langerhans’ cells), CD3 (T cells), CD15 (granulocytes), CD33 
(immature myeloid cells), CD79a (B cells), CD127 (innate lymphoid cells), CD163 
(type 2 macrophages), S100 (dendritic cells) and tryptase (mast cells) (Figure 1). Since 
CD127 expressing naïve and memory T cells were expected to represent minor 
populations in the tumor microenvironment, CD127+ cells are assumed to 
predominantly represent innate lymphoid cells. Staining for IL-17 was similar to what 
was observed in cultured Th17 cells and Crohn’s tissue (Supplementary Figure S1-3). 
The IL-17+ cells were primarily present in the tumor stroma. Strikingly, the majority of 
these IL-17+ stromal cells were granulocytes (mean: 66%) (Figure 2A). Since CD15 is 
expressed by both neutrophilic and eosinophilic granulocytes, the phenotype of the 
IL-17+CD15+ population was further investigated by a triple staining for IL-17, CD15 
and myeloperoxidase (MPO), a marker for neutrophilic granulocytes (Figure 3). 
Virtually all (>99%) of the IL-17+CD15+ cells expressed MPO, indicating these cells 
were neutrophils. The IL-17+ cells also composed a major fraction of the total 
granulocyte population (mean: 82%) (Figure 2B; Supplementary Table S2). Another 
large IL-17+ stromal population consisted of mast cells (mean: 23%). The innate 
lymphoid cells composed the third substantial population of stromal IL-17+ cells (mean: 
8%). The IL-17+ cells composed a considerable part of the mast cell (mean: 40%) and 
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Figure 2. Phenotype 
of IL-17+ cells in 
cervical carcinoma 
The percentage of   
IL-17+ cells expressing 
one of the cellular 
phenotype markers is 
shown for both the 
stromal (A) and 
intraepithelial (IE) (C) 
part of the tumor 
(mean and range). The 
total number of cells 
expressing one of the 
different phenotype 
markers counted per 
HPF (mean and range) 
is represented by the 
total bars for the 
tumor stroma (B) and 
tumor epithelium (D). 
The number of cells 
double positive for  
IL-17 and one of the 
phenotype markers is 
represented by the 
solid bar parts. 
 
 
Figure 1. Immunohistochemical double staining of IL-17 and different phenotype markers 
Representative images of double stainings for IL-17 (DAB) and CD1a (A), CD3 (B), CD15 (C), CD33 (D), 
CD79a (E), CD127 (F), CD163 (G), S100 (H) and tryptase (I) (all PermaBlue) at a x630 magnification are 
shown. Arrows indicate a double positive cell or cells positive for the two different markers in close vicini ty, 




Figure 3. Triple immunofluorescent staining of IL-17+ granulocytes 
Representative images for cells positive for IL-17 (A), MPO (B) and CD15 (C) at a x630 magnification. The 
white cells in the merged picture (D) combined with a Nomarski image are IL-17+MPO+CD15+ cells . 
CD33 was used as a marker for immature myeloid cells, including MDSCs. A fraction 
of these cells was found to express IL-17. However, the large majority of the CD33+ 
cells was observed to express tryptase and appeared to be mast cells (data not shown). 
Taken together, the CD33+tryptase- population composed less than 1% of the total IL17+ 
population. Other cell types also made minor contributions to the stromal IL-17+ 
population, including 4% T cells. No CD8+IL-17+ cells were observed in the five 
samples with most CD3+IL-17+ cells, while CD4+IL-17+ cells were detected (data not 
shown). We thus designated the CD3+IL-17+ cell population as Th17 cells. Type 2 
macrophages comprised 3% of the IL-17+ cells. Of the T cells and type 2 macrophages, 
1% and 2% expressed IL-17, respectively. IL-17+ cells were virtually absent in the B 
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Figure 1. Immunohi t chemical double staining of IL-17 and different phenotype markers 
Representative images of double stainings for IL-17 (DAB) and CD1a (A), CD3 (B), CD15 (C), CD33 (D), 
CD79a (E), CD127 (F), CD163 (G), S100 (H) and tryptase (I) (all PermaBlue) at a x630 magnification are 
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Representative images of double stainings for IL-17 (DAB) and CD1a (A), CD3 (B), CD15 (C), CD33 (D), 
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distribution was observed in the tumor epithelium, with the exceptions of a relative 
reduction in the number of IL-17+ type 2 macrophages and increase in the number of 
Th17 cells (Figures 2C and 2D). The relative number of IL-17+ mast cells was reduced 
as well, but this was due to the near absence of mast cells in the tumor epithelium.
Figure 4. Phenotype of IL-17+ cells in other carcinoma types
The number of cells expressing CD3 (A) or CD15 (C) counted per HPF (mean and range) is represented by 
the total bars. The number of cells that also express IL-17 is represented by the solid bar parts. The number of 
cells expressing IL-17 and CD3 (open bars) or IL-17 and CD15 (solid bars) as a percentage of the total 
number of IL-17+ cells is shown in B.
Phenotype of IL-17+ cells in other carcinoma types
Subsequently, we investigated whether a similar distribution of IL-17+ granulocytes and 
Th17 cells was present in other types of carcinoma. A double staining for IL-17 and 
CD3 or CD15 was performed on 22 tumor specimens, including head and neck, ovarian, 
endometrial, prostate, breast, lung and colon cancer. Since the lung carcinoma samples 
contained tumor cells expressing CD15, the CD15 single positive cells were excluded 
from counting in these samples. Analogous to cervical cancer, IL-17 was expressed by a 
minority of T cells (mean: 0-1%) (Figure 4A; Supplementary Table S3) and Th17 cells 
were a minor population of the IL-17+ cells (mean: 0-6%) (Figure 4B). Granulocytes 
composed a substantial fraction of the IL-17+ cells in all tumor types (mean: 21-69%) 
(Figure 4B). The reverse was also true: the IL-17+ cells composed a substantial fraction 
of the total granulocyte population (mean: 43-92%) (Figure 4C). Thus in all tumor types 
studied, Th17 cells were a minor IL-17+ population and granulocytes were a major
IL-17 expressing cell type.
64
Correlations between IL-17+ cells, survival and clinico-
pathological parameters
Finally, we investigated whether the cell types that contributed most prominently to the 
IL-17+ cell population (total IL-17+ cells, neutrophils, mast cells and Th17 cells) had 
different effects on survival. To study the potential prognostic correlations of IL-17 and 
the cell types that express it, a large series of cervical cancer tissues was stained for 
IL-17 (n=158), CD15 (n=140) and tryptase (n=146), see Supplementary Figure S4. A 
subcohort was used to identify the Th17 cells by a double staining for IL-17 and CD3 
(n=51). The number of IL-17+ cells was significantly correlated with the number of 
neutrophils (CD15+ cells; r = 0.822, p<0.001), mast cells (tryptase+ cells; r = 0.175, 
p=0.036) and Th17 cells (IL-17+CD3+ cells; r = 0.623, p<0.001). Although a high 
number of IL-17+ cells did not significantly correlate with disease-specific survival 
overall, a high number of IL-17+ cells was significantly correlated with poor survival in 
early stage disease (p=0.010; Figure 5A). A high number of neutrophils showed a trend 
toward poor survival in early stage disease (p=0.068; Figure 5B). Although the effect 
was not statistically significant when the groups were divided based on the median, the 
group of patients with the lowest number of mast cells based on a quartile division had a 
significantly worse disease-specific survival, both overall and for early stage disease 
(p=0.028 and p=0.011 respectively; Figure 5C). Interestingly, having a high number of 
Th17 cells was significantly associated with improved disease-specific survival 
(p=0.024; Figure 5D). This supports the hypothesis that the different IL-17+ cell 
populations contribute differently to survival. Univariate and multivariate Cox analyses 
including lymph node status, tumor size, vaso-invasion and infiltration depth were 
performed to study potential prognostic variables. A high number of IL-17+ cells was 
found to be an independent predictor for poor survival in early stage disease with a 
hazard ratio of 5.2 (95% CI=1.4-20.2; p=0.016; n=90; Table 2). When the parameters 
that are accounted for by TNM stage were replaced by the TNM stage, the correlation 
remained similar (data not shown). A high number of Th17 cells was found to be 
associated with a significantly decreased hazard ratio of 0.28 (95% CI=0.1-0.9; 
p=0.034; n=51; Table 3). Since the Th17 staining was performed on a smaller subcohort 
of patients treated before 1993, multivariate Cox regression analysis was performed by 
including TNM stage, known for all patients, rather than the separate parameters 
included before, some of which included missing data. Th17 cells were found to be an 
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Figure 5. Correlation between IL-17, CD15, tryptase, Th17 and survival
Kaplan-Meier survival curves for the presence of the main IL-17 expressing cell populations in cervical 
cancer patients. Early stage disease patients with a high number of total IL-17+ (A) and CD15+ (B) cells were 
compared with patients with a low number of cells. A comparison between early stage disease patients with 
the lowest versus a higher number of tryptase+ mast cells based on a quartile division is shown in C. A 
comparison of patients with a high versus a low number of Th17 cells is shown in D.
We studied whether the different cell populations were associated with critical 
prognostic clinico-pathological parameters (lymph node metastasis, tumor size, vaso-
invasion and infiltration depth). A high number of IL-17+ cells and neutrophils were 
found to be correlated with the absence of vaso-invasion (odds ratio=0.379; 95% 
CI=0.194–0.739 and odds ratio=0.340; 95% CI=0.166–0.696, respectively). By 
performing Mann-Whitney U tests, significant correlations with lack of vaso-invasion 
were found for both IL-17 (p=0.006) and CD15 (p=0.003).
Effect IL-17 on cervical cancer cell index in vitro
Administering IL-17 to the culture medium enhanced the cell index of cervical cancer 
cell lines CC8, CC10a and HeLa (Figure 6). A significant increase in the number of, or 
tightness between these cells, or both, was thus observed after administration of IL-17. 
This effect was not significant for the cell indices of CaSki, CC10b and SiHa. The cell 
index of CSCC7 decreased after administration of IL-17.
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Table 2. Cox regression analysis in early stage disease 
Variable Univariate hazard ratio 
(95% CI)
p-value Multivariate hazard ratio 
(95% CI)
p-value
Lymph node status 5.30 (2.70-10.40) <0.001 3.33 (0.84-13.14) 0.087
Tumor size 1.04 (1.02-1.05) <0.001 1.04 (1.00-1.09) 0.039
Vaso-invasion 2.20 (1.08-4.50) 0.031 0.54 (0.13-2.22) 0.395
Infiltration depth 1.03 (1.00-1.06) 0.054 1.05 (0.98-1.12) 0.199
IL-17+ cells 4.61 (1.28-16.52) 0.019 5.24 (1.36-20.18) 0.016
CD15+ cells 2.81 (0.88-8.98) 0.080
tryptase+ cells 0.28 (0.10-0.80) 0.018
Th17 cells 0.51 (0.14-1.80) 0.292
Univariate Cox regression analyses for the categorical clinico-pathological parameters lymph node metastasis 
and vaso-invasion presence, the continuous variables tumor size and infiltration depth and an above median 
number of cells positive for the different immunological markers on disease-specific survival in early stage 
disease. A multivariate Cox analysis is shown for a high number of IL-17+ cells corrected for the clinico-
pathological parameters. 
Table 3. Cox regression analysis Th17 cohort
Variable Univariate hazard ratio 
(95% CI)
p-value Multivariate hazard ratio 
(95% CI)
p-value
TNM stage 1.62 (1.26-2.07) <0.001 1.72 (1.21-2.45) 0.003
IL-17+ cells 1.05 (0.35-3.13) 0.932
CD15+ cells 1.30 (0.41-4.11) 0.652
tryptase+ cells 0.32 (0.10-1.06) 0.063
Th17 cells 0.28 (0.09-0.91) 0.034 0.24 (0.07-0.85) 0.026
Univariate and multivariate Cox regression analyses for TNM stage and an above median number of cells 
positive for the different immunological markers in a cohort of patients treated between 1985 and 1993. 
Figure 6. Effect of IL-17 on cervical cancer 
cells in vitro
Mean (black dots) and standard error of the 
mean (grey lines) of a representative 
experiment of the cell index of four wells per 
condition of cervical cancer cell line CC10a 
seeded at a concentration of 20,000 cells/well 
at time 0 is shown. At 6 hours, culture medium 
was refreshed, and at 24 hours, the culture 
medium was replaced by culture medium with 
or without 100 ng/ml IL-17A. The slope of the 
lines between 24 en 60 hours was found to 
differ significantly between the conditions 
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In the present study, formalin-fixed tissue was used to determine the phenotype and 
location of IL-17 expressing cells. By using immunohistochemistry to investigate the 
different cell types in the original tissue morphology, we showed for the first time that 
the predominant cell type expressing IL-17 in squamous cervical cancer is the 
neutrophilic granulocyte. In addition, mast cells and innate lymphoid cells composed 
substantial IL-17 expressing cell populations. Minor IL-17+ cell populations or cell 
types that did not express IL-17 were Th17 cells, macrophages, B cells, dendritic cells, 
Langerhans’ cells and MDSCs. Subsequently, we showed that the predominant IL-17+
cell type in head and neck, ovarian, endometrial, prostate, breast, lung and colon cancer 
was the granulocyte as well, while Th17 cells were a minor IL-17 expressing 
population. A limited number of studies described the phenotype of IL-17+ cells in solid 
cancer. In colorectal carcinoma, IL-17 was found in Th17 cells and macrophages, but 
the two cell populations were not quantified.13 Two studies in non-small cell lung 
cancer and advanced epithelial ovarian cancer described that most IL-17+ cells were 
lymphocytes, but IL-17 expression was also observed in polymorphonuclear cells.14,29
We observed a heterogenous pattern in the cell types expressing IL-17 in the different 
tumor types we analyzed, with 21-69% being granulocytes. Although we have not been 
able to measure IL-17 at RNA level in neutrophils in vitro, this might be caused by the 
short-lived and terminally differentiated state of neutrophils, which have been described 
to contain no or very low mRNA levels for the granule proteins they express.30,31 The 
frequent large size of the other IL-17+ cells observed, suggested that mast cells 
composed another substantial population. In accordance with this, Wang et al. recently 
described that Th17 cells and mast cells represented 2% and 72% of IL-17+ cells in 
esophageal squamous cell carcinoma, respectively, and 19% of total mast cells 
expressed IL-17.32 Our findings that 23% of the IL-17+ cells were mast cells and 40% of 
mast cells expressed IL-17 in cervical cancer, suggests that the relative numbers of mast 
cells and granulocytes varies in different types of cancer, and probably even in different 
patients. Thus there appears to be heterogeneity in the cell types expressing IL-17 
between different types of cancer. Overall, we showed that a predominance of IL-17 
expressing granulocytes and mast cells and limited numbers of Th17 cells seem to be a 
general feature in different types of carcinoma. This suggests that the correlations that 
have been described between IL-17, neutrophils and angiogenesis might be more tightly 
linked than previously suspected, since the neutrophils can produce IL-17 themselves 
and are also strongly associated with angiogenesis.
We further studied the association between the different IL-17+ cell populations and 
clinico-pathological parameters. The total number of IL-17+ cells was significantly 
correlated with poor disease-specific survival in early stage squamous cervical 
carcinoma. The fact that we did not find this correlation for all TNM stages, suggests 
that IL-17+ cells are mainly effective in early disease stages. This might be correlated 
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with their negative association with vaso-invasion, since both higher TNM stages and a 
low number of IL-17+ cells were correlated with vaso-invasion. In higher TNM stages, 
where vaso-invasion is more frequently present, IL-17+ cells do not seem to have a 
distinct effect. This heterogenous function corresponds with the literature that has 
reported on both tumor promoting14,33 and tumor suppressing29,34,35 effects of IL-17. In 
the present study, we show that this may also be the case because IL-17 is expressed by 
different cell populations, which have different effects in the tumor microenvironment. 
Their contributions might change during disease progression. One of the mechanisms 
through which IL-17 might be correlated with poor survival, is by directly contributing 
to tumor growth. The effect of IL-17 on tumor growth has been controversial, partly 
because IL-17 has indirect effects by stimulating other cells to produce a diversity of 
cytokines. We studied the effect of IL-17 on tumor cell growth in vitro and observed an 
enhanced cell index in three (CC8, CC10a and HeLa) out of seven cervical cancer cell 
lines. Since we measured changes in electrical impedance, this might reflect an increase 
in either cellular growth, or cellular tightening, or both. IL-17 has been described to 
increase the number of tight junctions in epithelial cells,17 supporting the hypothesis that 
cellular tightening may play a role. Previous studies did not find an effect of IL-17 on 
HeLa and IC1 cervical cancer cell growth.36,37 These results suggest that IL-17 may 
increase cellular tightness in cervical cancer cells. Additionally, both a high number of 
IL-17+ cells and a high number of neutrophils were significantly correlated with the 
absence of vaso-invasion in cervical cancer. These findings are also in accordance with 
the observation that IL-17 is able to increase the number of tight junctions in epithelial 
cells,17 further supporting the hypothesis that cellular tightening may play an important 
role. A similar finding was reported by Cunha et al., who showed that the absence of 
CD4+IL-17+ cells correlated with invasion into the underlying tissue in a multivariate 
analysis in differentiated thyroid carcinoma patients.38 Together, this suggests that IL-17 
may stimulate cellular tightening and decrease the occurrence of vaso-invasion.
Corresponding to the majority of IL-17+ cells expressing CD15 and the majority of 
CD15+ cells expressing IL-17, the number of IL-17+ cells strongly correlated with the 
number of CD15+ neutrophils. These CD15+ neutrophils did not show a significant 
effect on disease-specific survival in cervical cancer. This corresponds to the finding 
that most of these cells express IL-17, which overall did not have an association with 
survival either. This does suggest that it is primarily the production of IL-17 that is 
associated with poor survival in early stage disease, since its main cell source is not 
significantly correlated but does show a trend. However, the presence of neutrophils in 
the tumor microenvironment was associated with an N2 phenotype and both IL-17 and 
neutrophils were correlated with angiogenesis and poor survival in, among others, 
colorectal and hepatocellular cancer.13,39,40 The reason for this discrepancy is unclear. 
Part of the explanation may be the heterogeneity of the CD15+ cell population. This 
population may include both tumor suppressing N1 and tumor promoting N2 type 
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neutrophils were shown to produce CCL2 and CCL20, ligands for CCR2 and CCR6, 
respectively, expressed by Th17 cells.41 This might be a mechanism for neutrophils to 
drive the Th17 pathway.42 Although circulating CD15+ neutrophils have been shown to 
be an important source of IL-17 in humans, and mouse liver infiltrating neutrophils 
were shown to express both IL-17 and the transcription factor crucial for IL-17 
differentiation retinoic acid receptor-related orphan receptor-γt ( γt),43 the 
functional properties of neutrophils expressing IL-17 are not clear yet.
Although not as strongly as for CD15, the number of IL-17+ cells also significantly 
correlated with the number of tryptase+ cells. The lowest quartile of mast cells was 
significantly correlated with poor disease-specific survival in our study. Although total 
mast cells are frequently associated with angiogenesis and tumor progression, as was 
described for cervical cancer,44 the intratumoral rather than the peritumoral mast cells 
were described to be associated with improved survival in prostate and breast 
cancer.45,46 The latter observations are in agreement with our findings. 
According to expectations, a strong correlation was observed between the numbers of 
IL-17+ cells and Th17 cells. Surprisingly, despite the small fraction the Th17 cells 
represent, high Th17 numbers were found to be significantly correlated with improved 
disease-specific survival. A high number of Th17 cells proved to be an independent 
prognostic factor for survival. We conclude that this association is at least a reflection of 
a beneficial immune response in cervical cancer. The role of Th17 cells in cancer is 
controversial with both tumor promoting and tumor suppressing functions being 
reported. For instance, Tosolini et al. found that a Th17 gene expression profile was 
correlated with poor survival in colorectal cancer.47 However, in agreement with our 
results, Kryczek et al. reported that a high amount of Th17 derived IL-17 in the ascites 
of ovarian cancer patients was correlated with improved survival.48 Based on these 
results, Th17 cells are suggested to be part of a tumor suppressing immune response. 
Indeed, Th17 cells have been shown to be correlated with interferon-gamma production 
and infiltration of cytotoxic T cells.49
To conclude, we found that IL-17 in different types of carcinoma was primarily 
expressed by granulocytes and mast cells. These granulocytes were shown to be 
neutrophils in squamous cervical cancer and while total IL-17+ cells were independently 
associated with poor survival in early stage disease, neutrophils showed a trend toward 
association with poor survival. Since we showed that IL-17 enhanced the cell index in 
three out of seven cervical cancer cell lines, IL-17 seems to directly contribute to 
tumorigenesis. Additionally, both IL-17+ cells and CD15+ cells were significantly 
correlated with the absence of vaso-invasion in cervical cancer. These data suggest that 
IL-17 may primarily function by inducing tumor cell tightness, which might play an 
important role in early stage disease, where vaso-invasion less frequently occurs. A high 
number of mast cells was correlated with improved disease-specific survival. Th17 cells 
were an independent prognostic factor for improved disease-specific survival in 
squamous cervical cancer. These data support our hypothesis that the different cell types 
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expressing IL-17 play different roles in the tumor microenvironment and have different 
effects on survival.
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results, Th17 cells are suggested to be part of a tumor suppressing immune response. 
Indeed, Th17 cells have been shown to be correlated with interferon-gamma production 
and infiltration of cytotoxic T cells.49
To conclude, we found that IL-17 in different types of carcinoma was primarily 
expressed by granulocytes and mast cells. These granulocytes were shown to be 
neutrophils in squamous cervical cancer and while total IL-17+ cells were independently 
associated with poor survival in early stage disease, neutrophils showed a trend toward 
association with poor survival. Since we showed that IL-17 enhanced the cell index in 
three out of seven cervical cancer cell lines, IL-17 seems to directly contribute to 
tumorigenesis. Additionally, both IL-17+ cells and CD15+ cells were significantly 
correlated with the absence of vaso-invasion in cervical cancer. These data suggest that 
IL-17 may primarily function by inducing tumor cell tightness, which might play an 
important role in early stage disease, where vaso-invasion less frequently occurs. A high 
number of mast cells was correlated with improved disease-specific survival. Th17 cells 
were an independent prognostic factor for improved disease-specific survival in 
squamous cervical cancer. These data support our hypothesis that the different cell types 
70
expressing IL-17 play different roles in the tumor microenvironment and have different 
effects on survival.
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Supplementary Figure S1. Confocal analysis of activated memory T cells including Th17 cells
Stimulated CD4+CD45RO+ memory T cells were mixed with HeLa cervical cancer cells, formalin fixed and 
embedded in paraffin. Cells positive for CD3 (blue), IL-17 (green) and DAPI (grey) are shown for two donors 
in A and B. Arrows indicate CD3+IL-17+ double positive cells (all IL-17+ cells were positive for CD3). The 
double positive cells from B are shown enlarged (at original magnification 250x) in C.
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Cells double positive for CD3 (blue) and IL-17 (green) were observed in FFPE tissue from colon biopsies 
from Crohn’s disease patients. Nuclei are stained by DAPI, shown in grey in the merged image on the right. 
Arrows indicate double positive cells. Representative pictures from two random samples are shown (400x 
magnification).
Supplementary Figure S3. IL-17+ cells in healthy colon tissue
A different distribution of cells positive for CD3 (blue) and IL-17 (green) was observed in FFPE tissue from 
healthy colon tissue samples. Nuclei are stained by DAPI, shown in grey in the merged image on the right. 
Relatively more large IL-17 single positive cells and no Th17 cells seemed to be present. Representative 
pictures from two random samples are shown (250x magnification).
Supplementary Figure S4. Cervical cancer stained for IL-17, CD15 and tryptase
Representative immunohistochemical stainings (200x magnification) identifying IL-17 (A), CD15 (B) and 
tryptase (C) at a similar position in sections of the same tumor specimen.
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CD1a (LC) 0.3 (0-1)
180 (88-303)
0 (0-0.2) 5 (1-13) 0 (0-0)
CD3 (T cell) 2 (0-3) 31 (6-75) 1 (0-1)
CD15 (PMN) 38 (26-67) 30 (19-49) 7 (1-20) 5 (0-15)
CD79a (B cell) 88 (36-119) 0.2 (0-1) 1 (0-1) 0 (0-0)
CD127 (ILC) 26 (13-58) 4 (0-12) 4 (0-5) 1 (0-2)
CD163 (M 2) 67 (41-97) 1 (1-2) 15 (2-35) 0.1 (0-0.3)
S100 (DC) 10 (5-18) 0 (0-0.2) 10 (5-17) 0 (0-0.2)
tryptase (MC) 29 (11-73) 14 (3-40) 2 (0-3) 0.3 (0-1)
The mean and range of the total number of cells positive for each of the different phenotype markers are 
shown for the tumor stroma as well as for the tumor epithelium. The mean and range of these cells also 
expressing IL-17 is shown in an additional column. Abbreviations: LC=Langerhans’ cells; 
PMN=polymorphonuclear cell; ILC=innate lymphoid cell; M 2=macrophage type 2; DC=dendritic cell;
MC=mast cell













cervical 42 (15-59) 180 (88-303) 2 (0-3) 38 (26-67) 30 (19-49)
head/neck 31 (14-74) 194 (61-281) 2 (0-6) 21 (4-47) 19 (3-43)
ovar/endo 8 (2-17) 18 (7-46) 0.1 (0-0.3) 9 (4-14) 6 (3-10)
prostate 4 (1-6) 17 (4-26) 0 (0-0) 1 (0-2) 1 (0-2)
breast 9 (2-24) 33 (7-60) 0.2 (0-1) 4 (0-8) 3 (0-6)
lung 8 (3-14) 57 (20-112) 0.3 (0-1) NA 3 (1-5)
colon 29 (7-54) 59 (40-91) 1 (0-1) 24 (20-27) 17 (6-26)
In the different types of carcinoma, the total number of IL-17+ cells (mean and range), the total number of 
CD3+ and CD15+ cells, and of these cells, the number of cells expressing both IL-17 and CD3 or CD15 are 
shown. Abbreviations: ovar/endo=ovarian and endometrial carcinoma; NA=not applicable since part of the 
lung tumor cells expressed CD15
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Cervical adenocarcinoma comprises approximately 15% of cervical cancer cases. This 
histological subtype has different characteristics than cervical squamous cell carcinoma, 
which may influence disease progression. To study whether the infiltration of T cell 
subpopulations was correlated with cervical adenocarcinoma patient survival, similar to 
squamous cell carcinoma, the tumor infiltrating T cells, Tregs, Th17 cells and IL-17+
cell frequencies were analyzed in a cohort of cervical adenocarcinoma patients (n=67). 
Intraepithelial, stromal and total cell frequencies were scored using triple 
immunofluorescence. The majority of Tregs was present in the tumor stroma, while 
other T cells and IL-17+ cells infiltrated the tumor epithelium three times more 
frequently. A high total number of Tregs was significantly correlated with improved 
disease-specific and disease-free survival (p=0.010, p=0.007). Within the tumor 
epithelium, a high T cell frequency was significantly correlated with improved disease-
free survival (p=0.034). Especially a low number of both Tregs and IL-17+ cells was 
correlated with poor disease-specific survival (p=0.007). A low number of Tregs 
combined with Th17 cells present was also correlated with poor survival (p=0.018). An 
increased number of IL-17+ cells was significantly correlated with the absence of vaso-
invasion (p=0.001), smaller tumor size (p=0.030) and less infiltration depth (p=0.021). 
These results suggest that Tregs and IL-17+ cells represent a beneficial immune 
response, whereas Th17 cells might represent a poor response in cervical 
adenocarcinoma. This contrasts with the correlations described in squamous cell 
carcinoma, suggesting that the local immune response in cervical adenocarcinoma 
contributes differently to tumor growth than in squamous cell carcinoma.
Introduction
Cervical cancer is the second leading cause of cancer death in young women.1 The 
majority of cervical cancer cases can histologically be divided in squamous cell 
carcinoma (~75% of cases), adenocarcinoma and adenosquamous carcinoma (together 
20-25% of cases).2 Several studies have reported that the prognosis for patients with 
cervical adenocarcinoma is worse than for squamous cell carcinoma,3-8 although this is 
still controversial.9,10 Additionally, although the overall incidence of cervical cancer has 
declined in developed countries as a result of cytological screening programs, the 
incidence of adenocarcinoma has remained stable or even increased, predominantly in 
young women.11,12 Cervical adenocarcinoma differs from squamous cell carcinoma in 
growth pattern, molecular background and sensitivity to radio- and chemotherapy.13-15
However, because of the lower incidence, extensive analyses have been lacking. 
Since practically all cases of cervical cancer are caused by a persistent infection with 
high-risk human papillomavirus (HPV),16 immunosurveillance plays a critical role. 
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Most cervical HPV infections are cleared in over 90% of cases within two years.17 In 
case of tumor progression, the immune response is thought to contribute to tumor 
development rather than eradication.18 The type and number of immune cells present in 
the tumor microenvironment are both crucial for clinical outcome. T helper 1 (Th1) 
cells are required to overcome intracellular pathogens and can induce or stimulate a 
tumor targeting immune response. Th2 cells protect against extracellular pathogens, and 
have been shown to support cervical cancer progression,19 but their role in cancer has
not been fully elucidated. Th17 cells are essential to protect against extracellular 
pathogens, and play a dominant role in autoimmune diseases.20,21 Their role in cancer is 
unclear, since they have been shown to both be able to promote as well as to counteract 
tumor growth.22 Tregs suppress the activity of other T cells,23 which may dampen either 
a tumor suppressing or tumor promoting immune response. Especially the potentially 
different role of the immune response in squamous versus adenocarcinoma has not been 
thoroughly studied, although there are indications for differences between the 
subtypes.24
We have shown before that Tregs are more frequently present in cervical squamous cell 
carcinoma than adenocarcinoma and that these cells, relative to cytotoxic T cells, were 
correlated with poor survival in a representative cohort of cervical cancer patients, i.e. 
predominantly squamous cell carcinoma cases (77%).25 In addition, we have recently 
shown that Th17 cells were correlated with improved survival in a cohort of cervical 
squamous cell carcinoma patients.26 Strikingly, in the same cohort, interleukin-17
(IL-17) was predominantly expressed by neutrophils and correlated with poor 
survival.26 The aim of this study was to determine the number of intraepithelial, stromal 
and total T cells, Tregs, Th17 and other IL-17+ cells. The correlations between the 
different cell frequencies and patient survival in cervical adenocarcinoma were 
analyzed. The contrasts with the correlations described in cervical squamous cell 
carcinoma and other cancer types are discussed.
Materials and Methods
Patient material
Formalin-fixed, paraffin-embedded (FFPE) cervical adenocarcinoma specimens 
obtained from all patients who underwent primary surgical treatment for cervical cancer
between 1985 and 2005 with sufficient material available for analysis, were obtained 
from the archives of the Department of Pathology, Leiden University Medical Center 
(n=67). Cervical adenocarcinoma was defined as an invasive epithelial tumor showing 
glandular differentiation (moderate to highly differentiated) or staining Periodic Acid
Schiff Plus and Alcian Blue positive and lacking squamous elements 
(undifferentiated).27,28 None of the patients had received preoperative anticancer therapy 
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characteristics are listed in Supplementary Table S1. Patient samples were handled 
according to the medical ethical guidelines described in the Code of Conduct for Proper 
Secondary Use of Human Tissue of the Dutch Federation of Biomedical Scientific 
Societies.
Immunofluorescent stainings
Tri e i nof orescent stainin  as erfor e  on   t ic  FF  sections. fter 
antigen retrieval using Tris-ethylenediaminetetraacetic acid (EDTA) buffer (10 mM Tris 
plus 1 mM EDTA pH 9.0), rabbit anti-CD3 (ab828, Abcam, Cambride, UK), mouse 
IgG1 anti-FoxP3 (ab20034, Abcam) and goat anti-IL-17 (AF-317-NA, R&D Systems, 
Abingdon, UK) diluted in 1% w/v bovine serum albumin (BSA) in phosphate buffered 
saline (PBS) were incubated at room temperature overnight. Alexa Fluor labelled 
donkey anti-rabbit-A546 (A10040), donkey anti-mouse-A647 (A31570) and donkey 
anti-goat-A488 (A11055; all from Invitrogen, Life Technologies, Carlsbad, USA) were 
incubated at room temperature for one hour. Slides were mounted using VectaShield 
mounting medium containing DAPI (Vector Laboratories, Burlingame, USA). Omitting 
the primary antibodies and substituting them for antibodies of the same isotype class 
with an unknown specificity were used as negative controls.
Microscopic analyses
Immunofluorescent images were acquired with an LSM700 confocal laser scanning 
microscope equipped with an LCI Plan-Neofluar 25x/0.8 Imm Korr DIC M27 objective 
(Zeiss, Göttingen, Germany). In the majority of cases, four random images were 
obtained at a 250x magnification, sampling a total tumor area of generally 1.0 mm2, 
comprising vital areas of both tumor epithelium and stroma. Double or triple positivity 
of cells as well as the tumor epithelium and stroma area were determined using the 
overlay tool in the LSM Image Browser software (version 4.2.0.121, Zeiss). The 
numbers of single, double and triple positive cells were scored in the tumor epithelium 
and tumor stroma separately using the open source image processing program ImageJ 
version 1.47 (http://rsb.info.nih.gov/ij). Cells within blood vessels or lumina were not 
counted.
Statistical analysis
Statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, 
USA). Correlations between the number of positive cells and clinico-pathological 
variables were tested using the Spearman’s rank correlation rho (r) and Wilcoxon 
Mann-Whitney tests. Correlations between the number of positive cells and disease-
specific or disease-free survival were tested using the Kaplan-Meier and Cox 
proportional hazards models. For survival analyses, patients were divided in two groups 
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based on the median numbers of positive cells (high and low). All tests were two sided
and p-values below 0.05 were considered statistically significant.
Results
Infiltrating immune cells
The cell density for all cell types analyzed was higher in the tumor stroma than the 
epithelium (Figure 1). Although the IL-17+CD3+ cells might comprise bot  αβ an  γδ T 
ce s, e esi nate  t e res e  re o inant  αβ T ce  o ation e ressin  IL-17
and CD3 as Th17 cells. Tumor infiltration by CD3+ T cells was observed in all samples 
analyzed, while only a minor population of Th17 cells was observed (Supplementary 
Figure S1, Supplementary Table S2). FoxP3+ cells were always positive for CD3. Since 
a single FoxP3+IL-17+ cell was only observed in two tumor samples (0.02% of FoxP3+ 
cells), these cells were not analyzed. Although approximately three times more CD3+ T
cells and four times more (non-Th17) IL-17+ cells were present in the tumor stroma 
compared with the epithelium, especially Tregs were more strongly represented in the 
tumor stroma with on average over ten times higher cell counts compared with the 
epithelium.
Figure 1. T cells, Th17 cells, Tregs and IL-17+ cells in cervical adenocarcinoma
Representative image of a cervical adenocarcinoma stained by triple immunofluorescence for IL-17 (A), CD3 
(B) and FoxP3 (C), with the combined stainings together with DAPI counterstain (grey) shown in D. The 
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Figure 1. T cells, Th17 cells, Tregs and IL-17+ cells in cervical adenocarcinoma
Representative image of a cervical adenocarcinoma stained by triple immunofluorescence for IL-17 (A), CD3 
(B) and FoxP3 (C), with the combined stainings together with DAPI counterstain (grey) shown in D. The 
arrow indicates a cell double positive for IL-17 and CD3. Multiple CD3/FoxP3 double positive cells are 
present.
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Correlation between infiltrating immune cells and survival
A high total number of T cells was significantly correlated with improved disease-
specific (p=0.010, Figure 2A) and disease-free survival (p=0.001, Figure 2D). This was 
specifically due to a high number of CD3+FoxP3+ Tregs, since a high number of 
CD3+FoxP3- T cells was less strongly correlated with disease-free survival (p=0.032, 
Figure 2F) than a high number of Tregs (p=0.007, Figure 2E). More importantly, there 
was no significant correlation between a high number of CD3+FoxP3- T cells and 
disease-specific survival (p=0.254, Figure 2C), but high Tregs were significantly 
correlated with improved disease-specific survival (p=0.010, Figure 2B). Additionally, a 
high number of total CD3+ T cells within the tumor epithelium was significantly 
correlated with improved disease-free (p=0.034, Figure 3D) but not disease-specific 
survival (p=0.248, Figure 3A). These correlations were practically similar for the 
number of CD3+FoxP3- T cells (Figure 3C,F), because the number of FoxP3+ cells 
infiltrating in the tumor epithelium was relatively low. The number of Tregs in the 
tumor epithelium was not significantly correlated with disease-free or disease-specific 
survival (Figure 3B,E). The separate analyses of the correlation between the other cell 
types present in the tumor epithelium or the tumor stroma compartment and survival 
were not significant.
Figure 2. Correlation between total T cells, Tregs and survival
Kaplan-Meier survival curves for a high versus low number of total CD3+ T cells (A,D), CD3+FoxP3+ Tregs 
(B,E) and CD3+FoxP3- T cells (C,F) are shown for disease-specific (A-C) and disease-free survival (D-F). 
A high number of (non-Th17) IL-17+ cells per se was not significantly correlated with 
survival. However, when combining the Treg and IL-17 scores, patients could be better 
categorized in groups with poor or improved survival. Compared with a high number of 
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Tregs and a low Treg number but high IL-17+ cells, the combination of a low number of 
both Tregs and IL-17+ cells was correlated with worse disease-specific survival 
(p=0.007, Figure 4A). Since a high number of Tregs was correlated with favorable 
prognosis, the number of IL-17+ cells did not discriminate between patients with poor or 
improved survival in this patient group. Having a low number of Tregs and Th17 cells 
present was correlated with worse survival than high Tregs or low numbers of Tregs and 
absence of Th17 cells (p=0.018, Figure 4B). So despite the generally low numbers of 
Th17 cells present, their presence still contributed to the effect of the number of Tregs 
present. Both correlations were also significant for disease-free survival (data not 
shown).
Figure 3. Correlation between tumor epithelium infiltrating T cells, Tregs and survival
Kaplan-Meier survival curves for a high versus low number of CD3+ cells (A,D), CD3+FoxP3+ Tregs (B,E) 
and CD3+FoxP3- T cells (C,F) infiltrating in the tumor epithelium are shown for disease-specific (A-C) and 
disease-free survival (D-F).
Figure 4. Correlation between Tregs combined with IL-17, Th17 and survival
Kaplan-Meier survival curves for disease-specific survival based on a high (above median, abbreviated as 
med) number of Tregs compared with a low number of Tregs combined with high or low IL-17+ cells (A) or 
absence (abs) or presence (pres) of Th17 cells (B).
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both Tregs and IL-17+ cells was correlated with worse disease-specific survival 
(p=0.007, Figure 4A). Since a high number of Tregs was correlated with favorable 
prognosis, the number of IL-17+ cells did not discriminate between patients with poor or 
improved survival in this patient group. Having a low number of Tregs and Th17 cells 
present was correlated with worse survival than high Tregs or low numbers of Tregs and 
absence of Th17 cells (p=0.018, Figure 4B). So despite the generally low numbers of 
Th17 cells present, their presence still contributed to the effect of the number of Tregs 
present. Both correlations were also significant for disease-free survival (data not 
shown).
Figure 3. Correlation between tumor epithelium infiltrating T cells, Tregs and survival
Kaplan-Meier survival curves for a high versus low number of CD3+ cells (A,D), CD3+FoxP3+ Tregs (B,E) 
and CD3+FoxP3- T cells (C,F) infiltrating in the tumor epithelium are shown for disease-specific (A-C) and 
disease-free survival (D-F).
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Hazard ratio for low Tregs and IL-17+ cells infiltration
The hazard ratio for disease-specific survival in case of a low number of Tregs was 9.38 
(95% CI: 1.17-75.09, p=0.035, Table 1). This remained significant when correcting for 
tumor lymph node metastasis (TNM) stage. The hazard ratio for disease-specific 
survival for tumors with a low number of both Tregs and IL-17+ cells was 13.91 (95% 
CI: 1.67-115.73, p=0.015, Supplementary Table S3) when compared with a high 
number of Tregs, which also remained significant after correcting for TNM stage. A 
low number of Tregs combined with the presence of Th17 cells gave a hazard ratio of 
12.83 (95% CI: 1.43-114.93, p=0.023, Supplementary Table S4) when compared with a 
high number of Tregs, which also remained significant after correcting for TNM stage.
Table 1. Hazard ratio for a low Tregs frequency
Variable Univariate hazard ratio 
(95% CI)
p value Multivariate hazard ratio 
(95% CI)
p value
TNM stage 1.606 (1.133-2.276) 0.008 1.643 (1.144-2.361) 0.007
Tregs low 9.384 (1.173-75.093) 0.035 10.131 (1.256-81.719) 0.030
Univariate and multivariate Cox regression analyses for the TNM stage and a low number of Tregs on 
disease-specific survival are shown. The 95% confidence interval (95% CI) of the hazard ratio is indicated 
between brackets.
Correlation between IL-17+ cells and clinico-pathological 
parameters
Finally, we investigated whether the different cell populations were associated with 
prognostic clinico-pathological parameters (lymph node metastasis, tumor size, vaso-
invasion and infiltration depth). A high number of IL-17+ cells was significantly 
correlated with the absence of vaso-invasion (p=0.001, Figure 5A), decreased tumor 
infiltration depth (r = -0.29, p=0.021, Figure 5B) and decreased tumor size (r = -0.28, 
p=0.030, Figure 5C). No other significant correlations were found. 
Figure 5. Correlation between IL-17 and clinico-pathological parameters
The p value for the correlation between non-Th17 IL-17+ cells and vaso-invasion (A) was calculated using the 
Wilcoxon Mann-Whitney test. The correlations between non-Th17 IL-17+ cells and tumor infiltration depth 
(B) and tumor size (C) were calculated using the Spearman’s rank correlation rho test. 
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Discussion
The current study showed that a high total number of Tregs was significantly correlated 
with improved disease-free and disease-specific survival in cervical adenocarcinoma 
patients. Although tumor infiltrating immune cells are more frequently present in the 
tumor stroma than the tumor epithelium, especially Tregs were about three times less 
frequently present in the tumor epithelium than T cells and IL-17+ cells. Within the 
tumor epithelium, a high T cell frequency was significantly correlated with improved 
disease-free survival. Strikingly, specifically a low total number of both Tregs and IL-
17+ cells was strongly correlated with poor survival. The IL-17+ cells were inversely 
correlated with vaso-invasion, tumor size and infiltration depth. The number of IL-17+
cells could thus further discriminate between patient prognoses after Treg 
determination. In addition, a low number of Tregs combined with the presence of Th17 
cells was correlated with worse prognosis. 
The current data suggest that, of the immunological parameters studied, the total 
number of Tregs is the most important determinant correlated with survival for cervical 
adenocarcinoma patients. Tregs thus seem to represent a beneficial immune response in 
cervical adenocarcinoma, which contrasts with Tregs correlating with poor survival in 
cervical squamous cell carcinoma.25,29 This corresponds with studies that indicate that 
cervical adenocarcinoma differs substantially from squamous cell carcinoma,13-15,24 and 
suggests that the composition and effect of the tumor infiltrating immune cells differ per 
histological tumor subtype. However, a direct correlation between total Tregs and 
survival in cervical squamous cell carcinoma has not been shown: the significant 
correlations were specifically found within the tumor epithelium and especially when 
compared with the number of cytotoxic T cells present. A specific correlation between a 
high ratio of total T cells or CTL over Tregs and improved survival has recently also 
been shown in glioblastoma.30 When we studied the tumor epithelium separately, total T 
cell frequency was correlated with improved disease-free survival. The latter correlation 
was irrespective of Tregs, because the intraepithelial T cell frequency predominantly 
comprised FoxP3- cells. Thus, intraepithelial T cell infiltrate seems to be a general 
marker for improved survival. These intraepithelial T cells might predominantly be 
cytotoxic T lymphocytes (CTL). Another partial explanation for the differences found 
between the histological subtypes might be that the tumors of this cervical 
adenocarcinoma cohort were generally smaller in size than the squamous cell 
carcinomas, as was described before.27 Supporting our data, other studies have also 
reported correlations between Tregs and poor survival,31-33 indicative of the dampening 
of an anti-tumor immune response. However, Tregs have also been found to be 
correlated with improved prognosis in different types of cancer,34-37 suggesting they 
may also dampen a tumor promoting immune response. Indeed, the role of Tregs in 
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data support a predominant role in suppressing tumor growth favoring inflammation in 
cervical adenocarcinoma.
IL-17 has, in general, been shown to correlate with poor survival, and Th17 cells with 
improved survival in cancer.39 The pro-inflammatory cytokines IL-6 and IL-23, which 
are implicated in the induction of IL-17 expression,40 have also been shown to be 
correlated with poor survival in cervical cancer.41 Since IL-17 has been shown to be 
generally expressed by granulocytes,26 this suggests that a pro-inflammatory 
environment may attract granulocytes and other innate myeloid cells favoring tumor 
growth in cervical squamous cell carcinoma. The correlation between increased IL-17+
cells and improved survival especially in case of low Treg frequencies in cervical 
adenocarcinoma suggests that these cells might rather counteract tumor growth in 
cervical adenocarcinoma. We have previously shown that IL-17 producing cells 
represent a heterogenous cell population,26 and we propose that IL-17+ cells may 
predominantly represent tumor targeting myeloid cells in cervical adenocarcinoma, 
potentially mast cells and type 1 neutrophils and macrophages. Correspondingly, Chen 
et al. showed that a high number of infiltrating IL-17+ cells was significantly correlated 
with improved survival in a large cohort of gastric adenocarcinoma patients.42
Our results showed that the presence of Th17 cells, specifically when a low number of 
Tregs was present, was correlated with poor survival. A pro-inflammatory Th17 
response, despite the low frequencies, might thus rather be correlated with a tumor 
promoting immune response. This does correspond with a study by Yan et al., showing 
that an increased frequency of circulating Th17 cells is correlated with poor survival in 
hepatocellular cancer.43 Also this correlation is in contrast with its role in a beneficial 
immune response in cervical squamous cell carcinoma26 as well as other cancer types.39
These different correlations suggest that the local immune response in cervical 
adenocarcinoma differs substantially from the immune response in squamous cell 
carcinoma. This might be related to differences in the molecular constitution of the two 
cancer types. Cervical adenocarcinoma has recently been shown to contain more 
frequent TP5344 and KRAS mutations and less frequent PIK3CA and PTEN mutations 
compared with cervical squamous cell carcinoma.45 In our patient cohort, we found 
significantly more frequent somatic KRAS mutations in cervical adenocarcinoma, 
whereas PIK3CA mutations were more frequently found in squamous cell carcinoma 
(manuscript submitted). We have furthermore shown that CXC chemokine receptor 4 
(CXCR4), CXCR7 and epidermal growth factor receptor (EGFR) were more frequently 
expressed in cervical squamous cell carcinoma than adenocarcinoma.46 Additionally, we 
showed that HLA-E was overexpressed more frequently in cervical adenocarcinoma 
than in cervical squamous cell carcinoma.27 High HLA-E expression was significantly 
correlated with improved disease-free and disease-specific survival in cervical 
adenocarcinoma, while no correlation was found in squamous cell carcinoma. Cervical 
adenocarcinoma samples have also been shown to produce higher levels of transforming 
growth factor-β (T F-β) t an s a o s ce  carcino a sa es.24 Since we showed in 
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the present study that Tregs, Th17 cells and other IL-17+ cells also show opposed 
correlations in cervical adenocarcinoma compared with cervical squamous cell 
carcinoma, this suggests that the molecular differences are correlated with a different 
type of immune response. We speculate that the increased HLA-E and TGF-β 
expression might cause an effector T cell response to have limited efficacy. Under these 
circumstances, classically activated myeloid cells such as type 1 neutrophils might be 
more effective in cervical adenocarcinoma. Infiltration of T cells into the tumor 
epithelium was correlated with improved survival in both cervical cancer types.
To conclude, our data show that the role of T cells, including Tregs, Th17 cells and 
other IL-17+ cells is context and tumor type dependent. Tregs and IL-17+ cells 
represented a beneficial immune response correlated with improved survival, while 
Th17 cells might contribute to tumor progression and poor prognosis in cervical 
adenocarcinoma. Future research should determine how these cell types are correlated 
with improved prognosis, what other immune cell types are involved and how this 
might be used to guide patient prognosis and treatment.
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Supplementary Figure S1. Q uantification of tumor infiltrating cells
The mean and range of the number of total CD3+ T cells, FoxP3+CD3+ Tregs, CD3-IL-17+ cells and
CD3+IL-17+ Th17 cells observed infiltrating in the tumor epithelium, tumor stroma and combined total area 
per mm2 is shown (n=67).
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Supplementary Table S1. Patient and tumor clinico-pathological characteristics
Clinico-pathological parameter Category N = 67 (%)
Age Median 40
Range 26-80
FIGO stage1 IA 2 (3)
IB 59 (88)
IIA 6 (9)








Lymph nodes negative 54 (81)
positive 13 (19)
Tumor size (mm)2 <40 52 (78)
12 (18)
Vaso-invasion2 Absent 36 (54)
Present 17 (25)
Infiltration depth (mm)2 <15 46 (69)
1 17 (25)
HPV type 16 26 (39)
18 24 (36)
other 17 (25)
1FIGO=Fédération Internationale de Gynécologie et d’Obstétrique
2Data were not available for all patients.
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Supplementary Table S2. Number of T cells, Tregs and IL-17+ cells present in cervical adenocarcinoma
The mean, minimum, maximum and median number of total CD3+ cells, FoxP3+CD3+ Tregs, CD3-IL-17+
cells and CD3+IL-17+ Th17 cells observed infiltrating in the tumor epithelium, tumor stroma and combined 
total area per mm2 is indicated.
Supplementary Table S3. Effect of Tregs in combination with IL-17+ cells on survival
Variable Univariate hazard ratio 
(95% CI)
p-value Multivariate hazard ratio 
(95% CI)
p-value
TNM stage 1.606 (1.133-2.276) 0.008 1.545 (1.051-2.273) 0.027
Tregs high reference reference
Tregs low, IL-17 high 5.587 (0.506-61.635) 0.160 7.561 (0.659-86.742) 0.579
Tregs low, IL-17 low 13.906 (1.671-115.730) 0.015 12.261 (1.454-103.383) 0.021
Univariate and multivariate Cox regression analyses for the TNM stage and a low number of Tregs combined 
with a high or low number of (non-Th17) IL-17+ cells versus a high number of Tregs on disease-specific 
survival are shown. 
Supplementary Table S4. Effect of Tregs in combination with Th17 cells on survival
Variable Univariate hazard ratio
(95% CI)
p value Multivariate hazard ratio 
(95% CI)
p value
TNM stage 1.606 (1.133-2.276) 0.008 1.619 (1.131-2.317) 0.008
Tregs high reference reference
Tregs low, Th17 absent 8.361 (0.934-74.863) 0.058 8.460 (0.942-75.983) 0.057
Tregs low, Th17 present 12.825 (1.431-114.930) 0.023 14.668 (1.603-134.179) 0.017
Univariate and multivariate Cox regression analyses for the TNM stage and a low Tregs number combined 
with a high or low number of Th17 cells versus a high number of Tregs on disease-specific survival are 
shown.
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The tumor microenvironment comprises a network of immune response and 
vascularization factors. From this network, we identified immunological and 
vascularization gene expression clusters and the correlations between the clusters by
determining the expression of 42 genes in 52 fresh frozen squamous cervical cancer 
samples using qRT-PCR. Weighted gene co-expression network analysis and mixed-
model analyses were performed to identify gene expression clusters. We subsequently 
determined which factors were correlated with each other and with patient survival. We 
identified four immune response clusters: ‘T cells’ (CD3E / CD8A / TBX21 / IFNG /
FOXP3 / IDO1), ‘Macrophages’ (CD4 / CD14 / CD163), ‘Th2’ (IL4 / IL5 / IL13 / IL12)
and ‘Inflammation’ (IL6 / IL1B / IL8 / IL23 / IL10 / ARG1) and two vascularization 
clusters: ‘Angiogenesis’ (VEGFA / FLT1 / ANGPT2 / PGF / ICAM1) and ‘Vessel 
maturation’ (PECAM1 / VCAM1 / ANGPT1 / SELE / KDR / LGALS9). The ‘T cells’ 
module was correlated with all modules except for ‘Inflammation’, while 
‘Inflammation’ was most significantly correlated with ‘Angiogenesis’ (p<0.001). High 
expression of the ‘T cells’ cluster was correlated with earlier TNM stage (p=0.007). 
High CD3E expression was correlated with improved disease-specific survival 
(p=0.022), while high VEGFA expression was correlated with poor disease-specific 
survival (p=0.032). Independent predictors of poor disease-specific survival were IL6 
(hazard ratio=2.3, p=0.011) and a high IL6/IL17 ratio combined with low IL5
expression (hazard ratio=4.2, p=0.010). To conclude, ‘Inflammation’ marker IL6, 
especially in combination with low levels of IL5 and IL17, was correlated with poor 
survival. This suggests that IL6 promotes tumor growth, which may be suppressed by a 
Th17 and Th2 response. Measuring IL6, IL5 and IL17 expression may improve the 
accuracy of predicting prognosis in cervical cancer. 
Introduction
Cervical cancer is caused by a persistent infection with human papillomavirus (HPV) 
and represents the second leading cause of cancer-associated deaths among young 
women.1 Infection with HPV initiates an immune response that can generally clear the 
infection. In some cases the infection can lead to chronic inflammation, which may 
provide growth signals and support carcinogenesis.2 Once a tumor has been established, 
the type of immune response present in the microenvironment is thought to be important 
for clinical outcome. 
Tumor infiltrating T lymphocytes have been shown to be an independent predictor for 
survival in ovarian and colorectal cancer.3,4 T lymphocytes can be subdivided in 
different populations, including cytotoxic CD8+ T lymphocytes (CTL) and CD4+ T
100
helper 1 (Th1), Th2, Th17 and regulatory T cells (Tregs). CTL and Th1 cells are 
generally appreciated for their potential to induce or stimulate a specific tumor 
suppressing immune response. Synthetic long-peptide vaccination in women with 
HPV16+ high-grade vulvar intraepithelial neoplasia has been shown to induce CD4+ T
helper and CD8+ CTL responses, which were correlated with tumor regression.5 In 
cervical cancer, we have previously shown that a low number of CTL combined with a 
high number of Tregs is an independent predictor for poor survival.6 Since Tregs can 
control the activity of other T cells, these cells may dampen both a tumor suppressing 
and a tumor promoting immune response. Indeed, Tregs have been found to be 
correlated with less invasion in thyroid cancer and improved recurrence-free survival in 
head and neck cancer.7,8 A Th2-induced immune response has also been shown to 
support cervical cancer progression.9 The role of Th17 cells in cancer is still unclear, as 
they are capable of inducing both tumor growth and tumor regression.10
The innate immune system also plays an important role in cervical cancer progression. 
Our group has shown that mature CD14+CD163- M1 type macrophages are an 
independent predictor for improved survival.11 CD163+ M2 type macrophages have 
been correlated with poor survival, although the results of different studies are not 
consistent.12,13 Tumor associated neutrophils are a heterogeneous cell population 
associated with poor outcome in different types of cancer.14
Another important factor for an adequate immune response is the vascular system, 
which delivers nutrients, but also enables immune cells to enter the tumor site. There 
appears to be an inverse relationship between new vessel formation (angiogenesis), 
which supports tumor progression, and vessel adhesiveness (maturation), supporting 
infiltration of immune cells in the tumor tissue.15 Angiogenesis is induced by growth 
factors or cytokines such as vascular endothelial growth factor A (VEGFA), 
angiopoietin-2 (ANGPT2), fibroblast growth factors (FGFs) and interleukin-8           
(IL-8).15,16 Angiogenesis, as represented by a high number of blood vessels, has been 
associated with poor survival in cervical cancer.17 Vessel maturation, on the other hand, 
is characterized by signaling and adhesion proteins including vascular cell adhesion 
molecule-1 (VCAM1), intercellular adhesion molecule-1 (ICAM1), E-selectin (SELE) 
and ANGPT1.15,16
In the present study, we identified combinations of immunological and vascular factors 
(expression clusters) in cervical carcinoma and determined the associations between the 
different clusters, prominent genes and their correlations with clinico-pathological 
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Fresh frozen squamous cervical cancer specimens was obtained from the biobank of the 
departments of Pathology and Gynaecology from the Leiden University Medical Center.
Table 1. Patient and tumor clinico-pathological characteristics
Clinico-pathological parameter Category N = 52 (%)
Age Median 43
Range 24-77
FIGO stage1,2 IB 41 (79)
IIA 10 (19)







Lymph nodes Negative 33 (63)
Positive 19 (37)
Tumor size (mm)2 <40 20 (38)
29 (56)
Vaso-invasion2 Absent 22 (42)
Present 29 (56)
Infiltration depth (mm)2 <15 26 (50)
1 22 (42)
HPV type 16 31 (60)
18 11 (21)
Other 10 (19)
1FIGO=Fédération Internationale de Gynécologie et d’Obstétrique
2Data were not available for all patients.
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Patients had underwent primary surgical treatment for cervical cancer between 1989 and 
2005 and had not received preoperative therapy. Follow-up data were obtained from 
patient medical records. Samples with sufficient material available for analysis, 
containing 50-90% tumor epithelial cells and no uninvolved normal tissue were selected 
by staining a 4  section it  ae ato in an  eosin (n ). edian follow-up time 
was 6.2 years. Patient and tumor characteristics are listed in Table 1. Samples were 
handled according to the medical ethical guidelines described in the Code of Conduct 
for Proper Secondary Use of Human Tissue of the Dutch Federation of Biomedical 
Scientific Societies.
RNA isolation and quality control
N  as iso ate  fro  fo r   s i es sin  Tri o  (Life Tec nologies, Carlsbad, 
USA) and DNase treated and purified using RNeasy Mini columns (Qiagen, Hilden, 
Germany). The RNA integrity and quantity were analyzed using RNA 6000 Nano chips 
in a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, USA). Samples with RIN<5
were excluded from further analysis (n=4), because the Cq values of the reference genes 
were disproportionally low. The median RIN value was 7.9.
qRT-PCR array immune response markers
Genomic DNA removal, cDNA synthesis, pre-amplification and qRT-PCR were 
performed using RT2 Profiler PCR Arrays (Qiagen) according to the manufacturers’ 
instructions. In brief, 300 ng RNA was treated with DNA elimination mix and cDNA 
was subsequently synthesized. The intended PCR products were preamplified, followed 
by Side Reaction Reducer and heat inactivation. A Sybr Green-based qRT-PCR reaction 
was performed in duplicate on a CFX384 system (Bio-Rad, Hercules, USA). A custom 
combination of primer sets was used to analyze different T cell and macrophage 
markers: ARG1, CD14, CD163, CD3E, CD4, CD8A, FOXP3, GATA3, IDO1, IFNG, 
IL1B, IL10, IL12A, IL13, IL17A, IL17F, IL2, IL23A, IL4, IL5, IL6, RORC, T-bet 
encoding TBX21, TGFB1 and TGFB3. From the four reference genes included based on 
reported stability in cervical cancer tissue, the most stably expressed genes EEF1A1 and 
RPLP0 were used for normalization. Averaged duplicate measurements were scaled by 
standard deviation. Negative genomic DNA contamination and positive reverse 
transcriptase and PCR controls were included for each sample.
cDNA synthesis and qRT-PCR IL-17A and neutrophil markers
Since IL17A expression measured by the RT2 Profiler PCR Array was low for all 
samples and not detected in eight samples, an additional qRT-PCR with Primer-
BLAST18 designed primers for IL17A was performed on all samples. To further 
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fucosyltransferase 9 (FUT9) and neutrophil elastase (NE). cDNA was synthesized as 
described previously.19 Sybr Green-based qRT-PCR was performed in duplicate using 
1:125 diluted cDNA and 3 pmol primers. Primers and annealing temperatures used were 
for IL17A: forward 5’-CCCCCGGACTGTGATGGTCAAC-3’ and reverse 
GCGGCACTTTGCCTCCCAGAT at 56.7°C, FUT9: forward 5’-
AGGCCACCCTTCCAGAAATG-3’ and reverse 5’- TGCTTGGCACTTCAAACACG-
3’ at 64.5°C and NE: forward 5’- ATTCTCCAGCTCAACGGGTC-3’ and reverse 5’-
GATTAGCCCGTTGCAGACCA-3’ at 63.8°C. The PCR products were validated by 
sequencing. Reference genes EEF1A1 and RPLP0 were quantified using 4 pmol RT2
qPCR primer assays (Qiagen) at an annealing temperature of 60°C as per the 
manufacturers’ instructions. Replacing the cDNA template by milliQ was used as 
negative control. The qRT-PCR, normalization and scaling were performed as described 
for the RT2 Profiler PCR array. Since RNA expression was detected in all samples by 
the Primer-BLAST primers, all IL17A analyses were performed with the IL17A
expression measured by the Primer-BLAST primers.
cDNA synthesis and qRT-PCR vascularization markers
Vascularization markers ANGPT1, ANGPT2, basic fibroblast growth factor (bFGF), 
platelet endothelial cell adhesion molecule (PECAM1), placental growth factor (PGF), 
IL8, Galectin-1 (LGALS1), Galectin-3 (LGALS3), Galectin-9 (LGALS9), VEGFA, 
VEGFR1 encoding fms-related tyrosine kinase 1 (FLT1), VEGFR2 encoding kinase 
insert domain receptor (KDR), ICAM1, VCAM1 and SELE were measured on all 
samples, except for samples containing less than 100 ng RNA per µl (n=2). cDNA 
synthesis, primers and qPCR conditions were as described before.20,21 Reference genes, 
normalization and scaling were performed as described for the immune response 
markers.
Immunohistochemistry
In previous studies, immunohistochemistry (IHC) has been performed on at least ten 
formalin-fixed, paraffin-embedded (FFPE) samples corresponding to the fresh frozen 
samples used in this study. Briefly, CD3+CD8+ CTL were stained by a mixture of rabbit 
anti-CD3 (Abcam, Cambridge, UK), mouse IgG2b anti-CD8 (Novocastra, Newcastle, 
UK) and mouse IgM anti-CD57 (developed in-house), followed by goat anti-rabbit IgG-
A546, goat anti-mouse IgG2b-A647 and goat anti-mouse IgM-A488 (Invitrogen, Life 
Technologies, Carlsbad, USA).6 Fifteen images per slide were obtained in 26 samples
using an LSM510 confocal laser scanning microscope equipped with a PH2 Plan-
NEOFluar 25x/0.80 oil objective (Zeiss, Göttingen, Germany) in a multitrack setting. 
The number of IL-6+ cells was scored in 14 samples stained with rabbit anti-IL-6
(Abcam) followed by biotinylated swine anti-rabbit (Dako, Glostrup, Denmark) and
biotinylated HRP-streptavidin (Dako).22 The percentage of positive cells was counted in 
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six random high-power fields. The number of IL-1β+ cells was scored in 12 overlapping 
samples stained with goat anti-IL-1β (  ste s) and the goat HRP-polymer kit.22
Positive cells were counted in the tumor stroma of six random high-power fields. IL-17
was stained on all 52 samples by goat anti-IL-17 (R&D Systems, Abingdon, UK) 
followed by goat HRP-polymer (Biocare Medical, Concord, USA).23 Cells were 
digitally scored in 4-6 random images at a 200x magnification. CD3+IL-17+ cells were 
stained by a mixture of mouse IgG1 anti-CD3 (Dako) and goat anti-IL-17 followed by 
rat anti-mouse IgG1-AP (Southern Biotech, Birmingham, USA) and donkey anti-goat-
HRP (Abcam). Six random images were taken in 18 samples using a DM4000B spectral 
microscope equipped with a HC Plan APO 20x objective (Leica Microscopy CMS 
GmbH, Wetzlar, Germany).
Statistical analysis
Weighted gene co-expression network analysis (WGCNA) was performed using R 
version 3.0.2.24 Weights were computed using a power of 3 to obtain the best 
combination of power, scale-free topology and connectivity values. Average linkage 
hierarchical clustering was performed. The distance between subclusters was 
determined by using the average distances between all potential gene pairs. Small 
clusters were only assigned to clusters belonging to the same branch. Gene expression 
clusters were summarized using the first principal components.
To test for correlations between gene expression clusters and genes, mixed model 
analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, USA). All 
combinations between the six expression clusters were tested for correlations with a 
Bonferroni corrected significance level of p<0.003. A cutoff for single gene correlations
(r) of 0.3 and significance level of p<0.05 were used. Correlations between RNA 
expression and IHC data was tested using the Spearman’s rank correlation rho test. A p 
value<0.05 was considered statistically significant.
Correlations between gene expression clusters or separate genes and clinico-
pathological variables were tested using the independent samples t-test and Wilcoxon 
Mann-Whitney U test for categorical variables and the Pearson and Spearman’s rank 
correlation rho for continuous variables. Six gene expression clusters were tested for 
each parameter with a Bonferroni corrected significance level of p<0.008.
Normalized Cq values were converted to expression values to obtain correlations 
corresponding with increased presence of the gene product for Kaplan-Meier and Cox 
proportional hazards survival models. For Kaplan-Meier curve generation and log rank 
analyses, gene expression levels were divided in four equal quartiles and the lowest
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We investigated the expression of 27 immune response and 15 vascularization marker 
genes in 52 squamous cervical cancer samples by WGCNA, a method developed for 
network analysis of gene expression data.25 A gene expression cluster is composed of 
genes with similar expression patterns. Genes that were not included in a cluster due to 
lack of correlation with other genes were removed from cluster analysis, including 
bFGF, FUT9, LGALS1, LGALS3, GATA3, IL17A, IL17F, IL2, NE, RORC, TGFB1 and 
TGFB3, resulting in the dendrogram shown in Figure 1A. Of note, the neutrophil 
markers NE and FUT9 were expressed at very low levels and were not detected in 26 
and 34 out of 52 samples, respectively. IL17A was also generally expressed at levels 
lower than the other genes measured. 
Small gene expression distances represent strong correlations. The strongest correlations 
were found between the T cell markers, for instance between TBX21 and CD3E
(r = 0.939, p<0.0001). Additional clustering was found for the T cell (CD3E), CTL 
(CD8A), Th1 (TBX21, IFNG) and Treg (FOXP3, IDO1) markers. This gene cluster is
referred to as the ‘T cells’ cluster. A ‘Th2’ cluster was represented by the expression of 
IL4, IL5, IL13 (Th2 markers) and IL12 (Th1 marker). As the expression distance 
between IL12 and the other markers was high, IL12 only weakly correlated with the Th2 
markers. The expression of CD4, CD14 and CD163 represented a ‘Macrophage’ cluster. 
The last immune response cluster consisted of genes representative of an 
‘Inflammation’ response, including IL1B, IL6, IL8, IL10, IL23 and ARG1. In this 
cluster, IL10 and ARG1 were weakly correlated. The ‘Angiogenesis’ cluster included 
the genes ANGPT2, FLT1 (encoding VEGFR1), VEGFA, PGF and ICAM1, while the 
‘Vessel maturation’ cluster included the genes PECAM1, KDR (encoding VEGFR2), 
ANGPT1, VCAM1, LGALS9 and SELE (encoding E-Selectin). 
To analyze the correlations between the different gene clusters, we performed mixed 
model analyses, summarized in Figure 1B. All gene clusters significantly correlated 
with ‘Vessel maturation’, while the ‘T cells’ cluster significantly correlated with all 
other clusters except for ‘Inflammation’ (all p<0.001). The ‘Inflammation’ cluster 
significantly correlated with the ‘Vessel maturation’, ‘Angiogenesis’ and 
‘Macrophages’ clusters (all p<0.0001), although the individual ‘Inflammation’ genes 
did not significantly correlate with any of the individual ‘Macrophages’ genes.
In order to study the relationships of more distant genes, we also studied their 
correlation with separate genes. Extending on the ´Inflammation´ associations, 
expression of ´Inflammation´ marker IL6 was inversely correlated with ‘Vessel 
maturation’ marker VCAM1 (r = -0.340, p=0.021). The ‘Inflammation’ and ‘T cells’ 
clusters were not significantly correlated, but the ‘Inflammation’ marker gene IL1B
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Figure 1. Gene expression clusters
WGCNA was performed to detect gene expression clusters, as shown in Figure 1A. Expression clusters are 
indicated by color bars below the genes that are included in the different clusters. The smallest gene 
expression distances are present between the genes at the bottom of the figure, representing strong 
associations. Frequently used gene synonyms are shown between brackets. The correlations between the 
clusters were tested by mixed model analyses, represented in Figure 1B. Only correlations with p<0.003 are 





Figure 1. Gene expression clusters
WGCNA was performed to detect gene expression clusters, as shown in Figure 1A. Expression clusters are 
indicated by color bars below the genes that are included in the different clusters. The smallest gene 
expression distances are present between the genes at the bottom of the figure, representing strong 
associations. Frequently used gene synonyms are shown between brackets. The correlations between the 
clusters were tested by mixed model analyses, represented in Figure 1B. Only correlations with p<0.003 are 
shown, based on the Bonferroni correction for multiple testing.
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negatively correlated with CD3E (r = -0.384, p=0.009), CD8 (r = -0.384, p=0.009), 
FOXP3 (r=-0.307, p=0.031) and TBX21 expression (r=-0.307, p=0.032). Expression of 
the ‘Th2’ cluster gene IL12 was distant from other ‘Th2’ genes, and only significantly 
correlated with IL4 expression (r = 0.506, p=0.001). Similarly, ARG1 expression only 
weakly correlated with IL10 (r = 0.423, p=0.004) and IL23 expression (r = 0.400, 
p=0.007), but not with the other genes in the cluster. 
Correlations between gene expression and clinico-pathological 
parameters
Correlations between the gene cluster first principal components and the individual 
genes and clinico-pathological parameters were investigated. Increased expression of 
the ‘T cells’ cluster was significantly correlated with early tumor node metastasis 
(TNM) staging (r=0.37, p=0.007; see Table 2). This could mainly be attributed to the 
expression of FOXP3 (r=0.39, p=0.004) and CD3E (r=0.37, p=0.006). 














TNM T cells 0.37 0.007 FOXP3 0.388 0.004
CD3E 0.374 0.006
Vaso-










Correlations between normalized Cq values of cluster first principal components or separate genes and 
clinico-pathological parameters with p<0.008 are shown (for the correlation between LGALS9 and lymph 
nodes p=0.0077). The correlations between single gene expression and TNM stage were tested by the Pearson 
correlation test and since increased Cq values represent decreased expression, an inverse correlation was 
found. The correlations for separate genes and vaso-invasion or lymph nodes were tested using independent 
samples t-tests. Mean normalized Cq values of the gene expression within a category are given to indicate the 
direction of correlation (inverse for vaso-invasion).
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Low expression of CD3E was significantly correlated with poor disease-specific 
survival (p=0.022; Figure 2A). For disease-free survival, in addition to low CD3E
expression, low expression of both FOXP3 and CD8 were correlated with poor outcome 
(p=0.014, p=0.008 and p=0.034, respectively; Figures 2B-D). 
Figure 2. Correlations between immune response and vascularization markers and survival
Kaplan-Meier survival curves for gene expression divided in quartiles. Disease-specific survival for the 
quartile group with lowest CD3E expression compared with the other groups is shown in A. Disease-free 
survival with the same division for CD3E, FOXP3 and CD8 expression is shown in B, C and D. Disease-
specific survival for the quartile groups with highest IL6 and VEGFA expression compared with the rest are 
shown in E and F. Disease-specific survival for the quartile group with the highest ratio IL6/IL17 expression 
compared with the rest is shown in G. The combination of an above median IL6/IL17 ratio combined with a 
below median level of IL5 compared with the presence of above median expression of IL5 or relatively low 
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Figure 2. Correlations between immune response and vascularization markers and survival
Kaplan-Meier survival curves for gene expression divided in quartiles. Disease-specific survival for the 
quartile group with lowest CD3E expression compared with the other groups is shown in A. Disease-free 
survival with the same division for CD3E, FOXP3 and CD8 expression is shown in B, C and D. Disease-
specific survival for the quartile groups with highest IL6 and VEGFA expression compared with the rest are 
shown in E and F. Disease-specific survival for the quartile group with the highest ratio IL6/IL17 expression 
compared with the rest is shown in G. The combination of an above median IL6/IL17 ratio combined with a 
below median level of IL5 compared with the presence of above median expression of IL5 or relatively low 
IL6 expression is shown in H.
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High expression of the ‘Inflammation’ gene cluster was significantly correlated with the 
absence of vaso-invasion (r = 0.38, p=0.005), mainly as a result of the contribution of  
IL6 (p=0.002). High expression of IL6 was significantly correlated with poor disease-
specific survival (p=0.019; Figure 2E). 
Expression of the ‘Vessel maturation’ marker LGALS9 was correlated with lymph node
metastasis (p=0.008). This association was also observed for the expression of IL2
(p=0.003). 
Within the ‘Angiogenesis’ cluster, high expression of VEGFA (highest quartile) was 
significantly correlated with poor disease-specific survival (p=0.032; Figure 2F).
Hazard ratios for independent prognostic factors
We investigated which genes were independent prognostic factors for survival using a 
multivariate analysis with one representative gene per cluster (Table 3). High IL6
expression was the best predictor of poor disease-specific survival with a hazard ratio of
2.2 (p=0.002). After correction for clinico-pathological parameters, the hazard ratio of 
IL6 expression was 2.3 (p=0.011). IL-6 was a signature cytokine of the ‘Inflammation’ 
gene cluster, which included cytokines that are often associated with the induction of an 
IL-17 response: IL-1β, IL-6, IL-8 and IL-23.26 Studying the correlation between IL-17
and survival, we found that high expression of IL17 showed a trend toward an 
association with improved survival (p=0.087). Since IL6 and IL17 expression were not 
correlated in our study, we studied whether the ratio of IL6 and IL17 has an association 
with survival. Indeed, a high ratio of IL6 over IL17 expression was significantly 
correlated with poor survival (p=0.001; Figure 2G). Since the intratumoral immune 
response in cervical cancer is dominated by Th1, Th2, Th17 and Treg cells, we further 
analyzed the contribution of the Th1 marker TBX21 and Th2 marker IL5. In order to 
maintain sufficient group sizes for this analysis, groups were divided based on the 
median expression level. An above median IL6 over IL17 ratio remained significantly
correlated with poor survival (p=0.004). We did not observe a significant effect for the 
addition of TBX21, which was significantly correlated with Th1, Treg and CTL 
markers. In contrast, the combination of above median IL6 relative to IL17 expression 
combined with a below median level of IL5 was significantly correlated with a worse 
prognosis (p<0.0001; Figure 2H). This combination was shown to be an independent 
predictor for poor prognosis corrected for lymph node status, tumor size and infiltration 
depth with a hazard ratio of 4.2 (p=0.010; Table 3). For both multivariate Cox 
regression analyses, the results remained similar and significant upon adding 
postoperative therapy as a parameter.
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Univariate Cox regression hazard ratios are shown for the critical prognostic categorical clinico-pathological 
parameter lymph node tumor positivity and the continuous variables tumor size (per mm) and infiltration 
depth (per mm), as well as for the expression of genes representative for the different clusters. Normalized Cq 
values were converted to expression values to obtain hazard ratio’s corresponding with increased presence of 
the gene product. Multivariate Cox regression analyses are shown for the genes significant in the univariate 
analysis combined with the most critical clinico-pathological parameters (restricted by the number of 
patients). The combination of the IL6/IL17 ratio and IL5 is divided in three categories: a low ratio, a high ratio 
and high IL5 levels and a high ratio combined with low IL5 levels.
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Correlation between RNA and protein expression
We studied whether the expression levels of some of the most relevant genes 
determined by qRT-PCR on fresh frozen tissue correlated with the number of cells 
expressing the corresponding proteins determined by IHC in FFPE tissue. The RNA 
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expression level of CD8 was significantly correlated with the number of CD3+CD8+
cells (r = -0.640, p=0.0004; Figure 3A). The expression of IL6 and the percentage of 
IL-6+ cells were also significantly correlated (r = 0.574; p=0.032; Figure 3B). The 
number of cells expressing IL-1β was significantly correlated with IL1B RNA 
expression (r=0.628; p=0.029; Figure 3C). 
We further studied whether IL17 RNA expression was correlated with the number of 
IL-17+ cells, mainly comprising neutrophils, or specifically with Th17 cells. There was 
no significant correlation between IL17A RNA expression and the total number of 
IL-17+ cells (r = -0.048, p=0.737; Figure 3D), but there was a trend toward a positive 
correlation with the number of IL-17+CD3+ Th17 cells (r=-0.438, p=0.069; Figure 3E).
Figure 3. Correlations between RNA and protein expression
The RNA expression levels determined by qRT-PCR in fresh frozen tissue were compared with the number of 
cells expressing the corresponding protein as determined by IHC. Correlations were determined for CD8 
expression and the number of CD3+CD8+ cells (A), IL6 and the percentage of IL-6+ cells (B), IL1B and the 
number of IL-1β e ressin  ce s ( ), IL1  an  t e tota  n er of IL-17+ cells (D) and Th17 cells (E).
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Discussion
In the present study, we used WGCNA to identify gene expression clusters associated 
with immune response and vessel formation processes in cervical carcinoma. Six gene 
expression clusters were identified: ‘T cells’, ‘Macrophages’, ‘Th2’, ‘Inflammation’, 
‘Vessel maturation’ and ‘Angiogenesis’. The clusters were named according to the 
pathways the genes are involved in, but may be expressed and induced by tumor 
epithelial or infiltrating immune cells, or both. High expression of the ‘T cells’ cluster
was associated with early TNM staging, and low expression of CD3E, CD8 and FOXP3
were correlated with poor disease-specific and disease-free survival. This supports 
earlier observations where the absence of a lymphocytic infiltrate was shown to be a
predictor of poor survival.27 The ‘T cells’ cluster also showed strong correlations 
between the expression of CTL, Th1 and Treg marker genes. In agreement with these 
observations, we and others have previously shown that the number of FoxP3+ Tregs 
strongly correlates with the number of tumor infiltrating T cells.6,8 In contrast, we have 
shown before that a high number of FoxP3+ Tregs scored specifically within the tumor
epithelium, especially relative to the number of CD8+ CTL, was correlated with poor 
survival, an observation also made in other tumor types.27-29 Collectively, these data 
indicate that T cell infiltration is correlated with improved survival, whereas a relatively 
high number of Tregs, specifically within the tumor epithelium, counteracts the tumor 
suppressing immune response.
The ‘Th2’ gene expression cluster was characterized by IL4, IL5, IL13 and IL12
expression. Surprisingly, expression of the transcription factor GATA3 was not 
correlated with the expression of any of these genes, suggesting that GATA3 RNA 
expression may not be suitable marker for the Th2 response. Although a Th2 response is 
regarded as immunosuppressive in cervical cancer,9 HPV-specific T cells associated 
with regression of high-grade VIN lesions, have been shown to produce high levels of 
both IFNy and IL-5.5 In agreement with the latter observation, low IL5 levels were an 
indicator of poor prognosis in combination with high IL6 relative to IL17 levels. 
The ‘Inflammation’ gene expression cluster was not significantly correlated with the 
‘Th2’ and ‘T cells’ clusters, indicating that these clusters represent distinct pathways.
High expression of IL6 represented a dominant ‘Inflammation’ response and was 
significantly correlated with poor disease-specific survival. A high number of stromal 
IL-6+ cells was previously shown to be correlated with poor disease-specific survival in 
an overlapping patient cohort22 and other types of cancer.30 IL-6 might drive STAT3 
expression in tumor cells,31 induce angiogenesis and epithelial-mesenchymal 
transition32,33 and induce differentiation of dendritic cells and macrophages toward 
tumor promoting cells.34,35 Additionally, IL6 was correlated with the absence of vaso-
invasion. We have observed a significant correlation between IL-17 and IL-1β and the 
absence of vaso-invasion by IHC as well (reference 23 and unpublished data). β, 
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with regression of high-grade VIN lesions, have been shown to produce high levels of 
both IFNy and IL-5.5 In agreement with the latter observation, low IL5 levels were an 
indicator of poor prognosis in combination with high IL6 relative to IL17 levels. 
The ‘Inflammation’ gene expression cluster was not significantly correlated with the 
‘Th2’ and ‘T cells’ clusters, indicating that these clusters represent distinct pathways.
High expression of IL6 represented a dominant ‘Inflammation’ response and was 
significantly correlated with poor disease-specific survival. A high number of stromal 
IL-6+ cells was previously shown to be correlated with poor disease-specific survival in 
an overlapping patient cohort22 and other types of cancer.30 IL-6 might drive STAT3 
expression in tumor cells,31 induce angiogenesis and epithelial-mesenchymal 
transition32,33 and induce differentiation of dendritic cells and macrophages toward 
tumor promoting cells.34,35 Additionally, IL6 was correlated with the absence of vaso-
invasion. We have observed a significant correlation between IL-17 and IL-1β and the 
absence of vaso-invasion by IHC as well (reference 23 and unpublished data). β, 
also a member of the ‘Inflammation’ gene cluster, showed a trend toward a correlation 
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with the absence of vaso-invasion. These results suggest that this type of inflammatory
response may prevent metastatic spread of the tumor cells via the blood or lymphatic 
vasculature.
The ‘Inflammation’ gene cluster was characterized by cytokines that are often 
associated with the induction of an IL-17 response: IL-1β, IL-6, IL-8 and IL-23.26
However, IL17 expression was not significantly correlated with the ‘Inflammation’ 
cluster, T-cell or neutrophil related genes. Mature neutrophils have been shown to 
express no or very low mRNA levels for granule proteins.36 In our study, both IL17 and 
neutrophil markers NE and FUT9 were expressed at very low levels. Since we have 
shown by IHC that IL-17 is mainly expressed by neutrophils in cervical cancer,23 this 
suggests that IL17A RNA expression is primarily derived from Th17 cells. The absence 
of a correlation with T cell markers and the ‘Inflammation’ gene cluster is likely due to 
the small size of the Th17 population.
While a qRT-PCR analysis by Tosolini et al. showed that a Th1 cluster and high 
FOXP3 expression were correlated with improved disease-free survival in colon cancer, 
corresponding with our results, this group also found a correlation between a high 
Th1/Th17 gene cluster ratio and improved disease-free survival.37 In the current work, 
the ‘Inflammation’ gene cluster was more important for patient survival. To study 
whether IL17 might have an opposite effect on survival compared to IL6, the ratio of 
IL6 and IL17 was analyzed. Indeed, this ratio was significantly correlated with poor 
survival, corresponding with previous observations that a high number of Th17 cells is 
correlated with improved disease-specific survival in cervical carcinoma.23 Since the 
immune response in cervical cancer is predominantly characterized by Th1, Th2, Th17 
and Treg cells, the contributions of the ‘T cells’ signature marker TBX21 and the ‘Th2’ 
signature marker IL5 were studied. We did not observe a significant association with the 
Th1 marker TBX21, which is supposed to be critical for an tumor suppressing immune 
response.5 Strikingly, the most prognostic independent risk factor was a high IL6 over 
IL17 ratio combined with a low expression level of Th2 marker IL5, with a hazard ratio 
of 4.2 (p=0.010). Since we did not find a correlation between IL5 and IL6 expression in 
cervical cancer, this suggests that the effect of a high amount of IL6 is dampened by a
Th2 response.
‘Vessel maturation’ adhesion markers were correlated with KDR encoded VEGFR2
expression, which has been described before38 and suggests that VEGFR2 might 
primarily be involved in vessel maturation in cervical cancer. Expression of the ‘Vessel 
maturation’ marker LGALS9 was correlated with tumor positive lymph nodes, 
suggesting it might play a role in metastasis to the lymph nodes.
The ‘Inflammation’ cluster was most significantly correlated with the ‘Angiogenesis’ 
cluster. Although the ‘Angiogenesis’ cluster marker ICAM1 is an adhesion protein, 
VEGFA has been described to first induce ICAM1 expression to prepare endothelial 
cells for migration, after which ICAM1 is downregulated.39 The ‘Angiogenesis’ marker 
VEGFA was significantly correlated with poor disease-specific survival (p=0.032), 
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which is in agreement with our previous study where we showed that VEGFA
expression correlates with the number of blood vessels in cervical cancer, in its turn 
correlated with poor disease-free survival.40 Correspondingly, Yuan et al. showed that 
both RNA and protein expression of VEGFA were correlated with poor survival in non-
small-cell lung cancer.41
Although IL-17 has been reported to induce vascularization via VEGF-dependent and 
-independent mechanisms in cancer,42,43 we did not find a significant association 
between IL17 and angiogenesis or vessel maturation. Correspondingly, we did not find 
a correlation between the number of IL-17+ cells and the number of CD105+ vessels in a 
series of 151 squamous cervical carcinoma samples (data not shown). 
To conclude, by using a qRT-PCR array, we identified CD3E, IL6, VEGFA and a high 
IL6/IL17 ratio combined with low IL5 expression as the most prognostic factors in 
squamous cervical cancer. While high expression of T cell markers was correlated with 
improved prognosis, and high expression of angiogenesis marker VEGFA with poor 
prognosis, IL17 expressed by Th17 cells could counteract the tumor promoting effects 
of IL6, even more so combined with a Th2 response characterized by IL5. A proposed 
model of the factors most relevant for disease outcome is shown in Figure 4. 
Figure 4. Th17 counteracts the effect of IL6
Of the 27 immunological and 15 vascularization markers analyzed, CD3, IL5, IL6, IL17A and VEGFA were 
most significantly correlated with the clinical outcome of cervical cancer patients. A ‘T cells’ response, 
indicating the presence of Th1, CTL and Treg cells and represented by blue cells in the image, was correlated 
with improved prognosis. IL6 and VEGFA, the latter indicative of angiogenesis, were both correlated with 
poor prognosis. IL6, expressed by both tumor cells and infiltrating immune cells, may directly promote tumor 
growth, indicated by the interrupted arrow. High IL17 (Th17) and IL5 (Th2) expression were correlated with 
improved prognosis, specifically relative to IL6 expression. IL6 expression was also correlated with the 
absence of vaso-invasion, indicated by the blunted arrow on the tumor cell entering the vessel. We have also 
shown this correlation before for IL-17 protein expression,23 suggesting that the IL-6/IL-17 pathway may 
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Of the 27 immunological and 15 vascularization markers analyzed, CD3, IL5, IL6, IL17A and VEGFA were 
most significantly correlated with the clinical outcome of cervical cancer patients. A ‘T cells’ response, 
indicating the presence of Th1, CTL and Treg cells and represented by blue cells in the image, was correlated 
with improved prognosis. IL6 and VEGFA, the latter indicative of angiogenesis, were both correlated with 
poor prognosis. IL6, expressed by both tumor cells and infiltrating immune cells, may directly promote tumor 
growth, indicated by the interrupted arrow. High IL17 (Th17) and IL5 (Th2) expression were correlated with 
improved prognosis, specifically relative to IL6 expression. IL6 expression was also correlated with the 
absence of vaso-invasion, indicated by the blunted arrow on the tumor cell entering the vessel. We have also 
shown this correlation before for IL-17 protein expression,23 suggesting that the IL-6/IL-17 pathway may 
prevent tumor spread via the blood or lymphatic vasculature.
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Measuring IL6, especially in combination with IL5 and IL17 expression may improve 
the accuracy of predicting prognosis. Moreover, our data support the development of 
combined anti-IL-6 and anti-VEGF therapies. Since we have found correlations 
between ‘Inflammation’ markers and the absence of vaso-invasion, blocking IL-6 might 
increase the risk of tumor cell invasion. Since VEGFA expression has been correlated 
with tumor invasiveness,44,45 and the presence of vaso-invasion negatively affects 
clinical outcome, blocking both IL-6 and VEGFA has the potential to counteract both 
tumor growth and invasion.
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Cervical cancer is typically well infiltrated by immune cells. Because of the intricate 
relationship between cancer cells and immune cells, we aimed to identify both cancer 
cell and immune cell expressed biomarkers for survival. Using a novel approach, we 
isolated RNA from flow-sorted viable EpCAM+ tumor epithelial cells and CD45+
tumor-infiltrating immune cells obtained from squamous cell cervical cancer samples 
(n=24). Total RNA was sequenced and differential gene expression analysis of the 
CD45+ immune cell fractions identified TCL1A as a novel marker for predicting 
improved survival (p=0.007). This finding was validated using qRT-PCR (p=0.005) and 
partially validated using immunohistochemistry (p=0.083). Importantly, TCL1A was 
found to be expressed in a subpopulation of B cells (CD3-/CD19+/CD10+/CD34-).          
A high TCL1A/CD20 (B cell) ratio, determined in total tumor samples from a separate 
patient cohort using qRT-PCR (n=52), was also correlated with improved survival 
(p=0.027). These results suggest that intratumoral TCL1A+ B cells are important for 
controlling cervical cancer development.
Introduction
Cervical cancer is caused by persistent infection with human papillomavirus (HPV) and 
is currently the second-leading cause of cancer-related death in young women.1 The 
prognosis for patients with cervical cancer relapse is poor. Although the host’s immune 
system can usually clear an HPV infection, chronic inflammation can contribute to 
tumorigenesis.2 Cervical cancer is characterized by a large number of infiltrating 
immune cells, and observational and functional studies have revealed that several 
immune cell types can play a crucial role in the prognosis of patients with cervical 
cancer. A high number of cytotoxic T cells and T helper type 1 cells is correlated with 
improved survival in several cancer types,3,4 including cervical cancer.5 Cytokines 
derived from immune cells determine the type of immune response, but they can also 
directly promote tumor growth.6 For example, our group and others have shown that a 
high level of IL-6 expression is an independent predictor of poor survival.7-9 However, 
because tumor cells can also produce cytokines and suppress a tumor-targeting immune 
response,10 the complex interaction between tumor cells and the local microenvironment 
makes it challenging to discriminate between effects arising from the tumor cells and 
effects arising from immune cells.
Because of the intricate relationship between cervical cancer cells and the infiltrating 
immune cells, the infiltrating immune cells represent an opportunity to identify novel 
cell-specific biomarkers for improved patient survival. Immunohistochemistry (IHC) is 
a commonly used method for investigating separate cell types, but is suitable for 
studying only a select number of strongly expressed antigens. To detect global 
122
differences in gene expression, total RNA is usually studied. However, studying gene 
expression in tumor samples usually fails to provide information regarding the origin of 
the cells expressing a particular RNA. Therefore, to distinguish between genes 
expressed by tumor epithelial cells and genes expressed by tumor-infiltrating immune 
cells, these two cell subpopulations must first be separated. Although fluorescence-
activated cell sorting is a commonly used strategy for selectively identifying cancer 
stem cells11-13 and for studying the molecular genetics of tumor cell subpopulations,14,15
to the best of our knowledge flow cytometry has not been used for transcriptome 
analysis of matched tumor cell and immune cell subpopulations.
The aim of this study was to discover potential biomarkers for survival expressed by 
tumor cells or infiltrating immune cells using an unbiased approach. Tumor epithelial 
cells were separated from immune cells using flow cytometry. Subsequently, we 
performed total RNA sequencing (RNA-seq) and differential gene expression analysis 
to examine which genes may play a role in clinical outcome. Our analysis revealed that 
T-cell leukemia/lymphoma 1A (TCL1A) is a novel immune cell expressed marker for 
predicting improved survival in patients with cervical cancer. This finding was 
confirmed using both qRT-PCR and IHC analyses. In addition, we used multicolor
immunofluorescence to demonstrate that TCL1A is expressed by a subpopulation of B 




Tumor samples were obtained from patients who underwent primary surgical treatment 
for squamous cell cervical cancer from 1985 through 2005. Samples with sufficient 
material to dissociate and freeze cells available in the archives of the Department of 
Pathology (Leiden University Medical Center, Leiden, the Netherlands) were selected 
for this study (n= 36). None of the patients received preoperative therapy, and clinical 
and follow-up data were obtained from patient medical records. Samples were handled 
in accordance with the medical ethical guidelines described in the Code of Conduct for 
the Proper Secondary Use of Human Tissue established by the Dutch Federation of 
Biomedical Scientific Societies.
Tumor tissue dissociation and sample preparation 
Fresh tumor samples were dissociated as described previously.16-18 In brief, the tumor 
tissue was rinsed in RPMI medium (Gibco Life Technologies, Bleiswijk, the 
Netherlands) and subsequently dissected into 1-2 mm3 pieces, which were incubated 
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Tumor tissue dissociation and sample preparation 
Fresh tumor samples were dissociated as described previously.16-18 In brief, the tumor 
tissue was rinsed in RPMI medium (Gibco Life Technologies, Bleiswijk, the 
Netherlands) and subsequently dissected into 1-2 mm3 pieces, which were incubated 
overnight in 10 ml DMEM (Gibco) containing 0.5 mg/ml collagenase type II and 
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0.002% DNase I type II (both from Sigma-Aldrich, St. Louis, MO). The suspension was 
then incubated in 0.25% trypsin (Gibco) for up to one hour at 37°C until a single-cell 
suspension was obtained. The cells were then filtered through a 100-µm pore size nylon 
sieve (Verseidag-Industrietextilien GmbH, Kempen, Germany), and 10% (v/v) fetal calf 
serum (FCS) was added. The cells were frozen in 90% FCS/10% DMSO at -180°C until 
further use.
The protocol for preparing the samples for cell sorting was adapted from Tighe and 
Matthew.19 Cell suspensions were thawed rapidly in a 37°C water bath, added to a total 
volume of 10 ml RPMI medium and centrifuged at 1000xg at 4°C for 3 minutes. The 
cell pellet was washed in 100 U RNasin Ribonuclease Inhibitor (Promega, Madison, 
WI) in 1 ml phosphate-buffered saline (PBS), filtered through a 50-µm filter (BD 
Biosciences, San Jose, CA), stained with haematoxylin and counted. Depending on the 
total number of cells in each sample, 1-6 million cells were transferred to RNase-free 
tubes and centrifuged at 800xg at 4°C for 5 minutes. The cell pellets were resuspended 
in RNasin/PBS, RNasin/PBS containing 1:10 FITC-labelled mouse anti-CD45 antibody 
(clone T29/33; Dako, Glostrup, Denmark), 1:10 PE-labelled mouse anti-CD326 
antibody (i.e., anti-EpCAM; clone EBA-1; BD Biosciences), or RNasin/PBS containing 
both antibodies. The cells were then incubated in the dark at 4°C for one hour. The 
samples were washed three times in 1 ml RNasin/PBS by centrifuging at 800xg at 4°C 
for 5 minutes. The pellets were then resuspended in RNasin/PBS containing 1:4000 
TO-PRO-3 (Life Technologies, Carlsbad, CA) and transferred to RNase-free flow 
cytometry compatible tubes. Identical samples were pooled.
Flow cytometry
A FACSARIA IIu (BD Biosciences) was used for cell sorting. Prior to each sorting run, 
all parts of the sort chamber were cleaned with RNaseZap (Life Technologies), and the 
inlet tube and flow cell were cleaned with 10% Contrad70 followed by RNasin/PBS. 
Dead cells were excluded based on TO-PRO-3 staining.20 Blue and red lasers were used 
for excitation. A live gate was set using a FSC-A versus TO-PRO-3 fluorescence dot 
plot. A cut-off of 3% living TO-PRO-3- cells was used to exclude samples from further 
analysis (7 samples exceeded this cut-off and were excluded). Cell doublets were 
excluded using FSC-H versus FSC-W and SSC-H versus SSC-W pulse-processing. 
Single-stained samples were used to correct for spectral overlap. EpCAM+ and CD45+
single-positive cells in the double-stained samples were sorted using a 16,16 purity 
mode, a 100-µm nozzle at 20 psi and a drop frequency of 30.8 kHz. A representative 
example of the restricted gating strategy for sorting pure EpCAM+ tumor epithelial cells 
and CD45+ immune cells is shown in Figure 1. Cells were collected in 2-ml tubes 
containing 1 ml ice-cold RNAprotect Cell Reagent (Qiagen, Hilden, Germany), mixed 
and kept on ice until RNA isolation. 
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Figure 1. Example of EpCAM+ and CD45+ single-positive cells obtained from a cervical cancer cell 
suspension using flow cytometry
The negative control stained for TO-PRO-3 but not for EpCAM or CD45 is shown in A-D. Living cells were 
selected based on the absence of TO-PRO-3 staining (A), after which cell aggregates were excluded using 
forward scatter width (B) and side scatter height and width (C). Cell sorting was based on the expression of 
either EpCAM or CD45 in the double stained samples (E), but not in the unstained control (D). Restricted 
gates were used as indicated to obtain pure cell populations. Panel (F) shows the distribution of CD45 
expression in the CD45+ immune cells (in green) and the EpCAM+ tumor cells (in red). Similar results were 
obtained with respect to EpCAM expression (data not shown).
Total RNA sequencing
RNA was isolated and DNA was removed using the RNeasy Plus Micro kit (Qiagen). 
The RNA was eluted from the column using two rounds of 14 µl RNase-free water. 
RNA concentration was measured using a Nanodrop device, and RNA integrity was 
analyzed using RNA 6000 Pico chips in a model 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). A cut-off of 100 ng RNA and an RNA integrity 
number (RIN) of 8 were used to exclude samples with an insufficient amount of RNA 
and/or insufficient quality RNA (5 samples were excluded based on these criteria). The 
mean RIN value of the included samples was 9.2 (range: 8.3-10.0). 20 U RNasin was 
added to each sample, and the samples were stored at -80°C until use.
External RNA Controls Consortium (ERCC) EXfold spike-in mix (Life Technologies) 
was added for quality control to 50 ng of total RNA. The RNA was then converted to 
cDNA and pre-amplified using the SMARTer Ultra Low RNA kit (Clontech 




0.002% DNase I type II (both from Sigma-Aldrich, St. Louis, MO). The suspension was 
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and kept on ice until RNA isolation. 
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Figure 1. Example of EpCAM+ and CD45+ single-positive cells obtained from a cervical cancer cell 
suspension using flow cytometry
The negative control stained for TO-PRO-3 but not for EpCAM or CD45 is shown in A-D. Living cells were 
selected based on the absence of TO-PRO-3 staining (A), after which cell aggregates were excluded using 
forward scatter width (B) and side scatter height and width (C). Cell sorting was based on the expression of 
either EpCAM or CD45 in the double stained samples (E), but not in the unstained control (D). Restricted 
gates were used as indicated to obtain pure cell populations. Panel (F) shows the distribution of CD45 
expression in the CD45+ immune cells (in green) and the EpCAM+ tumor cells (in red). Similar results were 
obtained with respect to EpCAM expression (data not shown).
Total RNA sequencing
RNA was isolated and DNA was removed using the RNeasy Plus Micro kit (Qiagen). 
The RNA was eluted from the column using two rounds of 14 µl RNase-free water. 
RNA concentration was measured using a Nanodrop device, and RNA integrity was 
analyzed using RNA 6000 Pico chips in a model 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, CA). A cut-off of 100 ng RNA and an RNA integrity 
number (RIN) of 8 were used to exclude samples with an insufficient amount of RNA 
and/or insufficient quality RNA (5 samples were excluded based on these criteria). The 
mean RIN value of the included samples was 9.2 (range: 8.3-10.0). 20 U RNasin was 
added to each sample, and the samples were stored at -80°C until use.
External RNA Controls Consortium (ERCC) EXfold spike-in mix (Life Technologies) 
was added for quality control to 50 ng of total RNA. The RNA was then converted to 
cDNA and pre-amplified using the SMARTer Ultra Low RNA kit (Clontech 
Laboratories, Mountain View, CA). A sequencing library was generated from 1 ng 
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amplified cDNA using the Illumina Nextera XT kit (Illumina, San Diego, CA) as 
described previously.21 Paired end 100-base pair sequencing was performed using a 
HiSeq 2000 v3 (Illumina). FastQ files were generated from each sample using 
CASAVA version 1.8.2 (Illumina).
RNA-seq data analysis
Sequencing adapters in the FastQ files were detected using FastQC version 0.10.1 and 
removed using the cutadapt tool (version 1.4.2). Base quality trimming was performed 
using the sickle tool (version 1.200). RNA was aligned to a custom index based on the 
hg19 human genome (GSNAP version 2014-05-15; novel splicing flag set to true), 
supplemented with the ERCC spike-in sequences and replacing the published 
mitochondrial chromosome with the Revised Cambridge Reference Sequence (GenBank 
acc. no. NC_012920_1). The resulting alignment file was compressed, indexed and 
name-sorted using the samtools tool (version 0.1.19-44428cd). Reads mapping to 
ribosomal RNA (obtained from the UCSC rmsk track on the hg19 genome) were 
removed using a custom-written script. The count table was generated using htseq-count 
(HTSeq suite version 0.6.1p1; --format flag: BAM; --stranded flag: no; --order flag: 
name; --mode flag: intersection-nonempty). The UCSC genePredToGtf generated 
RefSeq annotation (raw database dump of the refGene table) was used as a GTF 
reference. One of the immune cell fractions was excluded from differential expression 
analysis because the correlation between the external RNA controls was insufficient     
(r<0.9).
Differential expression analysis was performed using the R22 package edgeR.23 This 
package uses an overdispersed Poisson model to account for both biological and 
technical variability. Empirical Bayes methods were used to moderate the degree of 
overdispersion across transcripts, enhancing the reliability of inference.23 The values 
were normalized using the trimmed mean of M (TMM) and the respective library 
sizes,24 after which the expression differences between two groups were estimated. 
Reported p values are false isco er  rate correcte   a es ca c ate  sin  t e 
Benjamini-Hochberg procedure. The Database for Annotation, Visualization, and 
Integrated Discovery (DAVID; david.abcc.ncifcrf.gov) was used to identify enriched 
GO terms.25
qRT-PCR analysis
RNA was obtained from 52 fresh-frozen squamous cell cervical cancer samples 
(obtained from 15 patients who were included in the RNA-seq analysis and an 
additional 37 samples) and is described in chapter 5. cDNA was synthesized as 
described previously.26 cDNA was also synthesized from 150 ng of the RNA from the 
remaining immune cell fractions. The resulting cDNA from the immune cell fractions 
was purified using the QIAquick PCR Purification Kit (Qiagen). Sybr Green-based 
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qRT-PCR was performed in duplicate using 1:25 diluted cDNA and 3 pmol RT² qPCR 
Primer Assay for amplifying human CD19, EEF1A1, MS4A1 (CD20), RPLP0 and
TCL1A (Qiagen) on a CFX384 system (Bio-Rad, Hercules, CA). Amplification of 
ACTB was performed using the forward 5’-GCCCTGAGGCACTCTTCCA-3’ and 
reverse 5’-CGGATGTCCACGTCACACTTC-3’ primers designed using Primer-
BLAST.27 As a negative control, the cDNA was replaced with milli-Q water. The most 
stably expressed genes (EEF1A1 and RPLP0) were used for normalization. Expression 
was scaled by standard deviation. For statistical analysis, gene expression levels were 
divided into four quartiles, and the lowest quartile (i.e., low expression) was compared 
with the other three quartiles; in addition, the lower two quartiles were compared with 
the upper two quartiles.
Immunohistochemistry
Immunostaining was performed as described previously7 on 4-  t ic  formalin-fixed, 
paraffin-embedded (FFPE) sections obtained from the patients included in the RNA-seq 
analysis. In brief, deparaffinized sections were treated with 0.3% H2O2 in methanol for 
20 minutes to block endogenous peroxidase activity. After rehydration, antigen retrieval 
was performed in 10 mM Tris and 1 mM EDTA (pH 9.0). The samples were incubated 
in monoclonal rabbit anti-TCL1A (EPR3949, Abcam, Cambridge, UK) diluted in 1% 
(w/v) bovine serum albumin (BSA) in PBS at room temperature overnight. The samples 
were then incubated in BrightVision poly-horseradish peroxidase (HRP) anti-
mouse/rabbit/rat antibody (Immunologic, Duiven, the Netherlands) at room temperature 
for 30 minutes. HRP activity was visualized using 3,3’-diamino-benzidine-
tetrahydrochloride (DAB+, Dako). The sections were counterstained with haematoxylin 
and mounted using CV Mount (Leica Biosystems, Newcastle, UK). The number of 
strong TCL1A+ cells was counted in two to four hot-spots in the center of the tumor 
using an Axioskop-20 microscope equipped with a Plan-Neofluar 20x/0.5 objective 
(Zeiss, Göttingen, Germany), sampling a total tumor area of 1.6-3.1 mm2 comprising 
vital tumor epithelium and stroma. For statistical analysis, the number of positive cells 
was divided into two groups based on the median of 56 cells/mm2.
Double- and triple-fluorescent IHC was used to stain TCL1A in combination with 
mouse IgG1 anti-CD3 (clone F7.2.31, Dako), mouse IgG2b anti-CD8 (clone 4B11, 
NCL-L-CD8-4B11, Leica Biosystems), mouse IgG1 anti-CD10 (clone 56C6, Dako), 
mouse IgG1 anti-CD19 (clone 3B10, LifeSpan Biosciences, Seattle, WA), mouse IgG2a 
anti-CD20 (clone L26, Dako), mouse IgG1 anti-CD34 (clone QBEnd 10, Dako), mouse 
IgG1 anti-CD79a (clone JCB117, Dako), and/or mouse IgG2a anti-DNTT (clone 41C, 
Abcam); all incubated at room temperature overnight. The samples were then incubated 
in a combination of Alexa Fluor-labelled goat anti-rabbit-A488 (A11008), goat anti-
mouse IgG1-A647 (A21240), goat anti-mouse IgG2a-A546 (A21133), and/or goat anti-
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strong TCL1A+ cells was counted in two to four hot-spots in the center of the tumor 
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(Zeiss, Göttingen, Germany), sampling a total tumor area of 1.6-3.1 mm2 comprising 
vital tumor epithelium and stroma. For statistical analysis, the number of positive cells 
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Double- and triple-fluorescent IHC was used to stain TCL1A in combination with 
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in a combination of Alexa Fluor-labelled goat anti-rabbit-A488 (A11008), goat anti-
mouse IgG1-A647 (A21240), goat anti-mouse IgG2a-A546 (A21133), and/or goat anti-
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hour. As negative controls, the primary antibodies were replaced with antibodies of the 
same isotype with unknown specificity. Images were acquired using an LSM700 
confocal laser-scanning microscope equipped with an LCI Plan-Neofluar 25x/0.8 Imm 
Korr DIC M27 objective (Zeiss). Two to four random images were obtained, sampling a 
total tumor area of 0.5-1.0 mm2 comprising vital tumor epithelium and stroma. Double 
and triple positivity of cells was determined using LSM Image Browser software 
(version 4.2.0.121, Zeiss). The numbers of TCL1A+, CD19+, and CD20+ single-, 
double-, and triple-positive cells were scored manually in TCL1A+ cell hot-spots at the 
center of the tumor using ImageJ version 1.47 (http://rsb.info.nih.gov/ij). For statistical 
analysis, the number of positive cells was divided into two groups based on the median 
of 43 TCL1A+ cells/mm2, 31 TCL1A+CD19+ cells/mm2, 18 TCL1A+CD19+CD20-
cells/mm2 and 5 TCL1A+CD19+CD20+ cells/mm2.
Statistical analysis
Correlations between qRT-PCR and IHC data and both disease-specific survival and 
disease-free survival were analyzed using Kaplan-Meier curves in SPSS version 20.0 
(IBM, Armonk, NY). Differences in expression between two groups were analyzed 
using the independent Student’s t-test. All tests were performed two-sided, and 
differences with a p-value <0.05 were considered statistically significant.
Results
Cervical cancer samples
The patient and tumor characteristics are summarized in Table 1. First, we determined 
whether our patient cohort (n=24) was representative of the total squamous cervical 
cancer patient cohort followed from 1985 through 2005 (n=173). The only significant 
difference identified was increased tumor size in our patient cohort (p=0.008), which 
was due to the requirement for larger tumors to prepare cell suspensions. We found no 
difference between the study cohort and the other patient samples with respect to 
survival or postoperative radiotherapy treatment (data not shown).
Separation of tumor cell and immune cell fractions
Following the dissociation of fresh tumor samples, TO-PRO-3-EpCAM+CD45- viable 
tumor epithelial cells (hereafter referred to as the tumor cell fraction) and TO-PRO-3-
EpCAM-CD45+ viable immune cells (hereafter referred to as the immune cell fraction) 
were sorted using flow cytometry (Figure 1). RNA-seq data were obtained from total 
RNA isolated from both cell fractions. The gene expression pattern in the tumor cell 
fractions differed considerably from the expression pattern in the immune cell fractions,
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Table 1. Patient and tumor clinico-pathological characteristics
Clinico-pathological parameter Category N = 24 (%)
Age Median 43
Range 26-63
FIGO stage1 IB 20 (83)
IIA 4 (17)







Lymph nodes Negative 15 (63)
Positive 9 (38)
Tumor size (mm)2 <40 4 (17)
19 (79)
Vaso-invasion Absent 11 (46)
Present 13 (54)
Infiltration depth (mm)2 <15 8 (33)
1 15 (63)
HPV type 16 13 (54)
18 5 (21)
Other 6 (25)
1FIGO=Fédération Internationale de Gynécologie et d’Obstétrique
2Data were not available for all patients.
as shown by two separate clusters of all tumor cell and immune cell fractions upon 
performing a principal component analysis of all fractions (Figure 2). 
Based on p value ranking, the most upregulated gene in the immune cell fractions was 
protein tyrosine phosphatase receptor-type C (PTPRC, p=6.54E-146; Figure 3, 
Supplementary Table S1), which is also known as CD45, the marker used to flow-sort 
the immune cells. The most significantly enriched biological process Gene Ontology 
(GO) terms in the immune cell fractions were immune response, leukocyte and 
lymphocyte terms. 
In the tumor cell fractions, the most significantly enriched biological process GO terms 
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as shown by two separate clusters of all tumor cell and immune cell fractions upon 
performing a principal component analysis of all fractions (Figure 2). 
Based on p value ranking, the most upregulated gene in the immune cell fractions was 
protein tyrosine phosphatase receptor-type C (PTPRC, p=6.54E-146; Figure 3, 
Supplementary Table S1), which is also known as CD45, the marker used to flow-sort 
the immune cells. The most significantly enriched biological process Gene Ontology 
(GO) terms in the immune cell fractions were immune response, leukocyte and 
lymphocyte terms. 
In the tumor cell fractions, the most significantly enriched biological process GO terms 
were cell cycle, tissue development and cellular process, confirming the identity of this 
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fraction as well. The most upregulated gene in the tumor cell fractions (i.e., with the 
lowest p value) was epithelial membrane protein 2 (EMP2, p=5.49E-36; Figure 3). In 
addition, another highly significantly upregulated gene was CDKN2A (also known as 
p16; p=7.08E-25), which is upregulated specifically in cervical cancer cells. 
The most strongly differentially expressed genes were upregulated in the immune cell 
fractions compared with the tumor cell fractions, as shown by the ranking of the 100 
most differentially expressed genes (Figure 3).
Prognostic factors identified in the tumor cell fractions
Within the tumor cell fractions, no genes were significantly differentially expressed
based on patient survival status five years after surgery. With respect to lymph node 
status, membrane metallo-endopeptidase (MME; log fold change: 9.1, p=0.02) and 
olfactomedin-like 2A (OLFML2A; log fold change: 3.0, p=0.02) were expressed at 
higher levels in patients without lymph node metastases compared with patients with 
lymph node metastases.
Figure 2. Principal component analysis of all fractions
Differential gene expression of the tumor cell fractions and immune cell fractions (n=46) obtained from 23 
patients (one sample was excluded based on the external RNA controls) was compared using principal 
component analysis. The numbers indicate the individual patient-matched fractions; “E” indicates a tumor
epithelial cell fraction, and “I” indicates an infiltrating immune cell fraction. The percentages in each 
dimension indicate the amount of variation explained by each dimension. Note that all tumor cell fractions 
clustered, and all immune cell fractions clustered.
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Figure 3. The most differentially expressed genes in the tumor versus the infiltrate fractions 
The 100 most significantly differentially expressed genes between the tumor cell (red dots) and infiltrate (blue 
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Figure 3. The most differentially expressed genes in the tumor versus the infiltrate fractions 
The 100 most significantly differentially expressed genes between the tumor cell (red dots) and infiltrate (blue 
dots) fractions are shown. The gene with the lowest p value (PTPRC) is listed at the top.
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Prognostic factors identified in the immune cell fractions
Among the immune cell fractions, 17 genes were significantly differentially expressed 
based on patient survival status (Supplementary Table S2 and Supplementary Figure 
S1). The most prominent gene was TCL1A, which encodes a lymphocyte-specific 
protein. Specifically, TCL1A was expressed in the majority of surviving patients, but it 
was not expressed in any of the patients who died within five years of surgery. 
Comparing patients with lymph node metastases and patients without lymph node 
metastases revealed that the expression level of protein phosphatase 3 regulatory 
subunit 1 (PPP3R1) was significantly higher in patients with metastases (log fold 
change: 5.6, p<0.001), and endothelin 2 (EDN2) was expressed only in patients without 
lymph node metastases (log fold change: 7.0, p=0.03). Because we could best 
discriminate between patients who survived versus patients who had died based on 
TCL1A expression, we continued to validate the correlation between TCL1A expression 
and patient survival.
Validation of the correlation between TCL1A expression and 
improved survival
Based on our RNA-seq data, the expression of TCL1A was significantly correlated with 
improved disease-free survival (p=0.047) and disease-specific survival (p=0.007; Figure 
4A). To validate the technique used, we performed a qRT-PCR analysis of TCL1A
expression using the same 24 immune cell fraction RNA samples that were used for 
generating the RNA-seq data. This analysis confirmed that TCL1A was expressed at 
significantly increased levels in patients who survived compared with patients who died 
within five years (p=0.0003; Figure 4B). Our qRT-PCR analysis confirmed that TCL1A
expression was significantly correlated with improved disease-free survival (p=0.033) 
and improved disease-specific survival (p=0.005), with Kaplan-Meier survival curves 
that were qualitatively similar to Figure 4A (data not shown). 
Figure 4. Correlation between TCL1A expression and survival
A Kaplan-Meier curve and log-rank survival analysis based on the presence or absence of TCL1A sequence 
reads is shown in A. The TCL1A qRT-PCR expression values were compared between patients who survived 
and patients who were deceased five years after surgery in B. The median and interquartile range are depicted. 
A survival analysis for a high number of TCL1A+ cells versus a low number of TCL1A+ cells based on 
immunohistochemistry is shown in C.
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To validate this correlation at protein expression level, the corresponding FFPE samples 
were stained for TCL1A using IHC. A survival analysis was performed by comparing 
patients with a high (i.e., above the median of 56 cells/mm2) versus a low (i.e., below 
the median) number of strong TCL1A+ cells (Figure 4C). One patient died despite 
having a high number of TCL1A+ cells; nevertheless, the data revealed a trend toward
improved disease-specific survival (p=0.083).
Phenotypic characterization of TCL1A+ cells
Immunofluorescence staining was used to determine the phenotype of the TCL1A+ cells 
in FFPE samples from four patients included in the RNA-seq analysis. Strikingly, the 
TCL1A+ cells did not express CD3 or CD8 (Figure 5A), but the majority of TCL1A+
cells expressed the pan B cell marker CD19 (Figure 5B). Upon further investigation of 
the B cell phenotype, we found that the majority of TCL1A+ cells also expressed CD10. 
A smaller population of cells expressed CD20 (Figure 5B,C); relatively few cells 
expressed CD79a (Figure 5D) or DNA nucleotidylexotransferase (DNTT; Figure 5E), 
and none of the cells expressed the pro B cell marker CD34 (Figure 5F). 
To quantify the relative frequencies of the two predominant TCL1A+ B cell 
subpopulations (i.e., TCL1A+CD19+CD20- and TCL1A+CD19+CD20+ cells), the 
numbers of these cell subpopulations were scored in the FFPE samples of all 24 patients 
who were included in the RNA-seq analysis. On average, 73% of the TCL1A+ cells 
expressed CD19 (range: 39-95%), and an average of 23% of these TCL1A+CD19+ cells 
also expressed CD20 (range: 0-84%).
Taken together, the majority of TCL1A+ cells expressed CD19 and CD10; in contrast, a 
minority of cells expressed CD20, and relatively few cells expressed CD79a or DNTT. 
Most of the DNTT+ cells did not express CD10. Interestingly, the CD19+ B cells were 
distributed throughout the stroma, although some were organized in B cell structures 
adjacent to tumor epithelial fields.
Correlation between B cells, TCL1A expression and survival
We examined the correlations between patient survival and TCL1A+CD19+ cells, 
TCL1A+CD19+CD20- cells and TCL1A+CD19+CD20+ cells on the FFPE samples 
(n=24). A high (i.e., above the median of 31 cells/mm2) number of TCL1A+CD19+ cells 
showed a trend toward improved survival, similar to the correlation for the total number 
of TCL1A+ cells (see Figure 4C). We found no significant correlation between 
TCL1A+CD19+CD20+ cells or TCL1A+CD19-CD20- cells and patient survival (data not 
shown), suggesting that TCL1A+CD19+ cells play the most clinically relevant role.
Next, we used qRT-PCR analysis to validate the correlation between TCL1A and 
CD19+ B cells and improved survival in cervical cancer patients by analyzing the 
expression levels of CD19, CD20 and TCL1A in fresh-frozen cervical cancer samples 
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expressed CD19 (range: 39-95%), and an average of 23% of these TCL1A+CD19+ cells 
also expressed CD20 (range: 0-84%).
Taken together, the majority of TCL1A+ cells expressed CD19 and CD10; in contrast, a 
minority of cells expressed CD20, and relatively few cells expressed CD79a or DNTT. 
Most of the DNTT+ cells did not express CD10. Interestingly, the CD19+ B cells were 
distributed throughout the stroma, although some were organized in B cell structures 
adjacent to tumor epithelial fields.
Correlation between B cells, TCL1A expression and survival
We examined the correlations between patient survival and TCL1A+CD19+ cells, 
TCL1A+CD19+CD20- cells and TCL1A+CD19+CD20+ cells on the FFPE samples 
(n=24). A high (i.e., above the median of 31 cells/mm2) number of TCL1A+CD19+ cells 
showed a trend toward improved survival, similar to the correlation for the total number 
of TCL1A+ cells (see Figure 4C). We found no significant correlation between 
TCL1A+CD19+CD20+ cells or TCL1A+CD19-CD20- cells and patient survival (data not 
shown), suggesting that TCL1A+CD19+ cells play the most clinically relevant role.
Next, we used qRT-PCR analysis to validate the correlation between TCL1A and 
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expression levels of CD19, CD20 and TCL1A in fresh-frozen cervical cancer samples 
obtained from 15 patients in the same cohort and an additional 37 samples. We found 
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no significant correlation between CD19 expression and disease-specific survival 
(p=0.125; Figure 6A); in contrast, high CD19 expression was significantly correlated 
with improved disease-free survival (p=0.036; Figure 6B). High expression of CD3E, 
CD20 or TCL1A was not significantly correlated with survival (data not shown), 
although a high ratio of TCL1A/CD20 expression showed a trend toward improved 
disease-specific survival (p=0.053). 
Figure 5. Phenotype TCL1A+ cells
A representative image of a squamous cervical cancer FFPE specimen stained for TCL1A (green), CD8 (red) 
and CD3 (blue) shows that all TCL1A+ cells were negative for T cell markers (A). A staining for TCL1A, 
CD20 (red) and CD19 (blue) indicates that TCL1A+ cells predominantly expressed CD19, and part of these 
cells also expressed CD20 (purple membrane, B). Similarly, a staining for TCL1A, CD20 and CD10 (blue) 
shows that the majority of the TCL1A+ cells expressed CD10 and part expressed CD20 (C). Few TCL1A+
cells were found to express CD79a (blue, D). An example of infrequent TCL1A+ cells expressing DNTT (red) 
is shown in E (CD10 is shown in blue). TCL1A+ cells did not express CD34 (blue, F). In all panels, the nuclei 
were counterstained with DAPI (shown in gray), and the scale bar represents 50 µm.
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Based on a quartile division, a low ratio (i.e., the lowest quartile) of TCL1A/CD20
expression was significantly correlated with poor disease-specific survival (p=0.027; 
Figure 6C) and showed a trend toward poor disease-free survival (p=0.051; Figure 6D). 
Lastly, the ratio of TCL1A/CD19 expression was not significantly correlated with 
survival.
Figure 6. B cell and TCL1A correlations with survival
Kaplan-Meier analyses are shown based on qRT-PCR analyses of fresh-frozen tumor samples. The correlation 
between high versus low CD19 expression and disease-specific (A) and disease-free survival (B) is shown.
The ratio of TCL1A/CD20 expression levels was divided in quartiles. The correlation between the lowest 
versus the other three quartiles and disease-specific (C) and disease-free (D) survival is shown.
Discussion
Tumors contain several cell types, including tumor cells, fibroblasts, endothelial cells 
and infiltrating immune cells. This heterogeneous nature of tumors can complicate the 
expression analysis of cell subpopulations in the tumor. Here, we report the first study 
in which RNA was isolated separately from viable tumor epithelial cells and tumor-
infiltrating immune cells using flow-sorted fresh-dissociated squamous cell cervical 
carcinomas. Our aim was to use this novel approach in an attempt to identify factors that 
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Based on a quartile division, a low ratio (i.e., the lowest quartile) of TCL1A/CD20
expression was significantly correlated with poor disease-specific survival (p=0.027; 
Figure 6C) and showed a trend toward poor disease-free survival (p=0.051; Figure 6D). 
Lastly, the ratio of TCL1A/CD19 expression was not significantly correlated with 
survival.
Figure 6. B cell and TCL1A correlations with survival
Kaplan-Meier analyses are shown based on qRT-PCR analyses of fresh-frozen tumor samples. The correlation 
between high versus low CD19 expression and disease-specific (A) and disease-free survival (B) is shown.
The ratio of TCL1A/CD20 expression levels was divided in quartiles. The correlation between the lowest 
versus the other three quartiles and disease-specific (C) and disease-free (D) survival is shown.
Discussion
Tumors contain several cell types, including tumor cells, fibroblasts, endothelial cells 
and infiltrating immune cells. This heterogeneous nature of tumors can complicate the 
expression analysis of cell subpopulations in the tumor. Here, we report the first study 
in which RNA was isolated separately from viable tumor epithelial cells and tumor-
infiltrating immune cells using flow-sorted fresh-dissociated squamous cell cervical 
carcinomas. Our aim was to use this novel approach in an attempt to identify factors that 
are correlated with the clinical outcome of cervical cancer patients.
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Differential gene expression analysis of the RNA-seq data revealed that the expression 
profile in the tumor cell fractions differed from the expression profile in the immune 
cell fractions. In addition, the most differentially expressed genes matched the epithelial 
cell and leukocyte origins of the flow-sorted fractions, thus validating the study 
approach. Interestingly, the most significantly differentially expressed genes were 
upregulated in the immune cell fractions as compared with the tumor cell fractions. One 
possible explanation for this finding is that the immune cells in these tumors are a 
highly heterogeneous population of cells characterized by a higher number of function-
specific proteins. The tumor epithelial cells on the other hand might represent a more 
homogeneous cell population characterized by a more uniform set of proteins. 
Our novel approach identified TCL1A as a novel putative biomarker for predicting 
survival in patients with cervical cancer. Specifically, TCL1A was not expressed in the 
immune cell fractions of the deceased patients. We validated the correlation between 
high TCL1A expression and improved survival using both qRT-PCR and IHC analyses. 
Despite the relatively small number of patients in our study, TCL1A expression was 
robustly correlated with improved survival in the flow-sorted immune cell fractions. A 
clear trend toward improved prognosis was also found based on the number of TCL1A+
cells in the FFPE samples obtained from the same patients that were included in our 
RNA-seq analysis. Noh et al. reported the presence of TCL1A protein in cervical cancer 
cells,28 which we did not observe in our patient samples. The reason for this discrepancy 
might be the use of different antibodies. Since that study did not find a correlation 
between TCL1A expression and survival, strong lymphocyte-specific expression might 
be specifically correlated with patient survival.
TCL1A is expressed in immature CD4-CD8- T cells and in several stages of developing 
B cells, including pre-B cells, virgin, mantle and germinal center B cells.29-31 TCL1A is 
also expressed in activated peripheral lymphocytes, promoting cell proliferation and 
survival by activating protein kinase B (Akt).32 In humans and mice, overexpression of 
TCL1A due to chromosomal rearrangement of the TCL1A gene to the T cell receptor 
locus causes mature T cell leukemia and lymphoma.33,34 Indeed, TCL1A overexpression 
is a common finding in both leukemia and lymphoma,34 although amplification of this 
gene was also reported in a pre-malignant cervical lesion.35 In addition, Hoyer et al. 
showed that TCL1A expression induces proliferation by increasing T cell receptor 
signaling in mature T cells.36 We found that TCL1A was not expressed by T cells in our 
patient samples. In contrast, TCL1A was expressed predominantly in CD19+ and 
CD10+, CD34 B cells. Some of these cells also expressed CD20 and—in rare cases—
some cells expressed CD79a or the pro/pre B cell marker DNTT. Based on these 
markers, we conclude that the TCL1A+ B cells seem to be predominantly germinal 
center or mature B cells, as well as a subpopulation of pre or immature B cells. 
Specifically, the presence of TCL1A+CD19+ cells was correlated with a trend toward
improved survival. Remarkably, high CD19 expression was significantly correlated 
with improved disease-free survival (based on fresh-frozen tumor tissue samples 
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obtained from an additional cervical cancer patient cohort), whereas CD3E, CD20 and 
TCL1A were not significantly correlated with survival. A low ratio of TCL1A/CD20 
expression was significantly correlated with poor disease-specific survival, indicating 
that high TCL1A expression relative to the expression of the B cell marker CD20 in total 
tumor samples is correlated with improved survival. These results suggest that CD19+ B 
cells are an important determinant of clinical outcome, and they suggest that the 
TCL1A+ and CD20+ B cell populations play an essential role in this  outcome. Further 
validation on an independent patient cohort is required for TCL1A to be used as a 
prognostic marker. 
TCL1A+ B cells were distributed throughout the stroma, although they were also 
organized in B cell structures located adjacent to tumor epithelial fields. We speculate 
that TCL1A+ B cells might indicate lymphoid follicular processes that facilitate B cell 
maturation, somatic hypermutation and isotype switching. Recently, intratumoral 
lymphoid structures were reported in several types of cancer,37,38 and the presence of 
these structures was correlated with improved survival.39,40 Compared to T cells, the 
role of B cells in cancer has been studied less extensively and is controversial. In 
addition to producing antibodies, tumor-infiltrating B cells can also function as   
antigen-presenting cells.41 In melanoma and breast cancer mouse models, 
CD19+CD20+CD137L+ B cells were reported to activate cytotoxic T cells.42,43 High 
numbers of tumor-infiltrating B cells have been correlated with improved patient 
survival in several cancer types.44,45 Moreover, antibodies can undergo antigenic 
selection and affinity maturation in cervical cancer.46 Our data indicate that intratumoral 
B cells may play an important role in controlling cervical cancer, and TCL1A is a 
potential marker for a beneficial B cell response. 
Based on both positive lymph nodes and death by disease, PPP3R1 was the most 
upregulated gene in the immune cell fractions. PPP3R1 encodes a regulatory subunit of 
calcineurin, which activates the transcription factor NFAT (nuclear factor of activated T 
cells).47 In addition, the vasoconstrictor endothelin 2 was expressed only in the immune 
cell fractions of patients without lymph node metastases. Because the expression levels 
of these two genes were inadequate for discriminating between patients and did not 
differ significantly within the tumor cell fractions, we did not pursue these proteins as 
potential targets. 
With respect to the tumor cell fractions, the only significantly increased  expression was 
observed in the genes  MME and OLFML2A in the patients without lymph node 
metastases. This low number of differentially expressed genes suggests tha t the tumor 
cell fractions were highly homogeneous. We could thus not identify a differential 
expression pattern based on positive lymph nodes or death by disease. Because of this 
relative homogeneity, we believe that this technique is a promising tool for identifying 
pathways that are specific to different cancer types.  
In summary, we report that RNA-seq data can be analyzed reliably using tumor cells 
and immune cells isolated from cancer samples using flow cytometry. The most 
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center or mature B cells, as well as a subpopulation of pre or immature B cells. 
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obtained from an additional cervical cancer patient cohort), whereas CD3E, CD20 and 
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expression was significantly correlated with poor disease-specific survival, indicating 
that high TCL1A expression relative to the expression of the B cell marker CD20 in total 
tumor samples is correlated with improved survival. These results suggest that CD19+ B 
cells are an important determinant of clinical outcome, and they suggest that the 
TCL1A+ and CD20+ B cell populations play an essential role in this  outcome. Further 
validation on an independent patient cohort is required for TCL1A to be used as a 
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TCL1A+ B cells were distributed throughout the stroma, although they were also 
organized in B cell structures located adjacent to tumor epithelial fields. We speculate 
that TCL1A+ B cells might indicate lymphoid follicular processes that facilitate B cell 
maturation, somatic hypermutation and isotype switching. Recently, intratumoral 
lymphoid structures were reported in several types of cancer,37,38 and the presence of 
these structures was correlated with improved survival.39,40 Compared to T cells, the 
role of B cells in cancer has been studied less extensively and is controversial. In 
addition to producing antibodies, tumor-infiltrating B cells can also function as   
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CD19+CD20+CD137L+ B cells were reported to activate cytotoxic T cells.42,43 High 
numbers of tumor-infiltrating B cells have been correlated with improved patient 
survival in several cancer types.44,45 Moreover, antibodies can undergo antigenic 
selection and affinity maturation in cervical cancer.46 Our data indicate that intratumoral 
B cells may play an important role in controlling cervical cancer, and TCL1A is a 
potential marker for a beneficial B cell response. 
Based on both positive lymph nodes and death by disease, PPP3R1 was the most 
upregulated gene in the immune cell fractions. PPP3R1 encodes a regulatory subunit of 
calcineurin, which activates the transcription factor NFAT (nuclear factor of activated T 
cells).47 In addition, the vasoconstrictor endothelin 2 was expressed only in the immune 
cell fractions of patients without lymph node metastases. Because the expression levels 
of these two genes were inadequate for discriminating between patients and did not 
differ significantly within the tumor cell fractions, we did not pursue these proteins as 
potential targets. 
With respect to the tumor cell fractions, the only significantly increased  expression was 
observed in the genes  MME and OLFML2A in the patients without lymph node 
metastases. This low number of differentially expressed genes suggests tha t the tumor 
cell fractions were highly homogeneous. We could thus not identify a differential 
expression pattern based on positive lymph nodes or death by disease. Because of this 
relative homogeneity, we believe that this technique is a promising tool for identifying 
pathways that are specific to different cancer types.  
In summary, we report that RNA-seq data can be analyzed reliably using tumor cells 





distinguishing gene identified by differential expression analysis was TCL1A. 
Specifically, TCL1A was not expressed in the immune cells of patients who died from 
cervical cancer. This correlation between TCL1A expression and improved survival was 
validated using qRT-PCR and IHC analyses. We also found that TCL1A was 
predominantly expressed in B cells, possibly reflecting intratumoral lymphoid follicular 
processes. Based on these findings, we conclude that TCL1A may be a prognostic 
biomarker for predicting improved survival in patients  with cervical cancer. This is the 
first study demonstrating the prognostic value of separating tumor epithelial cells from 
tumor-infiltrating immune cells and determining their RNA expression profile for 
identifying putative cancer biomarkers. Because B cell expressed TCL1A was the most 
prominent marker correlated with patient survival, perhaps we should broaden our T 
cells biased view to include B cells in cancer immunology. The emerging interest in 
cancer immunotherapy supports studying the use of B cells in anticancer treatments. 
Acknowledgements 
We thank Jaap D.H. van Eendenburg (Department of Pathology, Leiden University 
Medical Center) for dissociating and freezing the tumor samples, and we thank and Dr. 
Patty M. Jansen (Department of Pathology, Leiden University Medical Center) for 
consultation regarding the B cell phenotypes. 
References 
 1  Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J. Clin. 2014; 64: 9-
29. 
 2  Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 
539-45. 
 3  Ali HR, Provenzano E, Dawson SJ, Blows FM, Liu B, Shah M, Earl HM, Poole CJ, Hiller 
L, Dunn JA et al. Association between CD8+ T-cell infiltration and breast cancer survival 
in 12,439 patients. Ann. Oncol. 2014; 25: 1536-43. 
 4  Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human 
tumours: impact on clinical outcome. Nat. Rev. Cancer 2012; 12: 298-306. 
 5  Jordanova ES, Gorter A, Ayachi O, Prins F, Durrant LG, Kenter GG, van der Burg SH, 
Fleuren GJ. Human leukocyte antigen class I, MHC class I chain-related molecule A, and 
CD8+/regulatory T-cell ratio: which variable determines survival of cervical cancer 
patients? Clin. Cancer Res. 2008; 14: 2028-35. 
 6  Mantovani A. Cancer: Inflaming metastasis. Nature 2009; 457: 36-7. 
 7  Zijlmans HJ, Punt S, Fleuren GJ, Trimbos JB, Kenter GG, Gorter A. Role of IL-12p40 in 
cervical carcinoma. Br. J. Cancer 2012; 107: 1956-62. 
 8  Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, Teknos TN. 
Interleukin-6 predicts recurrence and survival among head and neck cancer patients. 
Cancer 2008; 113: 750-7. 
139 
 
 9  Chen MF, Chen PT, Lu MS, Lin PY, Chen WC, Lee KD. IL-6 expression predicts 
treatment response and outcome in squamous cell carcinoma of the esophagus. Mol. 
Cancer 2013; 12: 26. 
 10  Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene 2008; 27: 5894-
903. 
 11  Ho DW, Yang ZF, Yi K, Lam CT, Ng MN, Yu WC, Lau J, Wan T, Wang X, Yan Z  et al. 
Gene expression profiling of liver cancer stem cells by RNA-sequencing. PLoS One 2012; 
7: e37159. 
 12  Van den Broeck A, Vankelecom H, Van DW, Gremeaux L, Wouters J, Allemeersch J, 
Govaere O, Roskams T, Topal B. Human pancreatic cancer contains a side population 
expressing cancer stem cell-associated and prognostic genes. PLoS One 2013; 8: e73968. 
 13  Birnie R, Bryce SD, Roome C, Dussupt V, Droop A, Lang SH, Berry PA, Hyde CF, 
Lewis JL, Stower MJ et al. Gene expression profiling of human prostate cancer stem cells 
reveals a pro-inflammatory phenotype and the importance of extracellular matrix 
interactions. Genome Biol. 2008; 9: R83. 
 14  Corver WE, Ter Haar NT, Fleuren GJ, Oosting J. Cervical carcinoma-associated 
fibroblasts are DNA diploid and do not show evidence for somatic genetic alterations. Cell 
Oncol. (Dordr. ) 2011; 34: 553-63. 
 15  Corver WE, Ter Haar NT. High-resolution multiparameter DNA flow cytometry for the 
detection and sorting of tumor and stromal subpopulations from paraffin-embedded 
tissues. Curr. Protoc. Cytom. 2011; Chapter 7: Unit 7.37. 
 16  Hilders CG, Ras L, van Eendenburg JD, Nooyen Y, Fleuren GJ. Isolation and 
characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int. J. Cancer 
1994; 57: 805-13. 
 17  Corver WE, Koopman LA, van der Aa J, Regensburg M, Fleuren GJ, Cornelisse CJ. Four-
color multiparameter DNA flow cytometric method to study phenotypic intratumor 
heterogeneity in cervical cancer. Cytometry 2000; 39: 96-107. 
 18  Corver WE, Koopman LA, Mulder A, Cornelisse CJ, Fleuren GJ. Distinction between 
HLA class I-positive and -negative cervical tumor subpopulations by multiparameter 
DNA flow cytometry. Cytometry 2000; 41: 73-80. 
 19  Tighe S, Held MA. Isolation of total RNA from transgenic mouse melanoma subsets using 
fluorescence-activated cell sorting. Methods Mol. Biol. 2010; 632: 27-44. 
 20  Corver WE, Cornelisse CJ. Flow cytometry of human solid tumours: clinical and research 
applications. Current Diagnostic Pathology 2002; 8: 249-67. 
 21  Picelli S, Faridani OR, Bjorklund AK, Winberg G, Sagasser S, Sandberg R. Full-length 
RNA-seq from single cells using Smart-seq2. Nat. Protoc. 2014; 9: 171-81. 
 22  R Core Team (2014). R: A language and environment for statistical computing.  R 
Foundation for Statistical Computing, Vienna, Austria, 2014. 
 23  Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential 
expression analysis of digital gene expression data. Bioinformatics. 2010; 26: 139-40. 
 24  Robinson MD, Oshlack A. A scaling normalization method for differential expression 
analysis of RNA-seq data. Genome Biol. 2010; 11: R25. 
 25  Dennis G, Jr., Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, Lempicki RA. 
DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 






distinguishing gene identified by differential expression analysis was TCL1A. 
Specifically, TCL1A was not expressed in the immune cells of patients who died from 
cervical cancer. This correlation between TCL1A expression and improved survival was 
validated using qRT-PCR and IHC analyses. We also found that TCL1A was 
predominantly expressed in B cells, possibly reflecting intratumoral lymphoid follicular 
processes. Based on these findings, we conclude that TCL1A may be a prognostic 
biomarker for predicting improved survival in patients  with cervical cancer. This is the 
first study demonstrating the prognostic value of separating tumor epithelial cells from 
tumor-infiltrating immune cells and determining their RNA expression profile for 
identifying putative cancer biomarkers. Because B cell expressed TCL1A was the most 
prominent marker correlated with patient survival, perhaps we should broaden our T 
cells biased view to include B cells in cancer immunology. The emerging interest in 
cancer immunotherapy supports studying the use of B cells in anticancer treatments. 
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Supplementary Figure S1. Differentially expressed genes in infiltrating immune cell fractions based on 
patient survival status
143 1  
The significantly differentially expressed genes in the tumor-infiltrating immune cell fractions between 
patients who were alive (red dots) and patients who were deceased (blue dots) is shown. The gene with the 
lowest p value (PPP3R1) is shown at the top.
Supplementary Tables S1 and S2 were too extended to include in this thesis, and can be 
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Both IL-17 and Th17 cells have been ascribed tumor promoting as well as tumor 
suppressing functions. We reviewed the literature on correlations between IL-17 versus 
Th17 and survival in human cancer, following the PRISMA guidelines. Serum, formalin 
fixed paraffin embedded tissue and peripheral blood samples were most frequently 
studied. High IL-17 quantities were correlated with poor prognosis, whereas high Th17 
cell frequencies were correlated with improved prognosis. Since Th17 cells are a 
subpopulation of IL-17+ cells and had a different correlation with prognosis than total 
IL-17, we substantiate that a distinction should be made between Th17 and other IL-17+
cells.
Introduction
Interleukin-17 (IL-17) was discovered in 1993 and originally named cytotoxic T 
lymphocyte-associated-8 (CTLA-8).1 IL-17 was more recently renamed IL-17A and has 
five family members: IL-17B-F.2 Only IL-17F shows some homology and overlapping 
functions with IL-17A. The main functions of IL-17 are the attraction of neutrophils and 
stimulation of inflammation.3 The T helper 17 (Th17) cell, one of the predominant 
producers of IL-17 that was characterized in 2005,4 is essential to protect the host 
against pathogens that are not handled well by Th1 and Th2 cells.5 This pro-
inflammatory cell type plays a dominant role in a variety of autoimmune diseases.3
Antibodies targeting IL-17 and its receptor are now used in clinical trials to treat 
autoimmune diseases like psoriasis, rheumatoid arthritis and Crohn’s disease.6 Since
IL-17 can also be produced by innate immune cell types including both lymphoid 
eri e  (e. . γδT ce s, in ariant nat ra  i er T ce s an  innate oi  ce s)7,8 and 
myeloid derived cells (e.g. neutrophils, macrophages and mast cells),9 it may bridge the 
activities of the innate and adaptive immune system.10
Much less studied is the role of IL-17 in cancer. Both tumor suppressing and tumor 
promoting functions have been ascribed to the IL-17 protein and Th17 cells.11 This 
ambiguity about the function of IL-17 and Th17 cells in cancer has limited the potential 
for targeting the molecule or using cell-based immunotherapy. Part of the ambiguity 
may have arisen because different aspects of the IL-17 response are studied. Total 
protein amount or cells expressing IL-17 protein have been measured in serum and 
tumor associated fluids by ELISA and in formalin-fixed, paraffin-embedded (FFPE) 
tissue by immunohistochemistry, respectively. The effect of Th17 cells has been 
analyzed mainly in peripheral blood, but also in tumor associated fluids, FFPE and fresh 
frozen tissue by flow cytometry, immunohistochemistry or RT-PCR. A review on Th17 
cells in cancer by Wilke et al. in 2011 already noted that correlations between the IL-17 
protein and survival may be different from correlations with the Th17 cell population.12
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To systematically study the correlations between the IL-17 protein and Th17 cells and 
survival in human cancer, we investigated all publications in NCBI PubMed, Ovid 
Embase and Web of Science addressing this subject. The aim of our study was to 
identify the correlations between both IL-17 protein and Th17 cells and prognosis in 
cancer. The studies were classified by the sample type used to study IL-17 or Th17 
cells: serum, FFPE tissue, peripheral blood, tumor associated fluids and fresh frozen 
tissue. Subsequently, the effect on survival was analyzed for each of the sample types 
studied. The implications for further research of IL-17 and Th17 cells are discussed.
Results
Study design and selection criteria
Of the 2643 publications identified through database searching on IL-17 or Th17 and 
cancer, 56 studies met the inclusion criteria (Figure 1). The main reasons for a 
publication to be excluded were: being a conference abstract (23%), an animal study 
(24%), no study on cancer (27%) or not reporting on survival data (19%). Two articles 
were excluded due to lack of other references on the same method and survival analysis. 
One article reported on an IL-17 SNP analysis,13 while the other studied RNA levels of 
Th17 cell expressed retinoic acid receptor-re ate  or an rece tor a a ( γt).14
Neither of these studies found a correlation with survival. An overview of the included 
studies sorted by sample type and clinical outcome is shown in Table 1.
Studies reporting on survival analysis or risk of recurrence were included regardless of 
the outcome of the study. A potential publication bias was caused by excluding articles 
that reported on correlations with other clinico-pathological parameters but not survival. 
This bias was minimized by screening all articles that reported on correlations with 
clinico-pathological parameters for having performed a survival analysis. The survival 
criterion enabled us to focus on studies that are relevant for the potential targeting of 
IL-17 or Th17 cells in a clinical setting.
Generally, a random or consecutive group of patients was analyzed for relatively 
objective measures (see supplementary Tables S1-4). Although most studies did not 
provide details on the sample selection method, the majority of the studies used as a 
continuous variable or categorized IL-17 or Th17 cell numbers in groups based on the 
presence, mean or median to analyze the effect by Kaplan-Meier and Cox regression 
analyses. Potential risks of bias identified in categorizing IL-17 or Th17 expression 
were optimal cut-off values chosen arbitrarily15,16 or using a minimum p value,17-23 ROC 
curve24-27 or regression tree analysis.28 Furthermore, one study compared the six long 
(>3 years) versus short (<1.5 years) surviving patients.29 Another study reported that 
post-chemotherapy samples were used when no pretreatment samples were available for 
immunohistochemistry.30 A final potential risk factor was observed in a study of 
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eri e  (e. . γδT ce s, in ariant nat ra  i er T ce s an  innate oi  ce s)7,8 and 
myeloid derived cells (e.g. neutrophils, macrophages and mast cells),9 it may bridge the 
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protein amount or cells expressing IL-17 protein have been measured in serum and 
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To systematically study the correlations between the IL-17 protein and Th17 cells and 
survival in human cancer, we investigated all publications in NCBI PubMed, Ovid 
Embase and Web of Science addressing this subject. The aim of our study was to 
identify the correlations between both IL-17 protein and Th17 cells and prognosis in 
cancer. The studies were classified by the sample type used to study IL-17 or Th17 
cells: serum, FFPE tissue, peripheral blood, tumor associated fluids and fresh frozen 
tissue. Subsequently, the effect on survival was analyzed for each of the sample types 
studied. The implications for further research of IL-17 and Th17 cells are discussed.
Results
Study design and selection criteria
Of the 2643 publications identified through database searching on IL-17 or Th17 and 
cancer, 56 studies met the inclusion criteria (Figure 1). The main reasons for a 
publication to be excluded were: being a conference abstract (23%), an animal study 
(24%), no study on cancer (27%) or not reporting on survival data (19%). Two articles 
were excluded due to lack of other references on the same method and survival analysis. 
One article reported on an IL-17 SNP analysis,13 while the other studied RNA levels of 
Th17 cell expressed retinoic acid receptor-re ate  or an rece tor a a ( γt).14
Neither of these studies found a correlation with survival. An overview of the included 
studies sorted by sample type and clinical outcome is shown in Table 1.
Studies reporting on survival analysis or risk of recurrence were included regardless of 
the outcome of the study. A potential publication bias was caused by excluding articles 
that reported on correlations with other clinico-pathological parameters but not survival. 
This bias was minimized by screening all articles that reported on correlations with 
clinico-pathological parameters for having performed a survival analysis. The survival 
criterion enabled us to focus on studies that are relevant for the potential targeting of 
IL-17 or Th17 cells in a clinical setting.
Generally, a random or consecutive group of patients was analyzed for relatively 
objective measures (see supplementary Tables S1-4). Although most studies did not 
provide details on the sample selection method, the majority of the studies used as a 
continuous variable or categorized IL-17 or Th17 cell numbers in groups based on the 
presence, mean or median to analyze the effect by Kaplan-Meier and Cox regression 
analyses. Potential risks of bias identified in categorizing IL-17 or Th17 expression 
were optimal cut-off values chosen arbitrarily15,16 or using a minimum p value,17-23 ROC 
curve24-27 or regression tree analysis.28 Furthermore, one study compared the six long 
(>3 years) versus short (<1.5 years) surviving patients.29 Another study reported that 
post-chemotherapy samples were used when no pretreatment samples were available for 
immunohistochemistry.30 A final potential risk factor was observed in a study of 
leukemia patients treated with allogeneic stem cell transplantation after myeloablative 
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conditioning, which included donors that varied from related to unrelated and different 
prophylaxis regimens to prevent graft-versus-host disease.31 Additional study details 
and concerns are listed per sample type in supplementary Tables S1-4. Clinico-
pathological characteristics of the different studies per measurement method are 
provided in supplementary Tables S5-8.
Figure 1. PRISMA Flow diagram
Database searching identified 2642 publications on IL-17 or Th17 and cancer. One publication on this topic of 
our group published in this issue of OncoImmunology was added manually. Using the search term ‘tumor’ 
caused studies on tumor-necrosis factor to be selected regardless of whether the study was on cancer. 
Although tumor necrosis factor was excluded as a major topic, many publications that were not on cancer had 
to be excluded manually. All inclusion criteria were met by 56 articles. Five studies were excluded from 
analysis for using different sample types or methods than all other articles. Another 32 studies were excluded 
from meta-analysis because not enough studies were available on sample types other than tissue analyzed for 
IL-17 expression or insufficient data were provided. Figure adapted from Moher et al.80
High IL-17 serum levels are correlated with poor survival
Serum, paraffin tissue, peripheral blood mononuclear cells (PBMCs) and occasionally 
tumor associated fluids or fresh frozen tissue were used to measure IL-17 protein or 
RNA and Th17 cells. Since the cell source and related activity measured may differ in 
different sample types, we sorted and analyzed the studies by sample type. The amount 
of IL-17 protein in serum was measured by ELISA (Table 1.1). Since total protein 
quantity was measured, the IL-17 could have been derived from Th17 cells but also 
from innate immune cell types. Five studies out of ten reported that a high amount of 
serum IL-17 protein was correlated with poor survival.17,24-26,31 One study showed a 
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correlation between a high IL-17 level and improved survival in leukemia.32 Four 
studies did not observe a significant correlation between high serum IL-17 levels and 
survival,33-36 although one group did find a trend toward poor prognosis (p=0.05).36
Overall, a high amount of IL-17 protein in serum has predominantly been correlated 
with poor survival (Table 2).
Table 1.1. Correlation between IL-17 in serum and survival
Cancer type N Outcome Correlation Multivariate Cox p<0.05 Notes Ref #
NSCLC 128 OS Poor Yes 25
HBV-related HCC 105 OS, DFS Poor DFS: Yes OS: NA 26
Leukemia treated with 
myelo-ablative 
conditioning and SCT
95 DFS Poor Yes 31
Gastric carcinoma 85 OS Poor Yes 17
CRC 80 DFS Poor NA 24
Acute leukemia 93 OS Improved No 32
CLL 294 OS No correlation sample type: plasma 33
CLL 84 OS No correlation 34
Pancreatic AC 62 OS Trend toward poor 36
Multiple myeloma 50 OS No correlation peripheral blood, bone marrow 35
Table 1.2. Correlation between IL-17+ cells in tissue and survival
Cancer type N Outcome Correlation Multivariate Cox p<0.05 Notes Ref #
HCC 323 OS, DFS Poor No 40
HCC 300 OS, DFS Poor (intratumoral) NA 18
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Table 1.4. Correlation between IL-17 and Th17 cells in tumor associated fluids and survival 
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Table 1. Correlation between IL-17 or Th17 and survival 
All studies describing a correlation between a measurement of IL-17 or Th17 cells and overall or disease-free 
survival are shown. The analyses were sorted by clinical outcome, cancer type and study size. N indicates the 
number of patients on which the correlation between the IL-17 measurement and survival was reported. The 
column ‘Correlation’ indicates whether a high IL-17 or Th17 cell measurement was correlated with poor or 
improved survival. If this correlation was significant under a certain condition (e.g. for OS or DFS only, or for 
a scoring location), this is also indicated. A dark grey row indicates a correlation with poor survival, a white 
row a correlation with improved survival and a light grey row no significant correlation. Whether or not the 
correlation found was independently correlated with survival when corrected for clinico-pathological 
parameters in a multivariate Cox regression analysis is also indicated. A multivariate analysis including both 
the IL-17 measurement as well as another variable also containing this IL-17 measurement (e.g. a ratio) was 
not included in our analysis since the potential effect might be lost by correcting for it. Measurement 
deviances are indicated under ‘Notes’. Only if a study on a certain cancer type was performed by the same 
research group as another included study, a note is included because of potential sample overlap. An asterisk 
behind a reference number indicates that the study was not included in the quantitative analyses in Table 2 and 
Figure 2. Table 1.1 shows analyses on IL-17 quantifications in serum by ELISA. Table 1.2 is a representation 
of studies on tumor infiltrated IL-17+ cells quantified by immunohistochemistry on FFPE tissue slides or 
tissue microarrays. If ‘intratumoral’ is indicated, peritumoral cells were scored as well. Table 1.3 shows 
analyses of Th17 quantification on FFPE tissue, peripheral blood PBMCs and fresh frozen samples. Table 1.4 
represents the analyses on tumor associated fluids sorted by measurement type. Abbreviations: 
AC=adenocarcinoma; Bref=brefeldin A; CLL=chronic lymphocytic leukemia; CRC=colorectal carcinoma; 
CT=chemotherapy; FC=flow cytometry; GVHD=graft-versus-host disease; HCC=hepatocellular carcinoma; 
Iono=ionomycin; Mon=monensin; MPE=malignant pleural effusion; NA=not applicable or not mentioned in 
the article; NS=not significant; NSCLC=non-small cell lung carcinoma; PMA=phorbol 12-myristate 13-
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Table 2. Correlations per measurement type














IL-17 Serum ELISA 1 5 4 10 0.2
FFPE tissue IHC 5 18 4 27 0.3
Tumor associated fluid ELISA 1 1 0 2 1.0
Total 7 24 8 39 0.3
Th17 FFPE tissue IHC Th17 1 0 1 2 NA
Peripheral blood Flow cytometry 4 2 3 9 2.0
Tumor associated fluid Flow cytometry 2 0 0 2 NA
RT-PCR 1 0 0 1 NA
Fresh frozen tissue RT-PCR 0 0 2 2 NA
Total 8 2 6 16 4.0
The number of analyses per sample and measurement type of IL-17 protein or Th17 cells showing a 
correlation with improved or poor prognosis or no effect is indicated. The final column denotes the ratio of the 
number of analyses showing a correlation with improved prognosis over the number of analyses showing a 
correlation with poor prognosis, as an indication of the factor difference. A white box indicates a correlation 
with improved survival, a dark grey box a correlation with poor survival and a light grey box no clear 
correlation.
A high number of IL-17+ cells in tissue is correlated with poor 
survival
The total number of IL-17+ cells was quantified on cancer tissue FFPE whole slides or 
tissue microarrays using immunohistochemistry. This type of analysis allows for 
quantification of the total number of IL-17+ cells within the tumor microenvironment. 
IL-17 is expressed by different types of tumor infiltrating immune cells in cancer, 
predominantly neutrophils and mast cells.37-39 The total number of IL-17+ cells was 
correlated with poor prognosis in 18 out of 27 studies (Table 1.2).15,16,18-20,30,37,40-50 Five 
studies reported on a correlation between a high number of IL-17+ cells and improved 
survival.21,28,29,51,52 It is important to note that in two of these five studies, the IL-17+
cells were scored in areas with the densest lymphocytic infiltrate, one of which was on 
pancreatic ductal adenocarcinoma patients who had received immunotherapy (the 
correlation between IL-17 and survival was based on 12 patients).21,29 Four studies did 
not observe a significant correlation between total IL-17+ cells in the tumor and 
survival.22,23,53,54 Again the scoring in two of these four studies had been performed in 
hot-spot or dense lymphocytic infiltrate areas, while only three of the 18 studies 
reporting on a negative correlation had focussed on hot-spots. Three more studies did 
154
not focus on IL-17+ tumor infiltrating immune cells and are included with their reported 
correlations in Table 1 for completeness, but not in the quantitative analyses.39,55,56
Collectively, 18 studies reported on a significant correlation between high IL-17 and 
poor prognosis, over 3.5 times more than the studies showing a correlation with 
improved prognosis (n=5, Table 2). To visualize the overall correlation, forests plots are 
shown for the hazard ratio of a high number of IL-17+ cells on overall (Figure 2A) and 
disease-free survival (Figure 2B). Of the 22 studies reporting on overall survival, 7 were 
excluded from the meta-analysis due to insufficient Cox regression data. Of the 16 
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Figure 2. Forest plots for IL-17+ cells in tissue
Schematic quantitative analyses of the studies on the number of IL-17+ cells in FFPE tissue is shown by forest 
plots. Cox regression hazard ratios and 95% confidence intervals for the correlation between a high number of 
IL-17+ cells and overall survival (A) and disease-free survival (B) were obtained from the articles or via 
personal communication with the authors. An asterisk (*) indicates that a multivariate Cox regression analysis 
was used because a univariate analysis was not provided. A dagger (†) indicates that part of the data were 
obtained via e-mail. The cut-off value used to divide the IL-17+ cell frequency in a high and low group is 
indicated for comparison. The center of the random effects model represents the pooled hazard ratio, while the 
95% confidence interval is represented by the diamond horizontal borders.
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Correlation between IL-17 RNA expression in fresh frozen 
tissue and survival inconclusive
Two studies have analyzed IL-17 RNA expression in fresh frozen samples using RT-
PCR (Table 1.3). Both studies, on small study populations, did not find associations 
with survival. One study analyzed IL-17 expression in tumor adjacent normal appearing 
biopsies (~10 cm from the tumor center) from 19 colorectal cancer patients.57 The other 
study in 17 ovarian cancer patients only measured the presence of PCR products on 
agarose gel.58 Insufficient data were available to conclude on an association between 
IL-17 RNA expression in fresh frozen tissue and survival.
A high number of Th17 cells in tissue is correlated with 
improved survival
The total number of Th17 cells can be quantified using a combination of a T cell marker 
and IL-17 in FFPE slides. Using immunohistochemistry, our group has shown that a 
high number of Th17 cells was correlated with improved prognosis in squamous 
cervical cancer,37 while another study found a trend toward improved disease-free 
survival (p=0.06) in differentiated thyroid cancer (Table 1.3).59 We did not include 
analyses on the ratio of the number of IL-17+ cells over the number of CD3+ or CD4+ T 
cells, because we do not regard this as a measure for Th17 cells since IL-17 is also 
produced by other cell types.
A high number of Th17 cells in peripheral blood is correlated 
with improved survival
Flow cytometry was used to quantify the Th17 cell frequency among PBMCs, usually 
defined as CD4+IL-17+ cells (see Table 1.3 for details). A high number of Th17 cells 
was correlated with improved survival in four studies.32,38,60,61 Two studies found a 
correlation with poor survival,41,62 while three studies did not find a significant 
correlation.33,63,64
Two studies focused on a different aspect of the Th17 response and are included in the 
overview in Table 1 for completeness, but not in the quantitative analyses.65,66 Notably, 
while two studies reported on a correlation between a high number of Th17 cells and 
poor prognosis, twice as many studies (n=4) reported on a correlation with improved 
prognosis (see Table 2).
A high number of Th17 cells in tumor associated fluids is 
correlated with improved survival
Tumor associated fluids have infrequently been studied for the correlation between




Figure 2. Forest plots for IL-17+ cells in tissue
Schematic quantitative analyses of the studies on the number of IL-17+ cells in FFPE tissue is shown by forest 
plots. Cox regression hazard ratios and 95% confidence intervals for the correlation between a high number of 
IL-17+ cells and overall survival (A) and disease-free survival (B) were obtained from the articles or via 
personal communication with the authors. An asterisk (*) indicates that a multivariate Cox regression analysis 
was used because a univariate analysis was not provided. A dagger (†) indicates that part of the data were 
obtained via e-mail. The cut-off value used to divide the IL-17+ cell frequency in a high and low group is 
indicated for comparison. The center of the random effects model represents the pooled hazard ratio, while the 
95% confidence interval is represented by the diamond horizontal borders.
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Tumor associated fluids have infrequently been studied for the correlation between
IL-17 or Th17 numbers and survival (Table 1.4). Two studies have analyzed the number 
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of Th17 cells in lung cancer malignant pleural effusion by flow cytometry.67,68 Both 
found a significant correlation between a high number of Th17 cells and improved 
overall survival. 
One group has studied the correlation between high IL-17 protein levels in lung cancer 
malignant pleural effusion measured by ELISA and described a correlation with poor 
survival.27 Another study found a correlation between high IL-17 protein levels in 
ovarian carcinoma ascites and improved survival.69 Finally, a study in gastric cancer 
patients showed a significant correlation between high IL-17 RNA expression measured 
by qRT-PCR and improved survival in patients treated with curative resection.70
Collectively, of the five studies on tumor associated fluids, the studies quantifying Th17 
cells using flow cytometry (n=2) and qRT-PCR (n=1) found a correlation with 
improved prognosis. Of the two studies quantifying IL-17 using ELISA, one found a 
correlation with improved, and one with poor prognosis.
Differences between cancer types
While functional differences between IL-17 and Th17 cells may be due to the cellular 
source of IL-17 and the accompanying immune response, this might also depend on the 
cancer type. In studies on liver cancer (n=13), a negative (n=9) or no significant (n=3) 
correlation was found between high IL-17 or Th17 cells and prognosis, except for the 
study of hepatocellular cancer treated with transarterial chemoembolization. All studies 
on colorectal cancer (n=6) also found a correlation between high IL-17 and poor 
prognosis (n=4) or no significant correlation (n=1), except for one study that reported 
on IL-17 being expressed mainly by tumor rather than tumor infiltrating immune cells. 
The studies on non-small cell lung cancer (n=3) reported a significant correlation 
between IL-17 and poor prognosis as well. 
In contrast, all analyses described in six leukemia studies (n=8) showed a significant 
correlation between PBMC Th17 cells or serum IL-17 and improved prognosis (n=3) or 
no effect (n=4), except for one study of serum IL-17 in patients that received stem cell 
transplantation after myeloablative conditioning. This might indicate that the immune 
response in haematological malignancies may differ from solid tumors. Of the studies 
on ovarian cancer (n=4), two described a correlation between high IL-17 and improved 
survival. The other two groups did not find a significant correlation with disease-
specific survival, but one of the studies described a correlation between high IL-17 and 
improved progression-free survival. 
These findings indicate that there may be context specific effects on the IL-17 or Th17 
cell immune response, although the number of studies per cancer type was too limited to 




The clinical impact of Th17 cells has remained unresolved in cancer.71 The aim of this 
review was to identify the correlations between a high amount of IL-17 protein or high 
number of Th17 cells in human cancer and patient survival. Following an extensive 
electronic database search, publications were manually selected without format or 
language restrictions. Survival analyses were studied in the full article if any analysis 
regarding prognosis was mentioned in the abstract, minimizing the risk of publication 
bias. Although the risk of bias in included studies was limited, all studies used different 
cut-off levels to divide IL-17 or Th17 expression in a high and low expression group 
due to a lack of established cut-off levels. This study limitation makes it difficult to 
compare different studies directly. 
The sample type studied proved to be crucial for the correlation with clinical outcome. 
This may partly be explained by a difference in cell source. Some tumor 
microenvironments may be more favorable for Th17 cells, while others may be more 
readily infiltrated by IL-17 producing neutrophils. Additionally, the method used 
determines whether Th17 cells, IL-17 protein or all IL-17 producing cells are measured. 
A high amount of IL-17 protein, predominantly produced by neutrophils and mast cells 
in cancer37-39 and measured in serum, FFPE tissue and tumor associated fluids, was over 
three times more frequently correlated with poor than with improved prognosis. A meta-
analysis could only be performed for IL-17 in FFPE tissue due to the limited number of 
studies on the other sample types. The forest plots clearly showed that a high number of 
IL-17+ cells was correlated with an increased hazard ratio, despite the use of a range of 
cut-off values, which might depend on the type of cancer and analysis. In contrast, a 
high number of Th17 cells measured in FFPE tissue, peripheral blood or tumor 
associated fluids was four times more often correlated with improved than with poor 
prognosis. Since IL-17 RNA can generally not be quantified in neutrophils37,72 the data 
obtained by RT-PCR analyses most likely represent IL-17 produced by Th17 cells. The 
PCR measurements in tumor associated fluids and fresh frozen tissue are thus regarded 
as an indicator of the Th17 cell frequency. Because of limited data available, we could 
not conclude on an association between IL-17 RNA expression and survival. 
Th17 cells seemed to primarily have a tumor suppressing effect, whereas  IL-17 was 
generally associated with poor outcome. IL-17 has been shown to be produced by only a
small Th17 cell population.37-39 The tumor promoting function can be explained by the 
role of IL-17 in inducing angiogenesis73 and recruiting neutrophils.74 Neutrophils have 
been reported to convert to a tumor promoting phenotype and to induce angiogenesis.75
The immune cells capable of producing IL-17 include neutrophils as well as other cell 
types,7-9 which may determine an important part of the clinical outcome. The tumor 
suppression by Th17 cells is probably due to different properties than the secretion of 
IL-17. Th17 cells might stimulate the Th1 and cytotoxic T cell tumor targeting immune 
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role of IL-17 in inducing angiogenesis73 and recruiting neutrophils.74 Neutrophils have 
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The immune cells capable of producing IL-17 include neutrophils as well as other cell 
types,7-9 which may determine an important part of the clinical outcome. The tumor 
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IL-17. Th17 cells might stimulate the Th1 and cytotoxic T cell tumor targeting immune 
responses.76 Additionally, Th17 cells have been shown to have memory stem-cell like 
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properties and the ability to differentiate to Th1/Th17 cells that produce interferon-
gamma.77 Th17 cells may thus either directly or indirectly suppress tumorigenesis.
The type of IL-17 response is thus likely to be context dependent. Liver cancer, 
colorectal cancer and non-small cell lung cancer seem to be correlated with an 
unfavorable IL-17 response.15,16,18-20,24-26,40-46 Leukemia on the other hand might provide 
an environment favorable for Th17 cells to suppress tumor growth.32,38 Similarly, 
ovarian cancer might attract a tumor suppressing IL-17 response, as the majority of 
studies found a correlation with a favorable outcome.28,69 A possible explanation might 
be that different microenvironments favor infiltration of or differentiation toward more 
or less tumor promoting immune cell phenotypes. Not only Th17 cells, but also innate 
cell types capable of producing IL-17 may be correlated with improved prognosis, as we 
and others have shown for mast cells.37,39 Although we cannot discriminate whether the 
cancer type or method used is more important for the correlations found, it is likely that 
both are important for the cell source studied and thus clinical outcome.
Based on the findings described in the current review, cancer patients with high total 
IL-17 protein levels might benefit from anti-IL-17 treatment, blocking the tumor 
promoting response. Adoptive transfer of Th17 cells might be another promising 
treatment. The feasibility of both approaches needs to be investigated further. Human 
Th17 cells can be induced by a combination of IL-1β, IL-6 and IL-23, although the 
exact conditions required are still under debate.78 The functions of differentially 
obtained Th17 cell populations should be determined by functional studies. Animal 
models may be helpful to clarify this, as the induction of Th17 cells by IL-6 and TGF-β 
is clearer in mice than in humans, although the described effects on survival are still 
contradictory.12,79
We conclude that while IL-17 primarily promotes tumorigenesis, the subpopulation of 
IL-17 producing Th17 cells seems to have a tumor suppressing effect. Future research 
should use methodology that makes a distinction between soluble IL-17 protein, Th17 
cells and other IL-17+ cells. This will help to determine whether IL-17 and Th17 cells 
should be targeted or used in a clinical setting.
Materials and Methods
Study design
A systematic search in the NCBI PubMed, Ovid Embase and Web of Science 
bibliographic databases was conducted without language restriction in collaboration 
with information specialist JML following the PRISMA guidelines.80 Since IL-17 is 
frequently studied in autoimmune diseases and together with tumor necrosis factor, 
these terms were excluded as major topic. The full search terms are provided in 
Supplementary Table S9. 
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Selection criteria
All original research studies reporting on an IL-17A or Th17 cell measurement and 
overall (OS) or disease-free survival (DFS) in human cancer published until 10 
September 2014 were included. Articles that did not meet all inclusion criteria (e.g. 
conference abstracts; studies on IL-17 pro cin  γδT  or + cytotoxic T cells or 
only describing remission or progression-free survival) were excluded. All relevant 
references in reviews were manually checked for presence in the systematic search.
Data collection and analysis
Survival analyses, generally Kaplan-Meier survival curves, a log rank test and Cox 
regression analyses, but in some cases a Spearman’s rank correlation,33,68 Wilcoxon 
signed-rank test29 or Satterwaithe t-test61 were obtained. All included articles were 
reviewed by both SP and ESJ. If extracted data did not match, the data were discussed 
until a consensus was reached. Cox regression hazard ratios and confidence intervals 
were used to perform a meta-analysis. The authors of all articles that did not provide 
sufficient information on study details, clinico-pathological data or Cox regression 
analyses were contacted via e-mail. Due to the number of studies with sufficient data 
per sample type studied, only the analyses of the number of IL-17+ cells in FFPE tissue 
were suitable for meta-analysis. To keep the data as comparable as possible, scores in 
the tumor center were used in the cases where data were reported on different scores 
(e.g. invasive margin, peritumor).
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18 negligible: consecutive 
patients
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determined by minimum 
p value approach
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no prior anticancer therapy, 
metastasis or concurrent 
autoimmune disease
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no prior anticancer therapy or 
concurrent autoimmune disease, 
HIV or syphilis
potential: cutoff value 
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no concurrent HCV/HIV infection, 









no metastasis to lymph nodes 






potential: cutoff value 






16 potential: cutoff value 
arbitrarily chosen




15 no prior anticancer therapy potential: cutoff value arbitrarily chosen
30 TNM stage I-III and available 
clinical follow-up data
potential: if no 
prechemotherapy biopsy 
was available, a post-
chemotherapy sample was 






effective resection, no prior 
anticancer therapy and without 
distant metastasis, autoimmune 





primary surgical treatment, no 
prior anticancer therapy and 








no concurrent autoimmune 





49 no prior anti-cancer radio-, chemo-,
and bio-therapy
negligible: measurement 
divided by more/less 
than 10% positive
48
no prior RT, CT or immune 











no autoimmune diseases, other 






FIGO stage II undergoing primary 
radical hysterectomy and pelvic 
lymphadenectomy without 
preoperative CT/RT
potential: cutoff value 
determined by minimum 
p value approach
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no liver metastases, grossly 
residual tumors, immediate 
recurrence, ampullary/neuro-




continuous variables, but 
extremely long surviving 
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compared with poor 
surviving patients (n=6)
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anticancer therapy and without 
distant metasta is, autoi mune 
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stage III–IV with no prior anti-
cancer or anti-inflammatory 
treatment and sufficient 
histological sections for 
immunohistochemical staining
potential: cutoff value 




divided by more/less 
than 25% positive
39*
no concurrent autoimmune 











no prior anticancer therapy or 





Inclusion criteria and risks of bias at study and outcome level provided for the studies on IL-17 measured by 
immunohistochemistry reported in Table 1. An empty cell means no data were reported on this topic. A 
shaded cell indicates a potential risk of bias. An asterisk behind a reference number indicates that the study 
was not included in the quantitative analyses. Abbreviations: CT=chemotherapy; FIGO=Fédération 
Internationale de Gynécologie et d’Obstétrique; RT=radiotherapy
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64 negligible: means compared
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negligible: measurements 
divided by integer value near 
the mean/median value
65*
unresectable distant metastases at 
the time of blood draw, T cell 
reactivity against Melan-A and 









size possibly too 
small
potential: not very sensitive 
method (presence of RT-PCR 
product bands)
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Supplementary Table S4. Details of studies on IL-17 or Th17 cells in tumor associated fluid
Ref # Inclusion criteria Risk of bias 
(study level)




potential: cutoff value 
based on ROC curve
69







no anticancer therapy, corticosteroids, 
nonsteroid anti-inflammatory drugs, 
invasive procedures in the pleural 
cavity or suffering chest trauma within 





not receiving disease-modifying 
therapy; no autoimmune disease, 






not receiving prior anticancer therapy 
or having autoimmune disease, 





Inclusion criteria and risks of bias at study and outcome level provided for the studies on IL-17 and Th17 
measured on tumor associated fluids reported in Table 1. An empty cell means no data were reported on this 
topic. A shaded cell indicates a potential risk of bias.
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30% III-IV
4% BCLC 0, 
79% A, 17% B 13%
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18% TNM I, 
37% II, 28% 
III, 17% IV





68% AML, 32% 
ALL 45% 19 - 63
33 CLL
31% Rai 0, 
21% I, 30% II, 
6% III, 12% IV
55% 64(38 - 87)
9
(1 - 124)





11% TNM II, 
24% III, 65% 
IV





12% ISS I, 
36% II, 52% 
III
38% mean 60 ± 7 23(8 - 35)
Tumor histology and stage, female/male distribution and median age and follow-up are provided for the 
studies on IL-17 measured by ELISA reported in Table 1. Most studies provided the median and range of the 
age and follow-up distributions. Indications are given in cases where other units were provided, mainly the 
mean and standard deviation. Data of the studies by Tseng et al.24, Yamada et al.17 and Hus et al.33 are 
provided for the total study cohort rather than the subpopulation IL-17 was measured in. An empty cell means 
no data were reported on this topic. A dagger behind a reference number indicates that data have (partially) 
been obtained via e-mail. Abbreviations: AC=adenocarcinoma; ALL=acute lymphoid leukemia; AML=acute 
myeloid leukemia; BCLC=Barcelona Clinic Liver Cancer Classification; CLL=chronic lymphocytic 
leukemia; CML=chronic myeloid leukemia; CRC=colorectal carcinoma; HCC=hepatocellular carcinoma; 
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Supplementary Table S6. Clinico-pathological data of the studies on IL-17 in tissue
Ref # Cancer 
type








40 HCC 79% Edmonson grade I-II, 21% III-IV
48% TNM I, 
52% II-III 14% 1   
60
(2 - 74)
18† HCC 73% grade I-II, 27% III-IV
67% TNM I, 









II, 24% III 12%





16% well, 70% 
moderate, 14% poorly 
differentiated
61% TNM I-










massforming type;                                  
70% Edmonson grade 
I-II, 30% III-IV
51% TNM I,
23% II, 26% 
III
50% 55        (18 - 78)
13          
(4 – 111)
20† CRC
22% mucinous colloid 
type; 63% well, 35% 
moderate, 2% poorly 
differentiated
12% TNM I, 
33% II, 29% 
III, 26% IV
84% 26% < 65 36 (29-55)
45 CRC
15% well, 56% 
moderate, 30% poorly 
differentiated
33% TNM I-
II, 67% III-IV 44%
16 Colorectal 
AC
83% tubular, 17% 
mucinous type; 65% 
well-moderate, 35% 
poorly differentiated
TNM III 40% 62% < 60
46 NSCLC 43% SCC, 52% AC, 5% ASC
41% TNM I, 
26% II, 32% 
III
35% mean 65 (40 - 73) 30
15 NSCLC
31% AC, 44% SCC, 
25% other; 19% well-
moderate, 81% poorly 
differentiated
63% TNM I-
II, 37% III 21%




82% ductal, 4% 
lobular, 4% mixed, 
10% mucinous, 1% 
metaplastic; 30% 
grade I, 40% II, 30% 
III
20% TNM I, 
46% II, 34% 
III


















IB, 22% IIA, 
1% IIB;                                           
69% TNM I, 
28% II, 3% 
III, 1% IV







29% well, 38% 
moderate, 33% poorly 
differentiated
7% TNM I, 
36% II, 46% 
III, 12% IV





24% TNM I, 





26% well, 33% 
moderate, 41% poorly 
differentiated
15% TNM I, 
33% II, 39% 
III, 13% IV
35% mean 61 (43 - 75) 5 - 48
51 Gastric 
AC
3% well, 21% 
moderate, 76% poorly 
differentiated
4% TNM I, 
37% II, 49% 
III, 10% IV




II, 35% III-IV 22%
56
(33 - 79) 44 (1 - 87)
21 Cervical 
carcinoma














6% FIGO II, 
84% III, 4% 
IV
100% 34 - 77
29 Pancreatic 
ductal AC
22 HCC 48% grade I-II, 52% III-IV
62% TNM I-







1% SCC, 12% NKC, 
87% UC
6% TNM I, 
30% II, 37% 
III, 27% IV





74% serous, 6% 
mucinous, 10% 
endometrioid, 1% 
clear cell, 10% AC; 
12% grade I, 89% II-
III
90% FIGO 
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Tumor histology and stage, female/male distribution and median age and follow-up are provided for the 
studies on IL-17 measured by immunohistochemistry reported in Table 1. Most studies provided the median 
and range of the age and follow-up distributions. Indications are given in cases where other units were 
provided, mainly the mean and standard deviation. Data of the study by Lin et al.22 are provided for the total 
study cohort rather than the subpopulation IL-17 was measured in. An empty cell means no data were reported
on this topic. An asterisk behind a reference number indicates that the study was not included in the 
quantitative analyses. A dagger behind a reference number indicates that data have (partially) been obtained 
via e-mail. Abbreviations: AC=adenocarcinoma; CRC=colorectal carcinoma; FIGO=Fédération Internationale 
de Gynécologie et d’Obstétrique; HCC=hepatocellular carcinoma; NSCLC=non-small cell lung carcinoma; 
SCC=squamous cell carcinoma
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Tumor histology and stage, female/male distribution and median age and follow-up are provided for the 
studies on Th17 measured by immunohistochemistry, flow cytometry or PCR analysis reported in Table 1. 
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Supplementary Table S8. Clinico-pathological data of the studies on IL-17 or Th17 cells in tumor 
associated fluid








27 Lung cancer 
with MPE
86% AC, 6% SCC, 8% 







36% clear cell/ 
undifferentiated; 
13% grade G1,15% 
G2,69% G3,2% G4
6% FIGO 



















I, 23% II, 
27% III
27%  61(1 - 99)
Tumor histology and stage, female/male distribution and median age and follow-up are provided for the 
studies on IL-17 and Th17 measured in tumor associated fluids reported in Table 1. Most studies provided the 
median and range of the age and follow-up distributions. Indications are given in cases where other units were 
provided, mainly the mean and standard deviation. An empty cell means no data were reported on this topic. 
Abbreviations: AC=adenocarcinoma; FIGO=Fédération Internationale de Gynécologie et d’Obstétrique;
MPE=malignant pleural effusion; SCC=squamous cell carcinoma
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Supplementary Table S9. Database search strategies
Database Search Strategy
PubMed
(("Interleukin-17"[majr] OR "Interleukin-17"[tiab] OR "Interleukin 17"[tiab] OR  
"Interleukin17"[tiab] OR "IL17"[tiab] OR "IL-17"[tiab] OR "Th17 Cells"[Majr] OR 
"Th17"[tiab] OR "Th-17"[tiab]) AND ("Neoplasms"[majr] OR "Neoplasms"[tiab] OR 
"Neoplasm"[tiab] OR "cancer"[tiab] OR "carcinoma"[tiab] OR "malignancy"[tiab] OR 
"malignancies"[tiab] OR "tumor"[tiab] OR "tumour"[tiab] OR "tumors"[tiab] OR 
"tumours"[tiab] )) NOT ( "Tumor Necrosis Factors"[Majr] OR "Tumor necrosis factor"[ti] 
OR "Tumour necrosis factor"[ti] OR "Tumor necrosis factors"[ti] OR "Tumour necrosis 
factors"[ti] OR  "TNF"[ti] OR "Autoimmune Diseases"[Majr] OR “autoimmune”[ti] OR 
“auto-immune”[ti] OR “autoimmunity”[ti] OR “arthritis”[majr] OR “arthritis”[ti] OR 
“arthritic”[ti] OR “multiple sclerosis”[ti] OR “psoriasis”[majr] OR “psoriasis”[ti] OR 
“inflammatory bowel diseases”[majr] OR “inflammatory bowel disease”[ti] OR 
“inflammatory bowel diseases”[ti] OR “Crohn Disease”[majr] OR “crohn”[ti] OR 
“crohn’s”[ti] OR “lupus”[ti] OR “colitis”[majr] OR “colitis”[ti])
Embase
((*interleukin 17/ OR "Interleukin-17".ti,ab. OR "Interleukin 17".ti,ab. OR  
"Interleukin17".ti,ab. OR "IL17".ti,ab. OR "IL-17".ti,ab.) AND (*neoplasm/ OR 
"Neoplasms".ti,ab. OR "Neoplasm".ti,ab. OR "cancer".ti,ab. OR "carcinoma".ti,ab. OR 
"malignancy".ti,ab. OR "malignancies".ti,ab. OR "tumor".ti,ab. OR "tumour".ti,ab. OR 
"tumors".ti,ab. OR "tumours".ti,ab. )) NOT (*tumor necrosis factor/ OR "Tumor necrosis 
factor".ti. OR "Tumour necrosis factor".ti. OR "TNF".ti. OR exp *autoimmune disease/ OR 
"autoimmune".ti. OR "auto-immune".ti. OR "autoimmunity".ti. OR exp *arthritis/ OR 
"arthritis".ti. OR "arthritic".ti. OR *multiple sclerosis/ OR "multiple sclerosis".ti. OR exp 
*psoriasis/ OR "psoriasis".ti. OR *inflammatory bowel disease/ OR "inflammatory bowel 
disease".ti. OR "inflammatory bowel diseases".ti. OR *crohn disease/ OR *ulcerative colitis/ 
OR "crohn".ti. OR "crohn’s".ti. OR "lupus".ti. OR "colitis".ti.)
Web of 
Science
(TS=("Interleukin-17" OR "Interleukin 17" OR  "Interleukin17" OR "IL17" OR "IL-17") 
AND TS=("Neoplasms" OR "Neoplasm" OR "cancer" OR "carcinoma" OR "malignancy" 
OR "malignancies" OR "tumor" OR "tumour" OR "tumors" OR "tumours" )) NOT TI= 
("tumor necrosis factor*" OR "tumour necrosis factor*" OR "TNF" OR "autoimmune" OR 
"auto-immune" OR "autoimmunity" OR "arthritis" OR "arthritic" OR "multiple sclerosis" 
OR "psoriasis" OR "inflammatory bowel disease" OR "inflammatory bowel diseases" OR 
"crohn" OR "crohn’s" OR "lupus" OR "colitis")
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median and range of the age and follow-up distributions. Indications are given in cases where other units were 
provided, mainly the mean and standard deviation. An empty cell means no data were reported on this topic. 
Abbreviations: AC=adenocarcinoma; FIGO=Fédération Internationale de Gynécologie et d’Obstétrique;
MPE=malignant pleural effusion; SCC=squamous cell carcinoma
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Cervical cancer is caused by a persistent HPV infection. Although this infection induces 
an immune response that can generally clear the infection,1 chronic inflammation can 
promote tumor growth by causing DNA mutations, promoting tumor cell survival and 
suppressing the adaptive immune response.2,3 Because the roles of IL-17 and Th17 cells 
in cancer have been controversial and seem to be tissue and context dependent,4 the aim 
of this thesis was to elucidate the roles of IL-17 and Th17 cells in cervical cancer. 
Chapter 1 provides an introduction on cervical cancer, the immune response in general 
and the IL-17 and Th17 cell immune response.
In chapter 2, the roles of IL-12, IL-23, IL-6 and IL-1β ere escri e . e s o e   
RNA in situ hybridization that IL12p35, IL12p40 and IL23p19 were predominantly 
expressed by tumor cells, while the immunohistochemical stainings showed that IL-1β 
was mainly expressed by stromal cells and IL-6 was expressed by both tumor cells and 
infiltrating immune cells. A high level of IL12p40 expression represented a beneficial 
IL-12 related immune response. IL12p35 was never a limiting factor, and the only 
significant correlation was found between IL12p35 and IL12p40 levels. Since the 
affinity of IL12p40 for IL12p35 differs from the affinity for IL23p19, our data 
suggested that IL-12 is produced if high levels of IL12p40 are present, while IL-23 is 
produced when IL23p19 is present in combination with only low levels of IL12p40. 
While a high frequency of stromal IL-6+ cells was strongly correlated with poor 
survival, especially a high number of IL-6+ cells combined with IL-23 was correlated 
with worse prognosis. Interestingly, the absence of the shared IL12p40 subunit was also 
correlated with improved survival as compared with low IL12p40 levels.5 Since the 
absence of IL-12p40 implicates the absence of both IL-12 and IL-23, this indicates that 
the absence of IL-23 was more favorable than the presence of IL-12. Specifically IL-23 
secretion rather than the absence of IL-12 was thus correlated with poor survival, 
especially when combined with a high number of IL-6+ cells. 
IL-6 and IL-23 are part of a response correlated with poor survival in cervical cancer,
which is schematically indicated in a model of the IL-17 and Th17 cell immune 
response axes in cervical cancer in Figure 1 (page 184). Both IL-6 and IL-23 have been 
correlated with poor survival in different cancer types as well. This is thought to be due 
to the attraction of macrophages and neutrophils in the tumor microenvironment,6 or 
direct stimulation of tumor growth.7 Because both IL-6 and IL-23 also play an important 
role in the stimulation of a Th17 cell immune response,8 we hypothesized that Th17 
cells may have an immunosuppressive function in cervical cancer.
To study the function of Th17 cells in cervical cancer, we analyzed the frequency and 
localization of Th17 cells using immunohistochemistry (chapter 3). We did not find 
tumor cells expressing IL-17. Only a minority of tumor infiltrating IL-17+ cells were 
CD3+IL-17+ Th17 cells. This was further confirmed by using different antibodies 
against both CD3 and IL-17, as well as an antibody against CD4 (data not shown), and 
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only approximately 5% of all IL-17 expressing cells were found to be T cells. By 
performing double and triple immunostainings for a panel of immune cell phenotype 
markers, we found that 66% of the IL-17+ cells were neutrophils and 23% were mast 
cells. In a variety of different common types of cancer, we also found that IL-17 was 
mainly expressed by granulocytes, while Th17 cells were always a minor cell 
population. This indicates that the distribution of cell populations expressing IL-17 was 
not specific to cervical cancer. Interestingly, while IL-17 was found to be correlated 
with poor survival in early stage squamous cervical cancer, Th17 cells were correlated 
with improved disease-specific survival. As a potential mechanism for tumor growth in 
early stage disease, IL-17 was shown to increase the growth or intercellular adhesion of 
cervical cancer cell lines. These data suggest that IL-17 has a tumor promoting role in 
squamous cervical cancer, while Th17 cells are likely to stimulate a tumor targeting 
immune response (indicated in Figure 1).
While the role for Th17 cells in a tumor targeting immune response can be understood 
from their Th1 cell and CTL stimulating functions, the roles of both IL-17 and 
neutrophils in cancer are less clear. Neutrophil infiltration has been correlated with 
angiogenesis and poor survival in cancer,9,10 but extensive research has been lacking. 
Immature myeloid cells, which also comprise neutrophils, have recently been shown to 
be correlated with IL-17 expression, CCL4 dependent T helper cell infiltration and 
tumor growth in a melanoma mouse model, indicating that the myeloid cells may create 
a pro-inflammatory environment that induces tumor progression.11 A high total number 
of neutrophils only showed a trend toward poor survival in our study on squamous 
cervical cancer. This may be due to the heterogeneity of this cell population, suggesting 
that IL-17 may particularly be expressed by alternatively activated neutrophils. Several 
of the pro-inflammatory cytokines that induce IL-17 production are also involved in the 
generation of myeloid derived suppressor cells (MDSCs),12 suggesting that the IL-17 
response may also be correlated with concurrent infiltration of MDSCs, which is 
generally correlated with poor prognosis.13 Although granulocytic MDSCs have been 
described to resemble neutrophils, and there is no consensus on the markers to identify 
MDSCs yet,14 we did not find substantial overlap between the expression of granulocyte 
marker CD15 and MDSC marker CD33. We thus concluded that IL-17 was mainly 
expressed by CD15+MPO+ neutrophils, but we have not studied their correlation with 
(CD33+) MDSCs. Another mechanism for IL-17 to promote tumor growth is their 
potential to induce macrophage programmed death-ligand 1 (PD-L1) expression, which 
suppresses CTL activity.15
Since IL-17 signaling can induce IL-6 and IL-8 production,16 and IL-8 induces 
neutrophil recruitment,17 IL-17 production by neutrophils may induce a positive 
feedback loop to attract more neutrophils, leading to more IL-17 production. The 
transcri tion factor γt in ces IL-17 production and has been described to be 
expressed by both innate and adaptive IL-17-producing cells.18 IL-2  an  γt a e 
been shown to induce GM-CSF expression, which induces neutrophil infiltration and 
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produced when IL23p19 is present in combination with only low levels of IL12p40. 
While a high frequency of stromal IL-6+ cells was strongly correlated with poor 
survival, especially a high number of IL-6+ cells combined with IL-23 was correlated 
with worse prognosis. Interestingly, the absence of the shared IL12p40 subunit was also 
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absence of IL-12p40 implicates the absence of both IL-12 and IL-23, this indicates that 
the absence of IL-23 was more favorable than the presence of IL-12. Specifically IL-23 
secretion rather than the absence of IL-12 was thus correlated with poor survival, 
especially when combined with a high number of IL-6+ cells. 
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role in the stimulation of a Th17 cell immune response,8 we hypothesized that Th17 
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Figure 1. The IL-17 and Th17 cell immune response axes in cervical cancer 
Schematic representation of the results obtained from the studies described in this thesis. The encircled 
numbers indicate the chapters in which the indicated correlations have been described. IL-12 was described to 
stimulate a tumor targeting Th1/CTL response (discussed in chapter 2), while T cells were correlated with 
improved survival (chapter 5). Angiogenesis induced by VEGFA has been shown to characterize a detrimental 
tumor microenvironment, as was the case for IL-6 (chapter 5). IL-6 is produced by both tumor and infiltrating 
immune cells (chapter 2), and may directly promote tumor growth (interrupted arrow). IL-6 and IL-23 may 
also stimulate IL-17 production (interrupted arrow), which characterizes a poor immune response when 
produced by non-Th17 cells, predominantly neutrophils (chapter 3). IL-17 may directly stimulate tumor 
growth, angiogenesis and neutrophil infiltration. The IL-6 and IL-17 response may prevent metastatic spread 
via the vasculature (blunted arrows; chapter 3, 5). Th17 cells may stimulate the tumor targeting T cell 
response, and might counteract the tumor promoting effects of IL-6, especially when combined with an IL-5
response (chapter 5). The functions of IL-17 and Th17 cells are probably tumor type and context dependent, 
as described in chapters 4 and 7.
We and others have observed that the immune response present in cervical 
adenocarcinoma differs substantially from the immune response in squamous cervical 
cancer (reference 21 and unpublished data). The correlations between the number of 
total T cells, Tregs, Th17 cells and other IL-17 expressing cells and survival in cervical 






















activation.19,20 This may further amplify the positive feedback loop between IL-17
production and neutrophil attraction. IL-6 and IL-23 may thus primarily induce 
neutrophils to produce IL-17, rather than T cells (indicated in Figure 1).
The role that we have shown for innate IL-17 producing cells in squamous cervical 
cancer is probably tissue and context dependent. Indeed, we found different 
distributions of IL-17 producing cells in the different cancer types studied. However, in 
all cancer types studied, the frequency of granulocytes producing IL-17 exceeded the 
Th17 cell frequency. The obvious next question was whether the role of Th17 cells and 
other IL-17+ cells is similar in cervical adenocarcinoma.
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found between a high number of total intratumoral (intraepithelial and stromal) Tregs 
and improved disease-specific survival. IL-17 could further discriminate between 
patients with a low Treg frequency and poor prognosis, which was worse in case of a 
low frequency of IL-17+ cells. Low Tregs and the presence of Th17 cells was also 
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intraepithelial T cells was correlated with improved prognosis, which was not due to 
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IL6, especially in combination with IL5 and  IL17 expression may improve the accuracy 
of predicting patient survival. 
We also found a significant correlation between IL6 expression and the absence of vaso-
invasion, while β expression showed a trend toward a significant correlation. Total 
IL-17+ cells, IL-1β+ cells and neutrophils were also significantly correlated with the 
absence of vaso-invasion (described in chapter 3). This suggests that this type of 
inflammatory response may prevent metastatic spread of the tumor cells via the blood or
lymphatic vasculature (indicated in Figure 1). Together, these data support the 




correlation with absence of vaso-invasion, blocking IL-6 might increase the risk of 
tumor cell invasion. Since VEGFA expression has been correlated with tumor 
invasiveness,24,25 and the presence of vaso-invasion negatively affects clinical outcome, 
blocking both IL-6 and VEGFA has the potential to counteract both tumor growth and 
invasion. Blocking antibodies to neutralize IL-6 have been shown to lead to some 
clinical responses in different solid cancer types.26-28 VEGFA neutralizing antibodies 
have led to clinical responses in cervical cancer.29,30 These results warrant further 
investigation of the clinical effects of simultaneously blocking IL-6 and VEGFA in 
cervical cancer.
To further examine which factors are most important for patient survival, and determine 
whether these are derived from the tumor epithelial cells or infiltrating immune cells, 
we studied total mRNA sequence (RNA-seq) data from cervical cancer cell suspensions 
flow-sorted into a tumor cell and immune cell fraction (chapter 6). To test whether any 
pathways were differentially expressed, we performed weighted gene co-expression 
network analysis for the tumor and infiltrate samples.31 The tumor cell samples as well 
as the infiltrating immune cell samples showed clear cell source dependent clustering. 
However, although we found a substantial number of gene clusters, none of the clusters 
was significantly correlated with clinical outcome or IL17 expression after correcting 
for multiple testing. This indicates that the cell sorting technique worked well, and both 
the tumor cells and immune cells had similar expression patterns among patients when 
considering clinical outcome. The samples were thus relatively homogeneous, and the 
pathway toward tumorigenesis may be comparable between patients. This technique 
may therefore be useful to analyze and map differences between tumor types. 
Differential gene expression analysis of the sequencing data revealed that TCL1A was 
not expressed in lymphocytes of patients that had died within five years after surgery. 
This was confirmed by qRT-PCR and immunohistochemical analyses. We subsequently 
found that TCL1A was expressed by a subpopulation of B lymphocytes. Furthermore, 
high expression of CD19 and a high TCL1A/CD20 ratio were significantly correlated 
with improved survival on another cervical cancer patient cohort. These results suggest 
that intratumoral B cells are crucial to control cervical cancer, and the TCL1A+ and 
CD20+ B cell populations play an important role (see Figure 1). This warrants further 
investigation for the potential of B cells in anticancer treatment.
We also studied the differential gene expression when comparing IL17 RNA-seq 
positive with IL17 RNA-seq negative immune cell samples. IL17 was expressed at very 
low levels, corresponding with the small number of Th17 cells we have observed in 
cervical and other types of cancer (described in chapter 2). Additionally, the main cell 
source of IL-17 was the neutrophil, which has a short lifespan and is unlikely to have 
survived the sample preparation.32 We could not further elucidate the function of IL-17
or Th17 cells in cervical cancer using this technique, because no genes were 
differentially expressed in the immune cell fractions. Only three genes were expressed 
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at increased levels in the tumor cell fractions when comparing samples with matched 
IL17+ versus IL17- immune cell fractions. The most significantly differentially 
expressed gene, OMA1 zinc metallopeptidase, is involved in mitochondrial quality 
control, acting in stress situations.33 Since Th17 cells have been described to function 
well in hypoxic or other stress conditions, the tumor OMA1 response and Th17 cell 
immune response might be linked.
IL-17 is usually regarded as a marker for Th17 cells. A limited number of studies has 
been published on the correlation between IL-17 or Th17 cells and cancer patient 
survival. The opposing correlations between IL-17 versus Th17 cells and survival 
described in cervical cancer in this thesis might explain the controversy about their role 
in cancer. To test this hypothesis, we specifically studied the correlations between IL-17 
versus Th17 cells and survival in cancer patients in a systematic literature review 
described in chapter 7. We found that high IL-17 measurements were three times more 
frequently correlated with poor than with improved survival in cancer. A high Th17 cell 
frequency on the other hand was four times more frequently correlated with improved 
than with poor survival. So although the type of tumor microenvironment certainly 
determines for an important part whether IL-17 and Th17 cells have a tumor promoting 
or suppressing function, IL-17 seems to generally induce tumor promoting angiogenesis 
and neutrophil recruitment,9,17,34 corresponding with our results in squamous cervical 
cancer (described in chapter 3 and illustrated in Figure 1). Since IL-17 can be produced 
by a variety of cell types, the cell types present will also determine the type of immune 
response. Th17 cells seem to be predominantly involved in tumor suppression, 
potentially by stimulating Th1 and CTL immune responses (indicated in Figure 1).35,36
Since Th17 cells are a subpopulation of IL-17+ cells and had a different correlation with 
prognosis than total IL-17, it is important to distinguish between Th17 and other IL-17+
cells. The systematic review could thus substantiate our hypothesis on the opposing 
roles of IL-17 and Th17 cells in cancer.
Future prospects
The studies and insights described in this thesis have also led to new research questions. 
The most essential topics that require further investigation are described in this section 
of the discussion. For a start, the finding that IL-17 is predominantly expressed by 
neutrophils rather than Th17 cells in cancer, raises some interesting discussion points. 
For example, although the requirements for the differentiation of naïve T cells to Th17 
cells are still under debate, the conditions required to induce IL-17 production by 
ne tro i s are co ete  n no n. T e e ression of γt as een s o n to 
induce IL-17 in mouse neutrophils,37 but whether its expression is required for or 
supporting IL-17 production in human neutrophils is not known. Knowledge about the 
cytokines and transcription factors involved in IL-17 expression in neutrophils would 
187
208970-L-bw-Punt
V I I I
correlation with absence of vaso-invasion, blocking IL-6 might increase the risk of 
tumor cell invasion. Since VEGFA expression has been correlated with tumor 
invasiveness,24,25 and the presence of vaso-invasion negatively affects clinical outcome, 
blocking both IL-6 and VEGFA has the potential to counteract both tumor growth and 
invasion. Blocking antibodies to neutralize IL-6 have been shown to lead to some 
clinical responses in different solid cancer types.26-28 VEGFA neutralizing antibodies 
have led to clinical responses in cervical cancer.29,30 These results warrant further 
investigation of the clinical effects of simultaneously blocking IL-6 and VEGFA in 
cervical cancer.
To further examine which factors are most important for patient survival, and determine 
whether these are derived from the tumor epithelial cells or infiltrating immune cells, 
we studied total mRNA sequence (RNA-seq) data from cervical cancer cell suspensions 
flow-sorted into a tumor cell and immune cell fraction (chapter 6). To test whether any 
pathways were differentially expressed, we performed weighted gene co-expression 
network analysis for the tumor and infiltrate samples.31 The tumor cell samples as well 
as the infiltrating immune cell samples showed clear cell source dependent clustering. 
However, although we found a substantial number of gene clusters, none of the clusters 
was significantly correlated with clinical outcome or IL17 expression after correcting 
for multiple testing. This indicates that the cell sorting technique worked well, and both 
the tumor cells and immune cells had similar expression patterns among patients when 
considering clinical outcome. The samples were thus relatively homogeneous, and the 
pathway toward tumorigenesis may be comparable between patients. This technique 
may therefore be useful to analyze and map differences between tumor types. 
Differential gene expression analysis of the sequencing data revealed that TCL1A was 
not expressed in lymphocytes of patients that had died within five years after surgery. 
This was confirmed by qRT-PCR and immunohistochemical analyses. We subsequently 
found that TCL1A was expressed by a subpopulation of B lymphocytes. Furthermore, 
high expression of CD19 and a high TCL1A/CD20 ratio were significantly correlated 
with improved survival on another cervical cancer patient cohort. These results suggest 
that intratumoral B cells are crucial to control cervical cancer, and the TCL1A+ and 
CD20+ B cell populations play an important role (see Figure 1). This warrants further 
investigation for the potential of B cells in anticancer treatment.
We also studied the differential gene expression when comparing IL17 RNA-seq 
positive with IL17 RNA-seq negative immune cell samples. IL17 was expressed at very 
low levels, corresponding with the small number of Th17 cells we have observed in 
cervical and other types of cancer (described in chapter 2). Additionally, the main cell 
source of IL-17 was the neutrophil, which has a short lifespan and is unlikely to have 
survived the sample preparation.32 We could not further elucidate the function of IL-17
or Th17 cells in cervical cancer using this technique, because no genes were 
differentially expressed in the immune cell fractions. Only three genes were expressed 
186
at increased levels in the tumor cell fractions when comparing samples with matched 
IL17+ versus IL17- immune cell fractions. The most significantly differentially 
expressed gene, OMA1 zinc metallopeptidase, is involved in mitochondrial quality 
control, acting in stress situations.33 Since Th17 cells have been described to function 
well in hypoxic or other stress conditions, the tumor OMA1 response and Th17 cell 
immune response might be linked.
IL-17 is usually regarded as a marker for Th17 cells. A limited number of studies has 
been published on the correlation between IL-17 or Th17 cells and cancer patient 
survival. The opposing correlations between IL-17 versus Th17 cells and survival 
described in cervical cancer in this thesis might explain the controversy about their role 
in cancer. To test this hypothesis, we specifically studied the correlations between IL-17 
versus Th17 cells and survival in cancer patients in a systematic literature review 
described in chapter 7. We found that high IL-17 measurements were three times more 
frequently correlated with poor than with improved survival in cancer. A high Th17 cell 
frequency on the other hand was four times more frequently correlated with improved 
than with poor survival. So although the type of tumor microenvironment certainly 
determines for an important part whether IL-17 and Th17 cells have a tumor promoting 
or suppressing function, IL-17 seems to generally induce tumor promoting angiogenesis 
and neutrophil recruitment,9,17,34 corresponding with our results in squamous cervical 
cancer (described in chapter 3 and illustrated in Figure 1). Since IL-17 can be produced 
by a variety of cell types, the cell types present will also determine the type of immune 
response. Th17 cells seem to be predominantly involved in tumor suppression, 
potentially by stimulating Th1 and CTL immune responses (indicated in Figure 1).35,36
Since Th17 cells are a subpopulation of IL-17+ cells and had a different correlation with 
prognosis than total IL-17, it is important to distinguish between Th17 and other IL-17+
cells. The systematic review could thus substantiate our hypothesis on the opposing 
roles of IL-17 and Th17 cells in cancer.
Future prospects
The studies and insights described in this thesis have also led to new research questions. 
The most essential topics that require further investigation are described in this section 
of the discussion. For a start, the finding that IL-17 is predominantly expressed by 
neutrophils rather than Th17 cells in cancer, raises some interesting discussion points. 
For example, although the requirements for the differentiation of naïve T cells to Th17 
cells are still under debate, the conditions required to induce IL-17 production by 
ne tro i s are co ete  n no n. T e e ression of γt as een s o n to 
induce IL-17 in mouse neutrophils,37 but whether its expression is required for or 
supporting IL-17 production in human neutrophils is not known. Knowledge about the 
cytokines and transcription factors involved in IL-17 expression in neutrophils would 
187
208970-L-bw-Punt
provide insight in the type of immune response that induces IL-17 production and its 
associated effects.
The phenotypical differences between classically activated tumor targeting and 
alternatively activated tumor promoting neutrophils are still largely undetermined. 
Studying these different subpopulations could aid in identifying whether it is indeed 
alternatively activated cells that produce IL-17 and play a detrimental role in cervical 
cancer.38
There may also be substantial differences between the sources of IL-17 in autoimmune 
diseases, which would be interesting to investigate. Several studies have already 
indicated that IL-17 is expressed by mast cells, macrophages, eosinophils and 
neutrophils in different autoimmune diseases.39-44 Because the dependency of the 
function of secreted IL-17 on its cellular source is unclear, studying the composition of 
the microenvironment and the other stimulatory factors involved is important.
Although IL-17 was shown to predominantly correlate with poor survival and Th17 
cells with improved survival, there was substantial variance in the magnitude of the 
effect. This might be attributable to the tumor type, which might even affect the 
direction of the effect (described in chapter 7). In squamous cervical cancer, we showed 
that Th17 cells were significantly and independently correlated with improved survival, 
and could counteract the tumor promoting effects of IL6. In contrast, Th17 cells showed 
a trend toward poor survival in cervical adenocarcinoma. IL-17 was predominantly 
expressed by neutrophils in squamous cervical cancer, and was significantly and 
independently correlated with poor survival in early stage cancer. In cervical 
adenocarcinoma, non-Th17 IL-17+ cells showed a trend toward improved survival. The 
trends in adenocarcinoma thus contradict the general correlations described in this 
thesis. Whether this is true for adenocarcinomas in general needs to be studied further. 
Overall, the cancer types in which Th17 or other IL-17+ cells play an important role 
should be determined. It would also be interesting to determine the cell types that 
produce IL-17 per cancer type or perhaps even per patient. To study the significance of 
IL-17 produced by Th17 cells, the other immune cell types or factors correlated with the 
IL-17 and Th17 cell immune response should be studied. Functional assays should also 
be performed to study whether Th17 cell derived IL-17 is crucial to stimulate a 
Th1/CTL immune response, or rather reflects plasticity of stem-cell like cells that can 
differentiate toward Th1 cells.
Similarly, the mechanisms behind the correlations between Tregs and intraepithelial T 
cells and improved prognosis in cervical adenocarcinoma should be investigated. 
Studying the immune cell types correlated with the Treg and intraepithelial T cell 
responses will provide insight into how these cell types might be used to guide patient 
prognosis and treatment.
Based on the findings described in chapter 7, cancer patients with high IL-17 levels 
might benefit from anti-IL-17 treatment. Neutralizing IL-17 has been shown to inhibit 
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tumor growth in a lymphoma mouse model.45 Antibodies directed against human IL-17 
and its receptor are already used in clinical trials to treat a variety of autoimmune 
diseases.46 Adoptive transfer of Th17 cells might be another promising treatment, 
especially since adoptive transfer of Th17 cells in mice has been described as more 
efficient than Th1 cell transfer.47-49 Specifically, IL-17 antibodies did not affect the 
tumor targeting effect of Th17 cells, while IFNγ antibodies abrogated their efficacy,47 
again indicating that the effects of Th17 cells and IL-17 are not identical in cancer. The 
feasibility of both approaches should be further investigated. 
Finally, as mentioned previously, the efficacy of combination therapies should be 
investigated. Not only the combination of targeting IL-17 or IL-6 and VEGFA might be 
promising, but also combining immunotherapies and targeted therapies or radio - or 
chemotherapy. The potential efficacy of combination therapies lies beyond the scope of 
this thesis, but is a major interest of current investigations. 
Conclusion 
In conclusion, this thesis provides novel insights into the role of IL-17 and Th17 cells in 
cervical cancer. Figure 1 summarizes the results obtained from the studies described in 
this thesis. While IL-17 was shown to be predominantly produced by innate myeloid 
cells such as neutrophils and correlated with poor survival, Th17 cells were generally a 
small cell population correlated with improved survival. Since IL-6 and IL-23 were also 
found to be strongly correlated with poor survival, we hypothesize that these cytokines 
may induce IL-17 production by myeloid cells. Th17 cells may counteract this pro -
inflammatory response characterized by IL-6 and IL-17. The IL-6/IL-17 response was 
correlated with the absence of vaso-invasion. The immune responses described are 
tissue and context dependent, as indicated by the predominant correlation between 
Tregs and improved survival in cervical adenocarcinoma. In addition to innate and T 
lymphocytes responses, B lymphocytes may also play an important role in cervical 
cancer. Few studies have investigated this cell type. We found that B cells expressing 
TCL1A are strongly correlated with improved survival in squamous cervical cancer.  
These novel data will, together with the proposed future studies discussed in this 
chapter, provide a better understanding of the immune response in cervical cancer. This 
will advance our knowledge in cancer evolution, diagnostics, prognostics and 
therapeutics. 
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De IL-17 en Th17 cel immuunrespons in 
baarmoederhalskanker
In hoofdstuk 1 wordt een algemene introductie gegeven over baarmoederhalskanker en 
de immuunrespons gericht tegen kanker, waaronder de rol van IL-17 en Th17 cellen. 
Baarmoederhalskanker komt vooral voor bij jonge vrouwen, en is wereldwijd de vierde
voornaamste doodsoorzaak door kanker bij vrouwen. Dit komt met name door de hoge 
incidentie van baarmoederhalskanker in ontwikkelingslanden. De oorzaak van 
baarmoederhalskanker is een infectie met hoog-risico humaan papillomavirus (HPV). 
Hoewel naar schatting zo’n 80% van de vrouwen ooit wordt besmet met HPV, wordt 
het virus in meer dan 80% van deze besmettingsgevallen geëlimineerd. Slechts in 10-
20% van de infecties wordt het virale genoom ingebouwd in het humane genoom, wat 
expressie van de virale oncogenen E6 en E7 veroorzaakt en uiteindelijk kan leiden tot 
premaligne voorstadia en uiteindelijk kanker. Er zijn drie belangrijke histologische 
typen baarmoederhalskanker te onderscheiden: plaveiselcelcarcinoom, adenosquameus 
carcinoom en adenocarcinoom. Plaveiselcelcarcinoom heeft met 75% de hoogste 
incidentie.
De behandeling is afhankelijk van het FIGO stadium: een klinische beoordeling van de 
tumorgrootte, ingroei in het omliggende weefsel en uitzaaiingen op afstand. Tumoren 
die geclassificeerd worden met een laag FIGO stadium worden geopereerd, terwijl  
tumoren die geclassificeerd worden met hoge FIGO stadia doorgaans worden behandeld 
met (adjuvante) radiotherapie al dan niet in combinatie met chemotherapie. Klinische 
factoren die de prognose beïnvloeden zijn tumorgrootte, infiltratie in het omliggende
weefsel en de bloedvaten en uitzaaiing naar de lymfeklieren. Na de behandeling wordt 
het TNM stadium bepaald door een patholoog. De TNM stadiëring omvat een 
classificatie op basis van tumorgrootte en uitzaaiingen naar de lymfeklieren alsook 
uitzaaiingen op afstand.
Het immuunsysteem beschermt organismen tegen pathogenen (ziekteverwekkers), 
middels een grote variëteit aan witte bloedcellen met elk een specifieke functie. Deze 
immuuncellen kunnen de pathogenen of geïnfecteerde cellen fagocyteren, of aanvallen 
met behulp van zuurstofradicalen en enzymen. Daarnaast kunnen ze cytokinen 
produceren: kleine signaalmoleculen die cellen kunnen activeren en het type 
immuunrespons kunnen reguleren. Zo kan het immuunsysteem op een effectieve manier 
reageren op verschillende soorten pathogenen. Inmiddels weten we dat het 
immuunsysteem het lichaam ook beschermt tegen de ontwikkeling van kanker. Echter, 
zodra de getransformeerde cellen weten te ontsnappen aan de immuunrespons, kunnen 
deze uiteindelijk uitgroeien tot een tumor. Gedurende dit selectieproces kunnen de 
tumorcellen bijvoorbeeld ook cytokinen produceren en hiermee de immuunrespons 
reguleren. Er kan dan een chronische ontsteking ontstaan, die juist de tumorgroei 
bevordert. Door de expressie van niet-lichaamseigen virale eiwitten, induceren HPV 
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geïnfecteerde en getransformeerde cellen een natuurlijke immuunrespons. Deze 
immunogeniciteit wordt al preventief toegepast door middel van vaccinatie, maar 
therapeutische behandeling van baarmoederhalskanker met immuuntherapie heeft nog 
weinig efficiënte behandelingen opgeleverd. Het is daarom van belang om de lokale 
immuunrespons in baarmoederhalskanker verder te onderzoeken.
Een specifiek type immuuncel is de T lymfocyt. De T lymfocyt ontwikkelt in de thymus 
en heeft een unieke receptor, waardoor elke T cel uniek is voor een bepaald antigen, 
afkomstig van een pathogeen of anderszins abnormaal eiwit. Zodra het unieke antigen 
wordt herkend, kunnen deze cellen direct een doelwit cel lyseren (cytotoxische T
cellen). Daarnaast zijn er T helper cellen, die hulp bieden aan andere lymfocyten en 
andere cellen activeren middels cytokinen. Een voorbeeld van deze T helper cellen is de 
T helper 17 (Th17) cel, ontdekt in 2000. De naam van de Th17 cel berust op het feit dat 
dit celtype het cytokine interleukine 17 (IL-17) produceert. IL-17 induceert de groei van 
bloedvaatjes en indirect het aantrekken en de activatie van neutrofiele granulocyten. 
Neutrofiele granulocyten kunnen heel efficiënt pathogenen opruimen. Th17 cellen zijn 
met name van belang bij de eliminatie van bepaalde extracellulaire pathogenen, omdat 
ze verschillende ontstekingsbevorderende (pro-inflammatoire) cytokinen produceren 
waaronder IL-17. Aan de andere kant spelen Th17 cellen door het pro-inflammatoire 
karakter een dominante rol in verschillende auto-immuunziekten.
De rol van IL-17 en Th17 cellen in kanker is onduidelijk. De aanwezigheid van Th17 
cellen en IL-17 kan gepaard gaan met de productie van interferon-γ (IFNγ) en activatie 
van cytotoxische T cellen, en leiden tot afname van de tumorgroei. Daarentegen kunnen 
IL-17 en Th17 cellen ook vaatgroei (angiogenese) induceren en myeloïde cellen zoals 
neutrofiele granulocyten aantrekken, welke de tumorgroei bevorderen. Omdat er geen 
consensus bestaat over de rol van IL-17 en Th17 cellen in kanker, werd in dit 
proefschrift de rol van IL-17 en Th17 cellen in baarmoederhalskanker onderzocht.
In hoofdstuk 2 wordt de rol van de cytokinen IL-1β, IL-6, IL-23 en IL-12 beschreven. 
IL-12 stimuleert een immuunrespons gericht tegen de tumor, terwijl IL-1β, IL-6 en    
IL-23 een Th17 cel immuunrespons kunnen induceren. IL-12 en IL-23 bestaan uit twee 
ketens,  een gedeelde component (IL-12p40) en een unieke component (IL-12p35 
respectievelijk IL-23p19). De expressie van de cytokinen IL12p35, IL12p40 en IL23p19
werd onderzocht met RNA in situ hybridisatie. Alleen de expressie van IL12p40 was 
significant gecorreleerd met de expressie van IL12p35. Omdat IL12p35 altijd aanwezig 
was als IL12p40 aanwezig was, en de affiniteit voor IL12p35 verschilt van de affiniteit 
voor IL23p19, veronderstelden wij dat IL-12 wordt geproduceerd bij een hoge IL12p40
expressie, terwijl IL-23 wordt geproduceerd als IL23p19 aanwezig is in combinatie met 
lage IL12p40 expressie. De eiwitexpressie van IL-1β en IL-6 werd bestudeerd met 
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De IL-17 en Th17 cel immuunrespons in 
baarmoederhalskanker
In hoofdstuk 1 wordt een algemene introductie gegeven over baarmoederhalskanker en 
de immuunrespons gericht tegen kanker, waaronder de rol van IL-17 en Th17 cellen. 
Baarmoederhalskanker komt vooral voor bij jonge vrouwen, en is wereldwijd de vierde
voornaamste doodsoorzaak door kanker bij vrouwen. Dit komt met name door de hoge 
incidentie van baarmoederhalskanker in ontwikkelingslanden. De oorzaak van 
baarmoederhalskanker is een infectie met hoog-risico humaan papillomavirus (HPV). 
Hoewel naar schatting zo’n 80% van de vrouwen ooit wordt besmet met HPV, wordt 
het virus in meer dan 80% van deze besmettingsgevallen geëlimineerd. Slechts in 10-
20% van de infecties wordt het virale genoom ingebouwd in het humane genoom, wat 
expressie van de virale oncogenen E6 en E7 veroorzaakt en uiteindelijk kan leiden tot 
premaligne voorstadia en uiteindelijk kanker. Er zijn drie belangrijke histologische 
typen baarmoederhalskanker te onderscheiden: plaveiselcelcarcinoom, adenosquameus 
carcinoom en adenocarcinoom. Plaveiselcelcarcinoom heeft met 75% de hoogste 
incidentie.
De behandeling is afhankelijk van het FIGO stadium: een klinische beoordeling van de 
tumorgrootte, ingroei in het omliggende weefsel en uitzaaiingen op afstand. Tumoren 
die geclassificeerd worden met een laag FIGO stadium worden geopereerd, terwijl  
tumoren die geclassificeerd worden met hoge FIGO stadia doorgaans worden behandeld 
met (adjuvante) radiotherapie al dan niet in combinatie met chemotherapie. Klinische 
factoren die de prognose beïnvloeden zijn tumorgrootte, infiltratie in het omliggende
weefsel en de bloedvaten en uitzaaiing naar de lymfeklieren. Na de behandeling wordt 
het TNM stadium bepaald door een patholoog. De TNM stadiëring omvat een 
classificatie op basis van tumorgrootte en uitzaaiingen naar de lymfeklieren alsook 
uitzaaiingen op afstand.
Het immuunsysteem beschermt organismen tegen pathogenen (ziekteverwekkers), 
middels een grote variëteit aan witte bloedcellen met elk een specifieke functie. Deze 
immuuncellen kunnen de pathogenen of geïnfecteerde cellen fagocyteren, of aanvallen 
met behulp van zuurstofradicalen en enzymen. Daarnaast kunnen ze cytokinen 
produceren: kleine signaalmoleculen die cellen kunnen activeren en het type 
immuunrespons kunnen reguleren. Zo kan het immuunsysteem op een effectieve manier 
reageren op verschillende soorten pathogenen. Inmiddels weten we dat het 
immuunsysteem het lichaam ook beschermt tegen de ontwikkeling van kanker. Echter, 
zodra de getransformeerde cellen weten te ontsnappen aan de immuunrespons, kunnen 
deze uiteindelijk uitgroeien tot een tumor. Gedurende dit selectieproces kunnen de 
tumorcellen bijvoorbeeld ook cytokinen produceren en hiermee de immuunrespons 
reguleren. Er kan dan een chronische ontsteking ontstaan, die juist de tumorgroei 
bevordert. Door de expressie van niet-lichaamseigen virale eiwitten, induceren HPV 
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geïnfecteerde en getransformeerde cellen een natuurlijke immuunrespons. Deze 
immunogeniciteit wordt al preventief toegepast door middel van vaccinatie, maar 
therapeutische behandeling van baarmoederhalskanker met immuuntherapie heeft nog 
weinig efficiënte behandelingen opgeleverd. Het is daarom van belang om de lokale 
immuunrespons in baarmoederhalskanker verder te onderzoeken.
Een specifiek type immuuncel is de T lymfocyt. De T lymfocyt ontwikkelt in de thymus 
en heeft een unieke receptor, waardoor elke T cel uniek is voor een bepaald antigen, 
afkomstig van een pathogeen of anderszins abnormaal eiwit. Zodra het unieke antigen 
wordt herkend, kunnen deze cellen direct een doelwit cel lyseren (cytotoxische T
cellen). Daarnaast zijn er T helper cellen, die hulp bieden aan andere lymfocyten en 
andere cellen activeren middels cytokinen. Een voorbeeld van deze T helper cellen is de 
T helper 17 (Th17) cel, ontdekt in 2000. De naam van de Th17 cel berust op het feit dat 
dit celtype het cytokine interleukine 17 (IL-17) produceert. IL-17 induceert de groei van 
bloedvaatjes en indirect het aantrekken en de activatie van neutrofiele granulocyten. 
Neutrofiele granulocyten kunnen heel efficiënt pathogenen opruimen. Th17 cellen zijn 
met name van belang bij de eliminatie van bepaalde extracellulaire pathogenen, omdat 
ze verschillende ontstekingsbevorderende (pro-inflammatoire) cytokinen produceren 
waaronder IL-17. Aan de andere kant spelen Th17 cellen door het pro-inflammatoire 
karakter een dominante rol in verschillende auto-immuunziekten.
De rol van IL-17 en Th17 cellen in kanker is onduidelijk. De aanwezigheid van Th17 
cellen en IL-17 kan gepaard gaan met de productie van interferon-γ (IFNγ) en activatie 
van cytotoxische T cellen, en leiden tot afname van de tumorgroei. Daarentegen kunnen 
IL-17 en Th17 cellen ook vaatgroei (angiogenese) induceren en myeloïde cellen zoals 
neutrofiele granulocyten aantrekken, welke de tumorgroei bevorderen. Omdat er geen 
consensus bestaat over de rol van IL-17 en Th17 cellen in kanker, werd in dit 
proefschrift de rol van IL-17 en Th17 cellen in baarmoederhalskanker onderzocht.
In hoofdstuk 2 wordt de rol van de cytokinen IL-1β, IL-6, IL-23 en IL-12 beschreven. 
IL-12 stimuleert een immuunrespons gericht tegen de tumor, terwijl IL-1β, IL-6 en    
IL-23 een Th17 cel immuunrespons kunnen induceren. IL-12 en IL-23 bestaan uit twee 
ketens,  een gedeelde component (IL-12p40) en een unieke component (IL-12p35 
respectievelijk IL-23p19). De expressie van de cytokinen IL12p35, IL12p40 en IL23p19
werd onderzocht met RNA in situ hybridisatie. Alleen de expressie van IL12p40 was 
significant gecorreleerd met de expressie van IL12p35. Omdat IL12p35 altijd aanwezig 
was als IL12p40 aanwezig was, en de affiniteit voor IL12p35 verschilt van de affiniteit 
voor IL23p19, veronderstelden wij dat IL-12 wordt geproduceerd bij een hoge IL12p40
expressie, terwijl IL-23 wordt geproduceerd als IL23p19 aanwezig is in combinatie met 
lage IL12p40 expressie. De eiwitexpressie van IL-1β en IL-6 werd bestudeerd met 
immuunhistochemie. Een hoog aantal IL-6 positieve cellen in het stroma (steunweefsel 
rondom de tumorcellen) was gecorreleerd met slechte overleving. Met name de 
combinatie van een hoog aantal IL-6 positieve cellen en IL-23 expressie door de tumor 
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was sterk gecorreleerd met slechte overleving. De afwezigheid van zowel IL-12 als    
IL-23, in het geval van IL12p40 afwezigheid, was ook gecorreleerd met goede 
overleving, wat aangeeft dat de afwezigheid van IL-23 gunstiger is dan de aanwezigheid 
van IL-12 voor wat betreft de prognose. Met name IL-23 productie was dus 
gecorreleerd met slechte overleving, niet zozeer de afwezigheid van IL-12. Omdat IL-6
en IL-23 een belangrijke rol spelen bij de inductie van een Th17 immuunrespons, 
suggereert dit dat Th17 cel differentiatie een rol zou kunnen spelen bij suppressie van 
het immuunsysteem.
De sterke correlatie tussen IL-6 en IL-23 en slechte overleving leidde tot de hypothese 
dat de inductie van Th17 cel differentiatie gecorreleerd is met suppressie van het 
immuunsysteem in baarmoederhalskanker. Om deze reden werden de lokalisatie en het 
fenotype van IL-17 producerende cellen beschreven met behulp van immuun-
histochemie in hoofdstuk 3. Hoewel IL-17 doorgaans wordt beschouwd als marker 
voor Th17 cellen, vonden we tegen onze verwachting in dat IL-17 met name tot 
expressie kwam in neutrofiele granulocyten en mestcellen, en slechts in een kleine 
populatie Th17 cellen in baarmoederhalskanker. Ook in andere typen kanker werd IL-17
vaker tot expressie gebracht in granulocyten dan in T cellen. Vervolgens werd de 
frequentie van IL-17 positieve cellen, granulocyten, mestcellen en Th17 cellen in de 
tumoren van een cohort patiënten met plaveiselcelcarcinoom van de baarmoederhals 
bestudeerd. Een hoog aantal IL-17 positieve cellen in de tumor was gecorreleerd met 
slechte overleving in patiënten geclassificeerd met een laag TNM stadium (stadium I). 
Een mogelijke gedeeltelijke verklaring hiervoor is de directe stimulatie van tumorcel
proliferatie, gebaseerd op experimenten waarbij een toename in celindex van 
baarmoederhalskanker cellijnen werd waargenomen na toevoeging van IL-17 in een 
real-time cel analyse. Opzienbarend genoeg was een hoog aantal Th17 cellen juist 
gecorreleerd met goede overleving. Dit suggereert dat IL-17 de tumorgroei in 
baarmoederhalskanker stimuleert, terwijl Th17 cellen onderdeel zijn van een 
immuunrespons gericht tegen de tumor.
Aangezien IL-17 zorgt voor de infiltratie van neutrofiele granulocyten, zou de productie 
van IL-17 door de neutrofiele granulocyten zelf voor een positieve terugkoppeling 
kunnen zorgen die weer leidt tot meer infiltratie van neutrofiele granulocyten. Het lijkt 
er in ieder geval op dat IL-6 en IL-23 niet alleen zorgen voor de aantrekking van 
macrofagen en tumorgroei, maar ook neutrofiele granulocyten zouden kunnen 
stimuleren IL-17 te produceren, resulterend in slechtere overleving. 
De rol van T cellen en IL-17 in adenocarcinoom van de baarmoederhals zijn het 
onderwerp van hoofdstuk 4. Adenocarcinoom verschilt van plaveiselcelcarcinoom van 
de baarmoederhals in groeipatroon, moleculaire achtergrond en gevoeligheid voor 
radio- en chemotherapie. Omdat de incidentie van adenocarcinoom een stuk lager ligt, 
zijn er niet veel uitgebreide studies naar de rol van het immuunsysteem in dit type tumor 
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gedaan. Omdat de rol van IL-17 en Th17 cellen context en weefsel afhankelijk lijkt te 
zijn, en het ontstekingsinfiltraat in adenocarcinoom een andere samenstelling lijkt te 
hebben dan in plaveiselcelcarcinoom, onderzochten wij of de rol van T cellen en IL-17 
in deze twee histologische tumortypen vergelijkbaar is. Een laag aantal regulatoire T 
cellen gemeten op basis van immuunfluorescente score bleek sterk gecorreleerd te zijn 
met slechte overleving. Een laag aantal regulatoire T cellen gecombineerd met een laag 
aantal IL-17 positieve cellen was nog sterker gecorreleerd met slechte overleving. Zo 
was ook de combinatie van een laag aantal regulatoire T cellen en de aanwezigheid van 
Th17 cellen gecorreleerd met slechtere overleving. In tegenstelling tot onze bevindingen 
in plaveiselcelcarcinoom, was er  een trend naar goede overleving bij aanwezigheid van 
veel IL-17 positieve cellen in de tumor, en een trend naar slechte overleving bij 
aanwezigheid van Th17 cellen. Ook de rol van regulatoire T cellen is controversieel en 
lijkt context en tumortype afhankelijk te zijn. Het zou kunnen dat een pro-inflammatoir 
milieu in adenocarcinoom immuuncellen aantrekt die de tumorgroei onderdrukken. De 
Th17 cellen zouden een tumorgroei stimulerende immuunrespons kunnen 
vertegenwoordigen, die geremd wordt door de regulatoire T cellen. Dit komt niet 
overeen met onze bevindingen bij plaveiselcelcarcinoom en dient nog verder te worden 
bevestigd. Ook de correlaties met andere immuuncel typen dienen verder onderzocht te 
worden. Deze resultaten ondersteunen de hypothese dat de rol van het immuunsysteem, 
waaronder IL-17 en Th17 cellen, context en tumortype afhankelijk is.
Een tumor bestaat niet alleen uit tumorcellen, maar bevat ook bloed- en lymfevaten, 
immuuncellen en een matrix van cellen, eiwitten en suikerstructuren. In hoofdstuk 5
werden de correlaties tussen verschillende typen immuunrespons en factoren van 
invloed op vaatvorming beschreven. Op deze manier werd de rol van de IL-17 en Th17 
cel immuunrespons in baarmoederhalskanker verder onderzocht. De factoren werden 
bestudeerd met behulp van kwantitatieve reverse transcriptase PCR (qRT-PCR) analyse 
op vers ingevroren monsters van plaveiselcelcarcinoom van de baarmoederhals. Hoge 
expressie van T cel markers (CD3E, CD8A, FOXP3) was gecorreleerd met goede 
prognose, terwijl IL6 en de angiogenese marker VEGFA gecorreleerd waren met slechte 
overleving. Met name een hoge IL6/IL17 ratio gecombineerd met lage IL5 expressie 
was sterk gecorreleerd met slechte overleving. Opvallend genoeg bleken IL17 en 
neutrofiele granulocyten markers fucosyltransferase 9 (FUT9) en neutrophil elastase 
(NE) zeer laag tot expressie te komen. Aangezien neutrofiele granulocyten in weefsels
zeer weinig tot geen RNA tot expressie brengen dat codeert voor de eiwitten die ze in 
hun granules bevatten, is de IL17 expressie die we hebben gemeten waarschijnlijk 
afkomstig van Th17 cellen. Omdat we eerder hebben beschreven dat de Th17 cel 
populatie gering is in kanker (hoofdstuk 3), bevestigt dit de lage gemeten concentraties 
IL17 en kunnen we met deze  studie  de rol van neutrofiele granulocyten niet verder 
onderbouwen. Wel suggereren de data dat IL17 afkomstig van Th17 cellen de 
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was sterk gecorreleerd met slechte overleving. Opvallend genoeg bleken IL17 en 
neutrofiele granulocyten markers fucosyltransferase 9 (FUT9) en neutrophil elastase 
(NE) zeer laag tot expressie te komen. Aangezien neutrofiele granulocyten in weefsels
zeer weinig tot geen RNA tot expressie brengen dat codeert voor de eiwitten die ze in 
hun granules bevatten, is de IL17 expressie die we hebben gemeten waarschijnlijk 
afkomstig van Th17 cellen. Omdat we eerder hebben beschreven dat de Th17 cel 
populatie gering is in kanker (hoofdstuk 3), bevestigt dit de lage gemeten concentraties 
IL17 en kunnen we met deze  studie  de rol van neutrofiele granulocyten niet verder 
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aanwezigheid van IL5. Gezien de sterke correlaties met overleving, concluderen wij dat 
het meten van IL6, met name in combinatie van IL5 en IL17, zou kunnen bijdragen aan 
het meer nauwkeurig kunnen voorspellen van de prognose van de patiënt.
We vonden ook een significante correlatie tussen lage IL6 expressie en vaso-invasie, de 
aanwezigheid van tumorcellen in vaatjes. Hoge IL1β expressie gaf ook een trend naar 
een correlatie met afwezigheid van vaso-invasie. Een hoog aantal IL-17 en IL-1β
positieve cellen was ook significant gecorreleerd met de afwezigheid van vaso-invasie 
(hoofdstuk 3). Dit suggereert dat de IL-1β/IL-6/IL-17 respons uitzaaiing van 
tumorcellen via de bloed- of lymfevaten remt. 
Hoofdstuk 6 handelt over het meten van genexpressie specifiek afkomstig van ofwel 
tumorcellen, ofwel immuuncellen. Bij moleculaire analyses van de tumor als geheel, 
zoals in hoofdstuk 5, zijn de celtypen waar de moleculen vandaan kwamen vaak niet te 
achterhalen. Daarom hebben wij de tumorcellen en immuuncellen geïsoleerd uit 
baarmoederhalskanker celsuspensies met behulp van flowcytometrie. Uit deze twee cel 
fracties werd RNA geïsoleerd en de totale expressie van het RNA werd vervolgens 
gemeten met RNA sequentiebepaling. Binnen beide fracties werden de genen die 
significant hoger of lager tot expressie kwamen op basis van overleving, 
lymfekliermetastasen of Th17 respons geanalyseerd. Deze nieuwe aanpak leidde tot een 
duidelijke scheiding in genexpressie die overeenkwam met de originele celtypen. 
Gebaseerd op klinische uitkomst bleek er weinig variatie tussen de verschillende 
tumoren te bestaan, wat zou kunnen betekenen dat de RNA expressie in de tumoren 
relatief homogeen is. Omdat de ontwikkeling van een tumor tumortype-specifiek zou 
kunnen zijn, en vergelijkbaar tussen patiënten, zou deze techniek ook geschikt kunnen 
zijn om de verschillen tussen tumortypen in kaart te brengen. 
Binnen de immuuncel fracties bleek dat TCL1A expressie significant gecorreleerd was 
met overleving en dat TCL1A niet tot expressie kwam in deze cellen bij patiënten die 
binnen vijf jaar na de operatie overleden waren. Deze correlatie werd bevestigd met 
qRT-PCR en immuunhistochemische analyses. Vervolgens toonden we aan dat TCL1A
tot expressie komt in B cellen. Tot slot waren hoge expressie van B cel marker CD19 en 
een hoge TCL1A/CD20 (B cel marker) ratio in de ingevroren tumoren van een 
aanvullend patiënt cohort gecorreleerd met goede overleving. Deze data geven aan dat 
B cellen in de tumor mogelijk een belangrijke rol spelen bij het verloop van 
baarmoederhalskanker, met voornamelijk een belangrijke rol voor TCL1A en CD20 
positieve B cellen. Rijpe B cellen staan bekend om hun vermogen om antilichamen te 
produceren, maar kunnen ook antigenen presenteren. Recent onderzoek heeft 
aangetoond dat lymfoïde structuren, waar B en T cellen normaal geactiveerd worden, 
ook in tumoren aanwezig kunnen zijn. Deze lymfoïde structuren lijken gecorreleerd te 
zijn met goede overleving. Hoewel de rol van B cellen in kanker nog onduidelijk is, 
toont deze studie aan dat B cellen in baarmoederhalskanker een belangrijke rol kunnen 
spelen bij het onderdrukken van tumorgroei. Deze rol moet verder worden uitgezocht.
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Ook in deze studie werd IL-17 erg laag tot expressie gebracht. Omdat slechts drie genen 
verschillend tot expressie kwamen tussen IL-17 positieve en negatieve tumoren, was het 
niet mogelijk om de rol van IL-17 of Th17 cellen verder te verklaren op basis van deze 
resultaten. In de tumor fracties met corresponderende IL17 positieve immuuncel fracties 
kwam OMA1 zinc metallopeptidase het meest significant verhoogd tot expressie 
vergeleken met de tumoren met IL17 negatieve immuuncel fracties. OMA1 functioneert 
in situaties van stress, en omdat Th17 cellen hier ook om bekend staan, zou een OMA1 
respons in de tumor gerelateerd kunnen zijn aan een Th17 cel immuunrespons.
Th17 cellen worden doorgaans gekarakteriseerd door IL-17 expressie. De tegengestelde 
correlaties tussen IL-17 versus Th17 cellen en overleving in baarmoederhalskanker, 
zouden een mogelijke verklaring kunnen zijn voor de controverse over de rol van Th17 
cellen in kanker. Om deze hypothese te toetsen, werd in hoofdstuk 7 een systematische 
literatuurstudie naar de correlaties tussen IL-17 versus Th17 cellen en overleving in  
patiënten met kanker beschreven. In overeenstemming met onze bevindingen in 
plaveiselcelcarcinoom van de baarmoederhals, beschreef het merendeel van de studies 
naar de rol van IL-17 in kanker een significante correlatie met slechte patiënt 
overleving. Ook werd meestal een significante correlatie tussen Th17 cellen en goede 
overleving beschreven. Wel was er variatie in de richting en grootte van het effect, zoals 
ook aangetoond in onze studie in adenocarcinoom (hoofdstuk 4), een indicatie dat de 
effecten van IL-17 en Th17 cellen in kanker context en tumortype afhankelijk zijn.
Omdat IL-17 door verschillende celtypen kan worden geproduceerd, kunnen deze 
celtypen ook het type immuunrespons bepalen. Over het geheel lijkt IL-17 echter 
tumorgroei te stimuleren, waarschijnlijk via de inductie van angiogenese en aantrekking 
van neutrofiele granulocyten. Th17 cellen, hoewel een kleine cel populatie, zijn over het 
algemeen juist betrokken bij het onderdrukken van tumorgroei, wellicht door een Th1 
en cytotoxische T cel respons te stimuleren. We concluderen dat het belangrijk is om 
onderscheid te maken tussen Th17 en andere IL-17 positieve cellen.
Hoofdstuk 8 omvat een discussie van de resultaten beschreven in hoofdstuk 2 tot 7 en 
de implicaties voor verder onderzoek. Een samenvatting van de resultaten en discussie 
is hierboven beschreven. Een van de belangrijke vraagstukken die verder dient te 
worden bestudeerd betreft de factoren die IL-17 expressie bij neutrofiele granulocyten 
induceren. Alhoewel de factoren voor de inductie van Th17 cellen nog steeds niet 
geheel bekend zijn, zijn de factoren voor de inductie van IL-17 producerende 
neutrofiele granulocyten geheel onbekend. Deze kennis zou inzicht bieden in het type 
immuunrespons dat hierbij betrokken is, en de effecten ervan. Zo dient ook verder 
onderzocht te worden of IL-17 door een specifieke subpopulatie neutrofiele 
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B cellen in de tumor mogelijk een belangrijke rol spelen bij het verloop van 
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positieve B cellen. Rijpe B cellen staan bekend om hun vermogen om antilichamen te 
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zijn met goede overleving. Hoewel de rol van B cellen in kanker nog onduidelijk is, 
toont deze studie aan dat B cellen in baarmoederhalskanker een belangrijke rol kunnen 
spelen bij het onderdrukken van tumorgroei. Deze rol moet verder worden uitgezocht.
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In dit proefschrift is beschreven dat IL-17 voornamelijk gecorreleerd is met slechte 
patiënt overleving, en Th17 met goede overleving in kanker. Er was echter substantiële 
variatie in de mate van correlatie. Dit zou te maken kunnen hebben met het tumortype, 
zoals beschreven in het review (hoofdstuk 7). Dit werd ook belicht door de verschillen 
tussen plaveiselcelcarcinoom en adenocarcinoom van de baarmoederhals (hoofdstuk 3, 
4). Het is daarom van belang om te bestuderen in welke tumortypen IL-17 en Th17 
cellen welke rol spelen. Het is ook interessant om de celtypen te bestuderen die in de 
verschillende tumortypen IL-17 produceren, en welke andere celtypen of factoren 
hiermee gecorreleerd zijn.
Gebaseerd op de bevindingen die beschreven zijn in hoofdstuk 7, zouden kanker 
patiënten met veel IL-17 wellicht baat kunnen hebben bij het blokkeren van de werking 
van IL-17. Antilichamen tegen IL-17 worden momenteel al gebruikt in klinische trials 
voor de behandeling van verschillende auto-immuunziekten. Ook in een experimenteel 
diermodel werd de tumorgroei van een lymfoom geremd met antilichamen tegen IL-17. 
Aan de andere kant zou de toediening (‘adoptive transfer’) van Th17 cellen kunnen 
helpen bij het bestrijden van de tumor. Op grond van de resultaten verkregen uit 
diermodel studies is beschreven dat de toediening van Th17 cellen leidt tot meer 
tumorregressie dan de toediening van Th1 cellen. De haalbaarheid van beide 
benaderingen dient verder  onderzocht te worden.
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